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ABSTRACT 
In the last decade, a number of high profile medical device recalls have drawn attention to the 
regulatory approval process, particularly the streamlined process for devices considered “lower 
risk” known as the 510(k). Approval of medical devices through the 510(k) Process is not based 
on clinical data, but rather on “substantial equivalence” to predicate devices approved pre-1976 
or legally marketed thereafter. A predicate device is one that shares the same intended use as the 
new device and technological characteristics which are either the same or different without 
introducing new safety hazards. Many scholars believe that the premise of approving medical 
devices based on similarity to existing devices is inherently flawed. In particular, there is worry 
that presence of technology creep between predicate devices can lead to the approval of medical 
devices which ultimately do not resemble the original device for which clinical evidence exists, 
even as that evidence is used to validate device safety.  
 
Given these concerns about the safety of the established regulatory process, this thesis explored 
the impact of predicate creep within the 510(k) Process through a case study of a Robotic 
Assisted Surgery (RAS) devices, with particular focus on the Intuitive Surgical Da Vinci 
Surgical System. Through the development of new methodologies using publicly available data 
to measure predicate creep, this research traces the predicate ancestry of several RAS devices to 
assess the current impact and implications of predicate creep on the current regulatory process. 
The study concludes that there is significant evidence of predicate creep within the approval 
process and recommend new guidelines for classifying device risk and subsequent evidentiary 
requirements within the 510(k) Process, to reduce the number of devices with high levels of 
potential risk to public safety released onto the market.    
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GLOSSARY/ABBREVIATIONS 
Cryosurgery - Surgical procedure utilizing extreme cold to destroy abnormal or diseased tissue 
Direct Predicate – The predicate device to which a subject device claims first generation 
equivalence; the predicate device listed on a 510(k) approval application 
Endoscope - an instrument that can be introduced into the body to give a view of its internal 
parts 
Endoscopic and Laparoscopic Instruments - Surgical instruments specifically designed for use 
in laparoscopic or endoscopic surgical procedures. Typically featuring elongated shafts and 
cable-controlled mechanisms to allow the surgeon a range of motion inside the body through a 
small incision. 
Laparoscope - A small fiberoptic instrument inserted through the abdominal wall to view the 
interior of the abdominal cavity 
Laparoscopic Surgery - A surgical procedure performed using small incisions in the body, 
usually with the aid of a camera. Also known as minimally invasive surgery (MIS) 
Originating/Ultimate Predicate - The oldest device to which substantial equivalence can be 
traced in a branch line 
Predicate - A device upon which a determination of substantial equivalence is made 
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Predicate Creep – The introduction of technology creep over time in medical devices cleared 
via the 510(k) Process.  Typically refers to instances where new technological characteristics are 
introduces without significant scientific evidence to support claims of safety and efficacy 
Subject - The device receiving approval based on a given predicate 
Trocar - A pen-shaped medical device used in laparoscopic surgery to provide an access port for 
endoscopic instruments into the abdomen. The device consists of three components, an obturator 
(the pointed tip), a cannula (a hollow tube), and a seal.  
Technology Creep – The development of new technological advancements over time through a 
cumulative series of incremental changes from preceding technologies 
 
Table 1:  Definitions of commonly used abbreviations 
Abbreviation Term Definition 
510(k) 510(k) Process The process used to clear Class I and II 
medical devices for market 
CDRH Center for Devices and Radiological 
Health 
The Office of the FDA specifically in 
charge of medical devices 
FDA United States Food and Drug 
Administration 
The government agency responsible for 
medical device regulation 
MDA Medical Device Amendments of 1976 The law which created the current 
regulatory structure and classification 
system for medical devices 
NSE Not Substantially Equivalent A declaration that a device is not cleared 
via the 510(k) Process 
PMA Pre-market Approval Process The process used for approval of Class III 
medical devices 
SE Substantially Equivalent A declaration that a device meets the 
requirements for clearance via 510(k) 
  
8 
 
1 INTRODUCTION 
 
The current FDA regulatory guidelines for medical devices were created by the 1976 Medical 
Device Regulation Act (MDRA), which was passed by Congress in response to concerns about 
the safety of approved medical devices. The purpose was to create a standardized regulatory 
approval framework that would ensure safety, efficacy, and proper labeling of medical devices. 
The MDRA established a classification system for medical devices based on their intended use 
and level of potential risk to patients. Class I contains low risk devices, such as dental floss or 
tongue depressors. Class II contains moderate to high risk devices that are not considered life 
sustaining or supporting, ranging from acupuncture needles to robotic assisted surgical 
platforms. Class III contains the highest risk devices, those which are life sustaining or 
supporting, such as pacemakers and most medical implants.  
  
Devices which fall into Classes I and II may use a streamlined approval process, known as the 
510(k) Process. The process is based on “substantial equivalence” to devices approved pre-1976 
or legally marketed thereafter, known as predicate devices. The FDA determines the amount of 
testing performed based on the level of substantial equivalence to the identified predicate 
device(s) for both function and technological characteristics and any existing standards 
applicable to the device. Devices in Class III are required to go through a more stringent and 
individualized approval process, known as the Pre-Market Approval (PMA) process; this 
includes clinical trials and more extensive testing requirements. 
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In the last decade, several high profile device recalls have drawn attention to the regulatory 
approval process. After studies found that 71% of high risk recalls (those issued due to serious 
health risks or deaths) involved devices approved through the 510(k) Process, researchers began 
to raise questions about the validity of the 510(k) Process as a broad approval mechanism 
(Zuckerman, Brown & Nissen, 2011). 
  
One of the issues raised as a potential flaw is the use of “predicates” to streamline the approval 
process. A predicate is any existing legally marketed device which possesses the same intended 
use as the new device and either the same or, if specific criteria are met, different technological 
characteristics. The additional criteria for validation of a predicate possessing different 
technological characteristics is sufficient evidence to determine that the new device does not 
raise additional questions of safety or efficacy past those addressed in the predicate, and that it is 
at least as safe and effective as the established predicate (FDA, 2014). 
  
The use of a predicate device to establish safety and efficacy for a new device, when there are no 
substantial differences between the form or function of the two devices, is straightforward and 
logical. However, this same approval mechanism is also used under a clause in the definition of 
substantial equivalence permitting “different technical characteristics” for many Class II devices 
which possess significant differences in form or function, both physically and technologically, 
compared to the predicate device. Although the FDA does require some evidence of safety and 
efficacy in these cases, many scholars believe that the existing measures are insufficient to 
ensure the safety of the public (CDRH, 2010; Heneghan & Thompson, 2012; Hines, Lurie, Yu, 
& Wolfe, 2010). In a 2011 report conducted at the request of the FDA to evaluate the 510(k) 
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Process, the Institute of Medicine (IOM) concluded that the premise of approving medical 
devices based on similarity to existing devices was inherently flawed, and recommended that the 
510(k) Process should be replaced in its entirety (Institute of Medicine [IOM], 2011). 
 
In addition to concerns about the validity of the 510(k) Process as a whole, many scholars have 
expressed concerns that new devices approved based on another device previously approved via 
510(k) and so on, may create a cycle whereby devices are continually approved without 
introducing any new clinical evidence to support claims of device safety (Hines, Lurie, Yu, & 
Wolfe, 2010; Zuckerman, Brown, & Das, 2014). If these devices were all identical to each other, 
the risk of repeated, cumulative approvals via substantial equivalence would be mitigated by the 
evidence provided through the successful function of the predicate device on the market. 
However, the FDA permits manufacturers to use this same process for approval of devices with 
different technological characteristics than the identified predicate, thereby introducing 
technology creep into the approval process. This cycle of technology creep through repeated 
approval of devices based on predicates with slightly different technical characteristics is known 
as predicate creep. Researchers worry that the combination of predicate creep and minimal 
evidentiary requirements for the 510(k) Process will allow devices to be approved which are 
completely different from the original predicate device, even as they rely on the scientific 
evidence provided by that original predicate to prove safety claims (Hines, Lurie, Yu, & Wolfe, 
2010). 
 
Given the increasing number of technologically complex medical devices entering the market, 
lack of scientific research into mechanisms of the approval process, and growing concern about 
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the safety of the established regulatory process, this thesis aims to explore the 510(k) Process 
through a case study of a Robotic Assisted Surgery (RAS) device, the Intuitive Surgical Da Vinci 
Surgical System. In particular, this thesis aims to: 
 
1. Explore what information exists in publicly available FDA regarding device approval 
history via predicate relationships. 
2. Develop a methodology for the identification and analysis of predicate relationships via 
publicly available data. 
3. Assess whether predicate creep has occurred between predicates and identify any other 
patterns in the device approval history. 
4. Identify implications of finding for the current approval process and other related medical 
device policies 
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2 BACKGROUND: THE FDA AND THE 
REGULATORY PATHWAY 
 
The FDA was originally created after the passage of the Pure Food and Drug Act of 1906 in 
response to growing concerns about the safety of products marketed for human consumption.  In 
1938, the passage of the Food, Drug, and Cosmetic Act (FFDCA) gave the FDA jurisdiction over 
medical devices. However, that jurisdiction extended only to device which were considered 
“adulterated” or “misbranded”. The FDA was not given premarket approval power over devices 
until Congress passed the Medical Device Amendments of 1976 (MDA), which established the 
current definition of a medical device and the risk-based device classification framework and 
approval process in use today. 
  
The intention of the MDA was that the FDA would classify all existing devices into one of three 
risk categories, and that the level of regulatory rigor would be based on the category a device 
was placed in (90 Stat. 539). Any new device entering the market was automatically required to 
go through a strict pre-market approval process (PMA) intended for the highest risk devices, 
unless the device was shown to be substantially equivalent to an existing device with a low level 
of risk or was reclassified by the FDA into a lower-risk category. Lower risk categories did not 
have to meet the strict PMA requirements, but instead had to meet device based performance 
standards created by the FDA. New device manufacturers were required to give the FDA at least 
90-days’ notice of a new product to be brought to market, regardless of risk classification, to 
allow for the device to pass through FDA approval processes. 
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The 510(k) Process was developed from the MDA to reduce the amount of resources required for 
the FDA to meet the growing demand for device approvals. Rather than put each new device 
through the PMA process, the FDA developed a process based on the 90-day notification clause. 
The new process classified new devices as low(er) risk based on substantial equivalence to 
existing devices. However, even with the creation of the 510(k) Process, the FDA lacked 
sufficient resources to complete the tasks assigned in the MDA (IOM, 2011). As a result, the 
Safe Medical Devices Act (SMDA) of 1990 was passed to clarify and modify the guidelines set 
in the MDA in order to streamline the FDA’s work. 
  
The SMDA modified the definition of a Class II device to differentiate Class II devices from 
lower risk Class I devices. It also removed the previous requirement that all Class II devices have 
defined performance standards, replacing the mandatory standards with special controls for 
specific devices developed at the discretion of regulators. The SMDA formalized the 510(k) 
Process by creating a legal definition of substantial equivalence, although the only specifications 
provided for a “predicate device” was that it had to be legally approved for market. Additionally, 
the Act created a series of rules for post-market surveillance and adverse event reporting. 
  
The Food and Drug Administration Modernization Act (FDAMA) of 1997 was passed to further 
simplify the approval process in response to concerns that regulations were creating backlogs at 
the FDA (Merrill, 1999).  The FDAMA eliminated 510(k) notification requirements for most 
Class I and some Class II devices. It also created the De Novo approval process for new Class I 
or II devices that had no legally marketed predicate and would therefore had previously been 
required to undergo PMA as a Class III device by default. This process allows manufacturers to 
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seek approval for Class I or II medical devices using scientific evidence and existing regulatory 
guidelines without going through the full PMA process. Moreover, the FDAMA requires the 
FDA to take the “least burdensome approach” to demonstrating equivalence, which resulted in 
the creation of the Special and Abbreviated 510(k) Processes. The Act eliminated the FDA 
burden of creating performance standards for Class II devices by allowing for recognition of 
established standards created by a nationally or internationally recognized organization. 
  
The current definitions of each device class originally established by the MDA of 1976 and 
subsequently modified, and the general approval process followed by devices in each class, are 
detailed below. 
 
2.1 CLASS I DEVICES 
 
Class I devices are low risk and not life sustaining, and therefore subject only to general 
regulatory controls (US Food and Drug Administration [FDA], 2006). Examples of Class I 
devices include dental floss, elastic bandages, and tongue depressors. Many Class I devices are 
considered exempt from premarket notification requirements, meaning they do not need FDA 
approval to enter the market. If a device is not classified as exempt, the manufacturer must 
submit a 510(k) identifying a predicate device and providing evidence that the new device is 
substantially equivalent. 
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2.2 CLASS II DEVICES 
 
Class II medical devices pose a higher risk than those in Class I, but not life sustaining or 
supporting. The level of technical complexity of Class II devices varies widely, with examples 
ranging from plastic surgical drapes to infusion pumps. While the complexity of less technical 
Class II devices and Class I devices is often similar, the distinction between the two 
classifications is typically drawn based on the potential severity of device failure. Failure of 
dental floss, such as fraying or breakage, is merely an annoyance that poses little risk to the 
patient. However, failure of a plastic surgical drape, which is used to ensure equipment sterility 
in operating rooms, could potentially result in bacterial contamination of equipment that might 
cause life threatening infections in a patient. Class III devices that are considered to possess well-
understood technical characteristics may be placed under Class II by exemption to expedite the 
approval process. Class II devices are subject to both general controls and more specialized 
performance controls based on the functionality and potential risk of the individual device (US 
Food and Drug Administration [FDA], 2006). 
  
The approval pathway for a Class II device varies based on the intended use and level of 
potential risk inherent in the particular device design. Like many Class I devices, some low risk 
Class II devices have been exempted entirely from the premarket notification process. Other 
lower risk Class II devices are subject only to general controls and special controls well defined 
by official guidance documents or recognized standards, which allows manufacturers to file for 
approval using the Abbreviated 510(k) Process. If the manufacturer of a Class II device can 
utilize an existing device they marketed as a predicate for substantial equivalence, then the new 
device can be approved using a streamlined alternative process known as the Special 510(k). 
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This approach is typically only accepted by the FDA for generational product improvements, as 
it allows the manufacturer to declare conformity to design control requirements without 
providing data to support their claims. 
  
If a Class II device does not meet any of the requirements for exemption or streamlined 510(k) 
approval, it must go through the traditional 510(k) Process. This process relies on the 
performance of similar devices currently on the market, known as predicates, to provide proof of 
safety for the new device, rather than independently evaluating the device through lengthy 
clinical trials. The process begins with the manufacturer submitting an application detailing the 
device description, intended use, intentions for use, identified predicate devices, and 
performance data supporting the claim of substantial equivalence. The FDA then has 90 calendar 
days to declare the device either substantially equivalent (SE) or not substantially equivalent 
(NSE) to the predicate (s) based on the material presented in the 510(k) application. If a device is 
declared SE by the FDA, the manufacturer receives clearance to place the device on the market 
after registering and officially listing the device (Center for Devices and Radiological Health, 
2017b).  
  
If the FDA finds a device NSE, it will automatically be reclassified as a Class III device unless 
the manufacturer submits a De Novo approval application. The De Novo process evaluates the 
scientific evidence presented by the manufacturer and allows the FDA to grant approval without 
a predicate device if the evidence provides sufficient proof of safety, effectivity, and minimal 
risk (Center for Devices and Radiological Health, n.d.). 
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2.3 CLASS III DEVICES 
 
Class III medical devices are life sustaining or supporting, or present unreasonable potential risk 
to the user. These include most implantable devices, such as pacemakers, stents, and orthopedic 
prosthetics, as well as life supporting devices such as external defibrillators. The FDA has 
determined that general or special controls are insufficient to assess the safety and efficacy of 
these devices. Instead, the vast majority of Class III devices are approved via Premarket 
Approval (PMA) process, a rigorous scientific and regulatory review which requires device 
specific non-clinical and clinical testing to prove safety and effectiveness (US Food and Drug 
Administration [FDA], 2006). A limited number of Class III medical devices receive PMA 
exemptions, allowing them to be approved via the 510(k) Process instead. 
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3 A REVIEW OF THE LITERATURE ON THE 510(K) 
PROCESS 
 
Existing research has identified a variety of potential gaps in the 510(k) Process, including 
concerns about the validity of “substantial equivalence” as an approval mechanism, lack of 
scientific evidence to support claims, predicate creep, Class III device exemptions, and 
insufficient post market surveillance among others. Some major studies also presented 
suggestions for improvements to the process, which resulted new guidance documentation issued 
by the FDA beginning in 2012. 
 
3.1 GAPS IN THE 510(K) PROCESS 
 
3.1.1 VALIDITY OF SUBSTANTIAL EQUIVALENCE 
 
One major criticism of the 510(k) Approval Process commonly identified is the use of 
“substantial equivalence” as an approval mechanism for ensuring safety and efficacy of new 
devices. According to the current FDA definition a device is substantially equivalent if, in 
comparison to a predicate it: 
1. has the same intended use as the predicate; and 
2. has the same technological characteristics as the predicate; 
Or 
1. has the same intended use as the predicate; and 
2. has different technological characteristics and does not raise different questions of 
safety and effectiveness; and 
3. the information submitted to FDA demonstrates that the device is at least as safe and 
effective as the legally marketed device. 
(Center for Devices and Radiological Health [CDRH], 2017b) 
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Although this definition was intended to clarify when the use of substantial equivalence was 
appropriate for medical device approval, some scholars have expressed concerns about the 
vagueness of the definition. A 2010 CDRH working group report identified confusion 
surrounding the definition of “intended use” for substantial equivalence determinations 
compared to the term “indications for use”. The report defines “intended use”, a requirement for 
substantial equivalence, as based on the objective intent expressed by the manufacturer. 
“Indications for use,” a more general term often used in 510(k) applications but not required to 
be the same for substantial equivalence, describes the general disease or condition the device is 
designed to treat. However, among industry officials and in many official FDA documents the 
two terms are used interchangeably, creating a lack of clarity about the actual requirements of 
substantial equivalence (CDRH, 2010). 
 
Another issue identified is that, due to the lack of a clear official definition for the key term 
“intended use”, the FDA has allowed permissive interpretation of “intended use” by applicants. 
Since intended use is defined by the manufacturer rather than regulators, manufacturers are able 
to modify the wording of the stated intended use to make changes in device function appear 
minimal. Over time, this has resulted in the approval of significantly altered devices, or even 
novel devices, as substantially equivalent to established predicates (CDRH, 2010; Heneghan & 
Thompson, 2012; Hines et al., 2010).  
 
One example of this provided by the CDRH Working Group (2010) was the gradual approval of 
cryosurgical devices as a treatment for prostate cancer, rather than a tool for removal of 
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unwanted tissue these devices were initially designated for. A new cryosurgical device that could 
more readily be used to access the prostate area was approved in 1990 with an indicated use for 
“tissue destruction.” Manufacturers aggressively pushed to have the indicated use expanded to 
include “treatment of prostate cancer,” but were refused on the grounds that a clinical application 
carried different risks and implications than the general use. Instead, manufacturers went around 
the FDA by gradually changing the intended use, first to “tissue destruction in urology,” then 
including “removal of prostate tissue” and “prostate tumor – palliative.” At this point in time, 
with an intended use specifically indicated for prostate tumors, a growing number of researchers 
began experimenting with the tool as a treatment for prostate cancer, despite the lack of official 
approval for this express purpose. Caving to pressure from manufacturers and the increasing 
prevalence of the device as a treatment in clinical settings, in 1997 the CDRH allowed 
cryosurgical devices to be cleared for an indicated use of “treatment of prostate cancer” without 
ever identifying a new “intended use” or requiring clinical data to support device approval. 
Ultimately, many problems arose following the widespread adoption of cryosurgery as a 
treatment for prostate cancer, an application of the device that the CDRH never specifically 
evaluated for safety or effectiveness (CDRH, 2010). Many issues may have been prevented had 
the device undergone a full review prior to being placed on the market for this application.    
 
The example of cryosurgical devices as a treatment for prostate cancer shows the potential risk 
of permissive interpretation even in the case of a device which has already been on the market 
and proved safe for other applications. However, the potential risk of permissive interpretation 
increases drastically when combined with the provision within the definition of substantial 
equivalence that allows for approval of devices with different technological characteristics. This 
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provision expands the selection of predicates to include devices with different materials or 
mechanisms of action, if the new device has a similar safety profile to the predicate, which 
creates additional uncertainty about how a device will perform when placed on the market. 
 
3.1.2 OUTDATED PREDICATES 
 
One major concern identified by researchers is that the 510(k) Process makes the implicit 
assumptions that substantial equivalence means that a device is safe and effective, and that the 
predicates on which substantial equivalence determinations are based are safe. In his concurring 
opinion for the 1996 case of Medtronic v. Lohr, Supreme Court Justice O’Connor explained the 
court’s interpretation that a finding of substantial equivalence proves only that the device 
introduces no new safety hazards and functions at least as effectively as the predicate device 
(Medtronic vs. Lohr, 1996, pg. 513). However, if the predicate device poses risk or is ineffective, 
then the new device may perpetuate these flaws. Thus, there are concerns that the 510(k) Process 
can create a cyclical approval pattern of unsafe devices. There is disagreement, however, as to 
whether the process is invalid entirely or only for specific types of high risk or technologically 
complex devices (Ardaugh, Graves, & Redburg, 2013; Lennox, 2014; Zuckerman, Brown, & 
Das, 2014). 
  
3.1.3 PREDICATE CREEP 
 
Some literature pointed to the risks of using of multiple predicate devices for a single substantial 
equivalence determination. The CDRH working group report identified three types of 510(k) 
predicate submissions: single, multiple, and split (CDRH, 2010). While most academics agree 
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that single predicate submissions, which directly compare a new device to a single device on the 
market, provide significant assurance of safety and efficacy in most cases, many have raised 
questions about whether multiple and split predicates can provide the same level of assurance 
(Ardaugh, Graves, & Redburg, 2013; Zuckerman, Brown, & Das, 2014). For example, Ardaugh 
et. al examined the approval history of the DePuy ASR XL Acetabular Cup System, a metal-on-
metal hip implant that caused life altering injuries to hundreds of patients due to metal particle 
shedding within the body. The ASR XL was approved using three different devices as predicates, 
each with a unique technological characteristic which was incorporated into the XL. Since all 
three devices were deemed safe based on market performance, and the XL simply combined 
parts of the devices, it was placed on the market without undergoing clinical testing. However, 
after the discovery of particle shedding, it was determined that the cause of the failure was the 
unique combination of the material (from one predicate) and geometry (from a different 
predicate) of the ASR XL (Ardaugh, Graves, & Redburg, 2013). Regulators had reasoned that if 
these characteristics were safe independently, then they should be safe when put together. 
However, without any evidence from previous devices with this combination of material and 
geometry or actual testing of the device over time, that reasoning was mere assumption, which in 
this case proved disastrous. 
  
Another growing concern expressed in the literature is that, in many cases, the predicates on 
which evaluations of safety and efficacy are based were also approved via 510(k) (Hines et al., 
2010). Substantial equivalence allows a device to “piggyback” on the reasonable assurance of 
safety from existing predicate devices without undergoing independent testing. (CDRH, 2010; 
Lennox, 2014). However, when the predicate was also approved via substantial equivalence, as 
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was its predicate and so on, a cycle is created in which there may be a significant gap between 
the current device and the most recent device for which scientific evidence of safety was 
provided (Fargen et al., 2012). This creates an iterative process through which, over multiple 
cycles of small device modifications and subsequent substantial equivalence findings, a new 
device may be approved which is significantly dissimilar to the original predicate for which 
scientific evidence exists (Hines et al., 2010). This process is known as predicate creep (Hines et 
al., 2010; Zuckerman, Brown, & Das, 2014). While the exact impact of predicate creep is 
difficult to identify, a few researchers have attempted to construct ancestral equivalence trees 
utilizing the 510(k) database maintained by the FDA, with mixed results (Ardaugh, Graves, & 
Redburg, 2013; Waetjen et al., 2015; Zuckerman, Brown, & Das, 2014).  
 
 
Although there is very little evidence provided within the literature to prove the existence of 
predicate creep, two papers were found that used a technique constructing ancestral equivalence 
tree to identify information present in the predicate history of a specific device. Ardaugh et. al 
(2013) used documents obtained through the FDA 510(f) Database and Freedom of Information 
Act filings to trace the predicate history of the DePuy ASR XL Acetabular Cup System, a metal-
on-metal hip implant, over five decades with the purpose of identifying the cause of safety flaws 
present in the design. Zuckerman et. al (2014) used the FDA 510(k) Database to trace the 
predicate history as far back as available for a random sample of 50 newly cleared devices, with 
the stated purpose of identifying the most recent predicate to present definitive scientific 
evidence of safety and effectiveness to support a claim of substantial equivalence.  Neither 
article specified the exact methodology used to trace predicates. Examination of the database, 
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however, shows that in many cases the predicate device(s) is readily identified in the available 
paperwork. 
  
The research performed by Zuckerman et al. (2014) focuses on identifying the most recent point 
in the predicate history when scientific evidence was presented to support a claim of substantial 
equivalence, as part of a larger argument the researchers present about a lack of publicly 
available scientific evidence to support the safety and effectiveness of implantable medical 
devices. This group’s research focuses on whether evidence was provided to support claims of 
equivalence, and the type of evidence provided, rather than examining the technological 
relationship between the devices on which the claim was based. One notable finding presented in 
this research was the identification through an ancestral trace of predicate devices that have been 
recalled from the market due to safety concerns, which raises red flags about the safety of 
subsequent devices. 
  
Ardaugh et al. (2013) studied the predicate history of the ASR XL with the express purpose of 
discovering how a device with major design flaws was able to enter the market through the 
510(k) Approval Process. The researchers examined the technological relationship between 
predicates with the specific purpose of identifying when features which became “flaws” in the 
final device were introduced in predicates. However, the characterization of predicate 
relationships in this research was performed with the specific intention of locating technological 
characteristics present in the final device, rather than to understand and characterize predicate 
relationships in general. 
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3.1.4 SCIENTIFIC BURDEN OF PROOF 
 
Another flaw commonly identified in the literature is insufficient scientific evidence of safety 
and efficacy. The 510(k) Process requires only sufficient scientific evidence to prove substantial 
equivalence to a predicate and, in the case of new technological characteristics, mitigate any new 
concerns of safety and efficacy. This evidence is typically presented in the form of non-clinical 
data, which may range from descriptive device data, essentially physical characteristics, to more 
involved performance testing (Flaherty, 2008; Waetjen et al., 2015). While in some cases this 
evidence is clearly enough to demonstrate substantial equivalence and assure device safety, 
many worry that it is insufficient to ensure the safety of devices which are inherently higher risk, 
or which are declared equivalent to devices of questionable safety (Ardaugh, Graves, & Redburg, 
2013; Heneghan & Thompson, 2012; Janetos, Ghobadi, Xu & Walter, 2017; Waetjen et al., 
2015; Zuckerman, Brown, & Nissen, 2011). The lack of available scientific evidence supporting 
substantial equivalence claims may be partially due to inconsistently defined testing 
requirements dictated by the FDA. While the regulatory definition of a Class II device identifies 
“general and specialized performance controls” (FDA, 2006) as requirements for approval, what 
specifically defines those controls is not necessarily scientifically based and often unclear 
(Zuckerman, Brown, & Das, 2014). 
 
3.1.5 CLASS III DEVICE EXEMPTIONS 
 
Along with a lack of required clinical testing, another flaw identified with the 510(k) Process in 
the literature is the approval of devices identified as Class III (high-risk) through the less 
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stringent 510(k) Process. While Congress mandated in the 1990 Safe Medical Devices Act that 
the FDA either reclassify these devices or establish a schedule for requiring PMAs (Hines et al., 
2010), as of 2008, 20 of these device types could still be cleared via 510(k) (GAO, 2010). In fact, 
a GAO report found that between 2003 and 2007 more Class III devices were cleared for market 
via the 510(k) Process than the original PMA process (GAO, 2010). Many high profile failures 
of Class III devices approved via 510(k), including the DePuy ASR XL Acetabular Cup System 
and Poly Implant Prosthese (PIP) breast implants, have had increased calls for the removal of the 
Class III device exemption (Garber, 2010; Heneghan & Thompson, 2012; Kramer, Xu, & 
Kesselheim, 2012; Sorenson & Drummond, 2014). 
 
3.1.6 INSUFFICIENT POST MARKET SURVEILLANCE 
 
A comprehensive post market surveillance system is a necessary complement to premarket 
approval processes to mitigate potential patient exposure to harmful medical devices. The FDA 
maintains the Manufacturer and User Facility Device Experience (MAUDE) database, a 
centralized database for reporting data on device safety and efficacy (Dhruva & Redburg, 2012). 
Current post market surveillance rules require mandatory manufacturer reporting of serious 
adverse events or deaths associated with a device, although the decision of whether an event is 
associated with the device is left to the manufacturer (Sorenson & Drummond, 2014). Voluntary 
reporting by healthcare providers, fear of litigation, lack of causal association with a particular 
device, and several additional factors lead to severe underreporting of adverse events (Sorenson 
& Drummond, 2014). Druhva & Redburg (2012) found that only 5 -10% of all adverse events 
are reported to the FDA.  
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In addition to a lack of reporting, insufficient device traceability and a lack of formal review 
mechanisms make it difficult for the FDA to identify patterns in adverse events reports that may 
suggest serious safety risks (Dhruva & Redburg, 2012; Garber, 2010). This limited availability of 
data makes identification of hazardous devices difficult, and has led to calls for an improved post 
market surveillance system with more comprehensive data and traceability (Heneghan & 
Thompson, 2012; Hines et al., 2010; Janetos, Ghobadi, Xu & Walter, 2017). 
 
3.2 PROPOSED 510(K) PROCESS MODIFICATIONS 
 
3.2.1 CDRH WORKING GROUP REPORT (2010) RECOMMENDATIONS 
 
The lack of consistent testing requirements and potential for high risk devices to enter the market 
without clinical data supporting safety claims led the CDRH working group to propose a 
modification to the existing device classification system in their 2010 report. To prevent a 
complete overhaul of the existing regulatory structure while still improving regulatory 
predictability and safety outcomes, the group suggested the creation of Class II subclasses, Class 
IIa and IIb. Class IIa would contain the majority of devices for which guidance documentation 
exists or safety and efficacy is well established by existing predicates. Class IIb would contain 
those devices which, due to new technological characteristics, technical complexity, or inherent 
risk to patients, require higher levels of device specific testing and evidentiary support to prove 
safety and efficacy. This may include devices such as implantables, in vitro diagnostic devices, 
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or reclassified Class III exemption devices which typically pose more risk. Devices in Class IIb 
would be typically require significant scientific data, including animal testing and clinical data, 
for approval (CDRH, 2010). 
 
3.2.2 INSTITUTE OF MEDICINE REPORT: THE 510(K) PROCESS AT 35 
YEARS (2011) 
 
Following the publication of the 2010 Working Group Report identifying potential flaws within 
the 510(k) Process, and recognizing growing concerns within the industry, the Department of 
Health and Human Services tasked the Institute of Medicine with conducting a thorough review 
of the 510(k) Process (IOM, 2011). The report, published on October 25th, 2011, presented a 
comprehensive review of the 510(k) Process and considered a multitude of sources both internal 
and external to the regulatory process, including some found in this literature review (CDRH, 
2010; Hines et al., 2010; Zuckerman, Brown, & Nissen, 2011). 
  
The report ultimately concluded that the existing 510(k) Process was insufficient to adequately 
determining the safety and efficacy of new devices, and the committee recommended that the 
FDA design a new regulatory framework to replace the process entirely. However, the report 
specifically addressed the implications of that recommendation by stating that “The committee is 
not suggesting that all, many, or even any medical devices cleared through the 510(k) clearance 
process and currently on the market are unsafe or ineffective. Rather, the committee found that 
the available information is insufficient to support highly confident conclusions about the safety 
and effectiveness of 510(k)-cleared medical devices in clinical use” (IOM, 2011, pg. 193). 
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3.2.3 FDA RESPONSE 
 
Although the FDA declined to implement either of the major recommendations from (name the 
two) for a restructuring of the classification and approval process made in these reports, the FDA 
has responded to the concerns identified. Based on the findings of these two major reports, the 
FDA began implementing a series of reforms and new regulations in early 2012 to improve the 
510(k) Process. In 2014, the FDA issued new guidance documentation for evaluating substantial 
equivalence in 510(k) applications which addresses many of the concerns identified in the 
literature. The new documentation provides specific definitions for “intended use” and 
“intentions for use”, clarifications on the use of multiple predicates, and more detailed guidelines 
for the use of scientific evidence in supporting substantial equivalence claims (United States 
Food and Drug Administration [FDA], 2014). 
  
Additionally, in 2012 the FDA issued a strategy document detailing its approach to creating a 
comprehensive post market surveillance system. A key element of this strategy is the creation of 
a system of standardized Unique Device Identifiers (UDI) that can be incorporated into 
electronic health databases to increase device traceability and streamline the response to adverse 
events reports (Gross & Crowley, 2012).  
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3.3 SUMMARY OF LITERATURE REVIEW FINDINGS 
 
The review of current literature on the 510(k) Process conducted above identified two primary 
areas of concern regarding the effectiveness of the current process. First, many critics expressed 
concerns about vague definitions, lack of clear guidance or requirements for evidentiary support 
of equivalence claims, and subjective equivalence determinations by FDA officials which affect 
the consistency and predictability of the regulatory process. Second, scholars and regulators 
determined that the use of predicate devices as an approval mechanism may have adverse 
impacts on the safety of new devices due to the use of inappropriate predicates or the presence of 
predicate creep over time. The implication of the various concerns identified within the literature 
is that the current approval process has gaps which may allow the approval of devices for market 
without ensuring they are safe for use. 
 
Although the FDA has recently implemented changes the approval process to address some of 
the concerns identified within the literature, it has declined to implement any major changes to 
the overall approval process. Various reasons, including resource restrictions and approval time 
constraints, may have contributed to the approach the FDA chose to address the 
recommendations it received. However, another important factor the agency is obligated to 
consider is the balance of regulation versus innovation. While it is necessary to ensure that 
devices are safe and effective prior to placing them on the market, increasing regulatory 
requirements for new devices automatically makes it more difficult to bring innovative devices 
to market. Many device manufacturers already feel that the application process and approval 
times under current regulatory guidelines create barriers to innovation (California Healthcare 
Institute [CHI], 2011). Many medical device companies have begun launching initial product 
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offerings overseas where regulations are perceived as less stringent and more conducive to 
innovation, or relocating operations entirely (CHI,2011). As a result, any modifications made to 
the regulatory process within the United States must be carefully structured to allow for 
innovation without negatively impacting the safety of devices. 
3.4 RESEARCH GOALS 
 
The 510(k) Process was originally envisioned as a means to streamline the approval process and 
reduce the impact of regulatory requirements on devices which present minimal risk to patients. 
While scholars call into question whether the process effectively serves its intended purpose, 
there is a distinct lack of evidence to support the actual impact of many of the gaps identified by 
experts within the literature.  Most of the articles included in this review simply discussed 
potential flaws in the existing process, providing only one or two anecdotal examples of highly 
publicized failures to support claims. The internal review conducted by the CDRH Working 
Group is the only study identified which compiled data from a large number of approval 
applications to identify trends and potential regulatory flaws (CDRH, 2010). The review 
conducted by the IOM Committee used a combination of public workshops, literature reviews, 
expert opinions, internal CDRH reports, and information contained in public FDA databases to 
draw conclusions about the regulatory process. However, the IOM Committee expressly stated 
that it was unable to fully assess the quality of 510(k) submissions, including the types of data 
submitted to support equivalence claims, due to FDA statutory requirements that prevented the 
committee from reviewing applications to protect proprietary information. (IOM, 2011, pg. 20) 
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The limited availability of data due to intellectual property protections, as encountered by the 
IOM during its review, is a major restriction for determining the impact of predicate creep within 
the approval process. Still, it is possible to trace portions of the predicate history of current 
medical devices using data available through FDA databases or via Freedom of Information Act 
(FOIA) requests. Despite this, only two articles identified within this literature review made any 
attempt to trace the predicate relationships of devices in order to determine whether a lack of 
scientific evidence or predicate creep occur within the 510(k) Process.  
 
Given the overall lack of data presented within the literature to support concerns surrounding the 
510(k) Process, especially regarding the use of predicates as an approval mechanism, the aim of 
this thesis is to develop a methodology for identifying predicate relationships of devices 
approved via the 510(k) Process and evaluating the potential impact of predicate creep and other 
trends observed within this data. In order to concentrate on the development of an effective 
analysis method, this research will be structured as a case study of the Da Vinci Surgical System, 
a robotic surgical platform. The following section discusses in depth the methods used to select 
this case study, gather data, and identify instances of predicate creep. The Data Analysis section 
illustrates the data gathering process and relationship comparisons. Findings discusses the 
conclusions drawn from the relationships identified within the Analysis section, and the 
Conclusions section discusses the implications of those findings for policy and future research.   
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4 METHOD 
4.1 CASE STUDY SELECTION: THE INTUITIVE SURGICAL DA VINCI 
SURGICAL SYSTEM 
 
The method I have chosen to analyze the effectiveness of the current regulatory structure for 
developing biomedical technologies, particularly in robotics, is a case study of the Intuitive 
Surgical Da Vinci robotic surgical system. I will conduct a comprehensive review of the 
approval process by tracing the predicate history of the Da Vinci.  This methodology for 
analyzing the regulatory approval process of the Intuitive Da Vinci was selected based on the 
availability of data through public databases. 
  
One of the first and only examples of a robotic medical device approved for market is the 
Intuitive Da Vinci Surgical Platform, a Robotic Assisted Surgery (RAS) device initially 
approved by the FDA in 2000 for laparoscopic surgery. While Intuitive has subsequently brought 
multiple iterations of the Da Vinci to market, 16 years later it remains the only full RAS platform 
on the market as competitors struggle to develop a viable competitor around Intuitive’s strong 
patent foothold. While the Da Vinci served as a predicate device for subsequent models, as well 
as for RAS devices produced by competitors and potentially for other robotics technologies, the 
Da Vinci itself was initially approved under a 510(k) application. This approval was granted 
based on a complex web of component-level substantial equivalence, most likely supplemented 
by additional testing. 
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The Da Vinci Surgical System is a robotic-based laparoscopic surgical tool which replaces a 
surgeon’s hands with robotic arms for more precise control and motion. It is comprised of three 
physical components. A “cart” onto which three robotic arms are mounted, a “tower” which 
houses the computer systems, and a “console” where the surgeon sits to control the arms and 
view the procedure. The system also includes a software component which allows the surgeon to 
control the arms and a 3D vision system, so the surgeon can view inside the patient during 
surgery. Typically, the device is configured so that two robotic arms are mounted with surgical 
tools, and the third arm acts as an endoscope (Intuitive Surgical, 2017). Use of a Da Vinci 
System requires extensive training, and the estimated cost of installation in $2 million. 
  
The Da Vinci is an interesting case study for assessing the FDA approval process for several 
reasons. As stated, the Da Vinci is one of the only examples of robotics surgical devices on the 
market, and since it has been approved for over 15 years, its function is well documented. In fact, 
over 10,000 peer-reviewed articles have been published about the Da Vinci. Additionally, the Da 
Vinci is well documented legally, with over 800 patents registered to Intuitive Surgical and 3000 
product liability claims filed. The uniqueness of the device as an emerging technology with no 
direct competitor on the market makes it representative of many of the challenges the FDA will 
face with other developing medical technologies currently in development. Many of these 
upcoming medical technologies, such as personalized 3D printed prosthetics, nanotechnologies, 
and other devices with high levels of software integration, possess unique functions and 
challenges which do not necessarily fit within the existing regulatory structure. The Da Vinci 
was one of the first major medical technologies to pose similar challenges regarding software 
integration, in addition to the technical complexity of the device, so it serves as a good case 
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study to use as a basis for identifying the general regulatory approach to these types of complex 
devices. The methodology described here for evaluating the Intuitive Da Vinci seeks to give a 
more complete view of how the FDA adapts the existing regulatory process for innovative 
medical devices with high levels of technical complexity and no clear predicate. 
 
4.2 DATA GATHERING AND ANALYSIS 
 
The main objective of this research is to identify publicly available data pertaining to approval of 
medical devices via the 510(k) Process, with a focus on RAS devices, and examine that data to 
draw conclusions about how that process has been implemented. Therefore, the first step to 
conducting my research was to develop a methodology for identifying and compiling pertinent 
publicly available data in FDA databases.  
 
4.2.1 DATABASE EXPLORATION 
 
The FDA maintains a number of different databases related to various aspects of medical device 
regulation, including post-market surveillance, incident reporting, device recalls, and device 
approvals. As illustrated in Figure 1, there are a variety of different methods and databases which 
can be used to identify information relevant to this research. As this research is focused on Class 
II medical devices, the database containing the most directly applicable data is the 510(k) 
approval database. This database was created in the early 1990’s during the implementation of 
the Safe Medical Devices Act, which officially developed the 510(k) Process as a separate 
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approval process, to serve as a centralized location for all information pertaining to 510(k) 
approvals.   
Figure 1: Overview of database structure and locations of useable information for three FDA database searches; 
the 510(k) Database, the Product Code Database, and the Full FDA Website 
 
The existing search mechanisms allows for searches based on keywords, applicant, device name, 
decision date, approving panel, and 510(k) Number. The 510(k) Number (K#) is a unique 
identification number used to track approval applications. A K# corresponds to an approval 
application, which may be for a new device, a new functionality of an existing device, or a 
modification of an existing device. Inputting a search term into the database results in a list of 
relevant results, including the device name, applicant, K#, and decision date, which can be sorted 
alphanumerically based on a selected parameter. Clicking on either the device name or K# within 
the search results brings you to a standardized device-summary page containing information that 
pertains to that 510(k) application. This includes all the searchable parameters present on the 
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main search page, as well as additional information specific to the application filing, such as 
initial application date and applicant contact information, relevant regulations, the review 
information, and in some cases an attached PDF summarizing the information contained in the 
actual application. It is within the attached application summary, if one exists, that information 
required for determination of substantial equivalence, such as predicate devices, intended use, 
indications for use, and scientific evidence may be presented. 
 
In addition to the application summary, another useful piece of information contained on the 
device summary page is the device product classification code. This product code identifies a 
more device-specific classification based on the technological characteristics and intended use of 
a device. (Stuart, J., n.d.) This can be used to identify potential predicate devices based on the 
substantial equivalence parameters for a new device. For this research, it may also be useful to 
identify devices which are predicated on a particular device, information which cannot be easily 
found in the 510(k) database due to the nature of the application summary formatting. 
 
The FDA product classification database functions similarly to the 510(k) database, with a main 
page allowing for searches via parameters including device name, review panel, product code, 
and regulation number. As product classification codes are applied to all medical devices, not 
just Class II devices, the database also allows for specification of parameters based on medical 
device class. 
  
A search via product code results in a code summary window identifying the device to which the 
code pertains, a regulatory description, and details about the regulatory process for devices under 
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this classification. The code summary also includes a link to the Total Product Life Cycle 
(TPLC) Report which summarizes all regulatory activity associated with the code, including 
information about all devices with approval applications filed under this code. This can be used 
to directly identify devices with related predicate histories. 
 
If information about a Class II device cannot be found via the 510(k) or Product Code databases, 
a final option for investigating available public information is the “brute force” method. Rather 
than a targeted search through specialized databases, this method involves entering search terms 
in the general search bar on the FDA web page. This returns results from all FDA publications, 
including database information, conference presentations, regulations, and internal memos. 
Although this method returns significantly more results, the search function offers limited 
filtering options and requires manual sorting to determine whether results are relevant. 
 
4.2.2 DATA COMPILATION 
 
Although data on Class II medical device approvals does exist, multiple databases and layers of 
search results presented in different formats within the databases prevents direct analysis of 
device information and predicate relationships. Instead, manual construction of a separate 
database containing general device information and available approval details was required 
before meaningful data analysis could be performed. Identification of devices for inclusion in a 
manual database was guided by a database construction parameters. The two major construction 
parameters considered for this research were product code classification and predicate 
relationship, meaning a device was either a predicate of or predicated on the device, such as the 
39 
 
Da Vinci, around which the database was constructed. Each newly constructed database included 
the K#, device name, manufacturer, approval date, product code, and any predicate or intended 
use information available for all devices relevant to the database construction parameter.  
 
4.2.2.1 Da Vinci Initial Search 
 
The initial focus of my research was tracing the approval history of the Intuitive Da Vinci 
Surgical System. Using the previously described methodology, I searched the 510(k) database 
for applications filed by Intuitive Surgical and identified an application for the Da Vinci Si 
Surgical system, the second iteration of the device family offered by Intuitive. Examination of 
the regulatory summary revealed that this device is classified under the product code NAY, 
which refers to devices classified with the keywords “System, Surgical, Computer Controlled 
Instrument” under a regulatory description of endoscope and accessories (FDA, Product 
Classification- System, Surgical). 
 
As the Da Vinci was the first device of its kind, devices identified under the product 
classification code NAY are exclusively iterations of the Da Vinci itself, devices which serve as 
direct predicates, or devices that are directly predicated on the Da Vinci. Therefore, I was able to 
use the information contained in the Total Product Life Cycle report to construct a database of 
information about every 510(k) application Intuitive Surgical has ever filed directly related to the 
Da Vinci System. This new database includes the device name, 510(k) number, applicant, 
approval date, predicates identified, and the substantial equivalence determination (See 
Appendix 1).  
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4.2.3 EXPANSION TO RELATED DEVICES 
 
After observing the wide variety of technological characteristics present across a given predicate 
generation in the Da Vinci trace, I looked at how the technological characteristics of the Da 
Vinci compare to other devices in its own generation. While tracing backwards through 
equivalence identifies predicates with different characteristics ultimately present in a subject 
device, tracing forward from a given predicate to subsequent subject devices should reveal a 
group of devices which share the common characteristics of the initial predicate. Based on the 
definition of substantial equivalence, these devices should share a common intended use and 
similar technological characteristics. However, each device may incorporate different 
technological aspects of the identified predicate device(s) along with new technology to develop 
a device with unique benefits for users. As a result, it is possible that significant deviations in 
technological characteristics exist between two subject devices with the same predicate, even if 
the stated intended use is the same. When multiple predicate devices are identified in an approval 
application, the new device design may be composed of a combination of the technological 
characteristics of the predicates, including functions present only in one predicate device, 
potentially creating even more significant deviations in overall device function compared to the 
predicate.  
  
I chose to start my investigation by searching for subject devices predicated on Computer Motion 
Inc.’s Automated Endoscopic System for Optimal Positioning (AESOP) System, rather than any 
devices within the first generation of the Da Vinci trace, for three reasons. The first reason was 
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that the devices contained within the first generation were all identified as components of the 
previous Da Vinci model ISI 1000, which makes it unlikely that any subsequent subject device 
would be predicated on a component rather than the system as a whole. Secondly, the AESOP is 
the first recorded device in the NAY product classification family to which the Da Vinci belongs. 
Although I was already aware through the TPLC Report that no additional devices within this 
product code family were predicated on AESOP, I felt that using this device as the starting point 
would return subject devices with functionality closest to that of the Da Vinci. Finally, AESOP is 
one of the oldest and most well-known devices to appear in the tree, so I felt it was the most 
likely of the devices in the trace to have multiple subject devices predicated on it. 
  
Due to the construction of the 510(k) database, it is essentially impossible to search for a subject 
device, rather than a predicate, without knowing the product code of the device you are searching 
for. As I already knew no eligible devices were present in the NAY classification family, I was 
required to use the brute force approach to identify devices predicated on AESOP. This was done 
by searching the keywords “AESOP” and “Computer Motion” in the overall FDA search bar and 
manually sorting through the results to identify relevant devices. 
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4.2.4 PREDICATE TREE CONSTRUCTION 
 
Using the data gathered in these newly created databases, I constructed predicate trees, structured 
similarly to an ancestry tree, to help identify instances of predicate creep and any patterns present 
in the regulatory history of the device(s). Creation of an equivalence tree is a technique that has 
been used by two other research groups working in the space of FDA regulations to identify 
information present in the predicate history of a specific device. Ardaugh et al (2013) used 
documents obtained through the FDA 510(f) Database and Freedom of Information Act filings to 
trace the predicate history of the DePuy ASR XL Acetabular Cup System, a metal-on-metal hip 
implant, over five decades with the purpose of identifying the cause of safety flaws present in 
this design. Zuckerman et. al (2014) used the FDA 510(k) Database to trace the predicate history 
as far back as available for a random sample of 50 newly cleared devices, with the stated purpose 
of identifying the most recent predicate to present definitive scientific evidence of safety and 
effectiveness to support a claim of substantial equivalence.  Neither article specified the exact 
methodology used to trace predicates, however examination of the database shows that in many 
cases the predicate device(s) is readily identified in the publicly available paperwork. 
 
Following a similar method as Ardaugh et al. (2013) and Zuckerman et al. (2014), I constructed 
an ancestral equivalence tree using the information gathered from the FDA databases as 
described in the previous section. An example structure for a resulting equivalence tree is shown 
in Figure 2 below. 
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Figure 2: Sample predicate tree tracing the history of the “subject” device and illustrating major structural 
elements including a predicate generation (blue) and a predicate branch line (red). 
 
As illustrated in the sample predicate tree above, the subject device is the device from which the 
predicate trace originates. A question mark in the trace indicates that the device was approved 
via the 510(k) Process, indicating that a predicate device does exist, but there is insufficient 
information available in the databases to identify that predicate. For this research, a predicate 
generation is identified as a group of predicates that are the same number of steps removed from 
the subject device. The generation number is the total number of steps between the predicate and 
main subject device. For example, the generation identified in blue in Figure 2 is the 2nd 
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generation and contains a total of 3 different devices, C, D, and E. A branch is defined as a group 
of devices whose relation can be traced directly through single-step substantial equivalence 
determinations. In this example devices E, H, I, and J all belong to the device B branch. A 
branch line is a more specific group of devices which belong to a single branch, with each device 
belonging to a different generation as shown in red in Figure 2. Ultimate or originating 
predicates are defined as the oldest devices to which a branch line(s) can be traced, such as 
Predicates J for the sample branch line shown above. For purposes of clarity when discussing 
findings, a device within an ancestral trace will be defined based on the presence of a unique K-
number, even in cases where multiple K-numbers have been identified as part of a single device.  
 
For devices where overlapping or increased numbers of predicates appear make traditional tree 
diagrams unwieldy, an alternate diagram structure known as a network map was used to display 
predicate relationships within the approval ancestry. A network map represents each unique 
device with a dot corresponding in size to the number of predicate relationships associated with 
that device. The dots are arranged from left to right in reverse chronological order beginning 
from the subject device, in a similar manner to that shown in Figure 2. Each predicate 
relationship is represented by an arrow between two dots, with the arrowhead pointing from the 
subject device towards the predicate. Unlike the traditional ancestry tree structure illustrated in 
Figure 2, predicate arrows within a network map can overlap, create a significantly more 
compact diagram. 
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4.3 IDENTIFICATION OF PREDICATE CREEP 
 
Predicate creep is the introduction of technology creep into the 510(k) Process via the substantial 
equivalence relationship between devices. Researchers have theorized that accumulation of 
predicate creep may ultimately result in the approval of devices which possesses significantly 
different technological characteristics than earlier predicates with little assurance of safety, due 
to the minimal evidentiary requirements of the 510(k) Process. However, due to the nature of 
information contained within the public 510(k) databases, it is impossible to determine exactly 
what level of scientific evidence was provided to support each substantial equivalence claim. 
Therefore, this research focuses on identification of gradual changes in the technological 
characteristics of devices over multiple predicate generations based on small changes made 
within each predicate relationship. 
 
For this research, predicate creep is identified using three primary methods: direct comparison of 
technological characteristics, comparison via regulatory structures, and presence of multiple 
predicate devices. Direct comparison of technological characteristics is the traditional method for 
identifying technology creep involving identification of the technological characteristics of two 
or more related devices and observation of changes in technical characteristics between them. 
For this research, devices will be compared along branch lines, using the identified predicate 
relationship as a basis for comparison, and within a predicate generation. This method can be 
used to identify specific instances of predicate creep and illustrate potential impacts it may have 
on device functionality and safety. 
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In addition to direct comparison of technological characteristics, a second method for identifying 
predicate creep is through the use of existing mechanisms or structures which identify 
characteristics of the technology from a regulatory perspective. FDA product codes are 
particularly useful for this purpose, as they are designed to identify groups of devices with the 
same intended use and technological characteristics. As possessing the same intended use is a 
requirement for approval via substantial equivalence, it follows that any device approved via 
510(k) with a different product code that the predicate must either possess different technological 
characteristics, or be in violation of the requirements for substantial equivalence. Therefore, the 
introduction of new product codes in the predicate ancestry tree should be indicative of the 
introduction of new technological characteristics.  
 
Another indicator of technological creep within the approval tree is the presence of multiple 
predicate devices. Although it is perfectly permissible to have multiple predicated with the same 
intended use and extremely similar technological characteristics present on a 510(k) application, 
the inclusion of both devices is redundant if the subject device also possesses the same 
characteristics. Instead, an application including multiple predicate devices is often used when a 
new device contains a unique combination of the different technological characteristics present 
in the predicate devices. Although the technological characteristics of the subject device did exist 
individually before, they are present in this device in a unique combination that did not exist 
previously, which is a form of predicate creep.    
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4.4 PATTERNS IN THE REGULATORY HISTORY 
 
Patterns in the regulatory history will be identified using a combination of qualitative and 
quantitative observation to draw conclusions about how the general guidelines of the 510(k) 
Process have been implemented in practice by regulators and process users. As predicate creep, 
these patterns will be identified using the manually constructed databases and predicate approval 
trees developed from publicly available FDA data. Observations made during this portion of the 
analysis will include whether there is a common methodology used during the 510(k) application 
process for selection of predicate devices, the level of overlap between different predicate traces, 
comparison of the number of predicates identified in different traces, and other general 
observations. 
 
In addition to general observations, data collected from the FDA Medical Device Recall 
Database will be used to identify devices with documented safety concerns. Although it is 
difficult to identify the scientific evidence presented to support claims of safety between 
predicates, a correlation between the presence of predicate creep and issued recalls would be 
indicative that concerns expressed by researchers surrounding the effects of predicate creep are 
founded. 
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5 DATA ANALYSIS 
5.1 INITIAL PREDICATE TRACE DEVELOPMENT 
 
Using the information in the newly constructed NAY Product Code database, I was able to 
identify the earliest iteration of the Da Vinci System known as the Da Vinci Surgical System 
Model ISI 1000, which was first approved on May 30th, 2001. However, the 510(k) database 
contained no application summary or information regarding the direct predicates used in the 
approval process. Further investigation via additional FDA databases and Intuitive Surgical’s 
website revealed no additional information regarding the approval process for this model. In fact, 
Intuitive does not list or reference this model anywhere on its website (Intuitive Surgical, 2018).  
 
Although this the lack of information on the first Da Vinci System poses a problem for this 
investigation, information is available for the next iteration of the device approved in June 2002, 
the Da Vinci Surgical System Model IS1200. Using the information obtained from the TPLC 
Report, I was able to obtain the 510(k) application number for this device, K021036, which in 
turn allowed me to obtain the application summary. 
  
From the application summary I was able to identify the predicate of the Da Vinci Model IS1200 
as the Da Vinci Surgical System Model ISI 1000. This application referenced four K-numbers 
associated with the predicate device, including K011002, the number previously identified and 
investigated without success. Using the information found in the 510(k) database for the 
remaining three K-numbers and subsequently identified predicates, I was able to construct an 
ancestral equivalence tree going back four generations on the longest branch. 
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Figure 3: Intuitive Da Vinci Model IS1200 predicate ancestry tree, with predicates identified by K# (see Table 2 for 
device descriptions) and substantial equivalence relationships numerically identified in grey circles (see Table 3 for 
device characteristic comparisons). 
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There are a total 14 predicate devices listed in this tree, with four devices in the first generation, 
eight in the second, and two in the third. The tree contains 11 unique branch lines, but only two 
primary multi-generational branches. Unfortunately, the size of this trace is limited by the 
availability of information in the database, with the oldest identified predicate device receiving 
approval only ten years before the subject device, in May 1992. Additionally, one identified 
predicate device, K975001, was listed by K#, name, and manufacturer on the application 
summary for the Intuitive Surgical Reposable Endoscopic Instruments and Accessories, but no 
record of that K# or device exists in the 510(k) database. Further examination revealed that the 
identified device possessed the same name, Intuitive Surgical Endoscopic Instrument Control 
System and Select Instruments, as is identified by K002489 and within the application summary 
of K965001, which suggests that this may be an earlier model of the Intuitive Endoscopic 
Control System. However, the non-existence of the device within the 510(k) database and the 
extreme similarity between its identified K# K975001and the K# K965001, which was identified 
by the same name, leads me to believe that this may have been an error on the part of the 
summary writer, and that the correct predicate device may in fact be K965001. However, for 
purposes of this analysis I used the information as found in the database, regardless of suspected 
errors. Table 2 below contains a summary of the devices identified in this trace, including the 
stated intended use (if available), product code, and a brief device description. 
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Table 2: Summary of information for device contained within the Da Vinci IS1200 predicate history, including the 
intended use (if indicated) and a brief description of the technical characteristics of each device, 
K-Number Device Name Manufacturer 
Approval 
Date 
Product 
Code 
Intended Use* Device Description 
K021036 
Da Vinci Surgical System, 
Model Is1200 
Intuitive Surgical, 
Inc. 
6/26/2002 NAY 
Assist in accurate 
control of endoscopic 
instruments during 
laparoscopic surgical 
procedures 
Three manipulator arms (8 DOF 
each) with attached endoscope and 
endoscopic instruments, controlled 
by a surgeon from a console with a 
3D vision system, used to perform 
laparoscopic surgical procedures 
K965001 
Monarch Laparoscopic 
Manipulator ** 
Intuitive Surgical, 
Inc. 
7/31/1997 GCJ 
Precise and accurate 
control of instruments 
during thoracoscopic 
and laparoscopic 
surgical procedures 
Multiple manipulator arms (8 DOF 
each) with attached endoscope and 
endoscopic instruments controlled 
from a surgeon console to view and 
perform surgical procedures 
K002489 
Da Vinci Endoscopic 
Control System 
Intuitive Surgical, 
Inc. 
3/2/2001 NAY  
Multiple manipulator arms (8 DOF 
each) with attached endoscope and 
endoscopic instruments controlled 
from a surgeon console to view and 
perform surgical procedures 
K011002 
Da Vinci Surgical System, 
Model ISI 1000 
Intuitive Surgical, 
Inc. 
5/30/2001 NAY 
Assist in accurate 
control of endoscopic 
instruments during 
laparoscopic surgical 
procedures 
Two manipulator arms (8 DOF 
each) with attached endoscope and 
endoscopic instruments, controlled 
by a surgeon from a console with a 
3D vision system, used to perform 
laparoscopic surgical procedures 
K990144 
Intuitive Surgical Reposable 
Endoscopic Instruments 
and Accessories 
Intuitive Surgical, 
Inc. 
7/11/2000 NAY 
Assist in accurate 
control of endoscopic 
instruments during 
laparoscopic surgical 
procedures 
Various endoscopic instruments 
with control interfaces designed for 
use with the Intuitive Endoscopic 
Control System 
K931783 
AESOP (Automated 
Endoscopic System for 
Optimal Positioning 
Computer Motion, 
Inc 
11/22/1993 GCJ  
An endoscopic telemanipulator 
consisting of a motorized arm with 6 
degrees of freedom, controlled by a 
foot pedal to manipulate and 
stabilize an endoscope 
K936308 
Endex Endoscopic 
Positioning System 
Andronic Devices, 
Ltd. 
3/31/1994 FQO  
A jointed arm which can be 
manually positioned by a surgeon to 
position and stabilize an 
endoscope. A single motor-driven 
linear joint (1 DOF) controlled by a 
foot pedal is used to move the 
endoscope into and out of the body. 
K914190 
Auto Suture(R) Endoscopic 
Fan Retractor 
United States 
Surgical, A Division 
of Tyco Healthcare 
5/6/1992 GAD  
An endoscopic instrument with 
multiple prongs which can be 
expanded inside the body using a 
cable-driven mechanism into a fan-
like shape to keep tissue away from 
the operating area. 
K933169 Endoscopic Blunt Dissector 
Inman Medical 
Corp. 
4/19/1994 GCJ  
A manually controlled endoscopic 
instrument with a rounded tip used 
to manipulate tissue during 
laparoscopic surgical procedures 
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K-Number Device Name Manufacturer 
Approval 
Date 
Product 
Code 
Intended Use* Device Description 
K953059 Kittner Dissector 
Medical 
Perspectives Corp. 
9/14/1995 GDY  
A non-absorbable gauze sponge for 
use with an endoscopic blunt 
(rounded tip) dissector 
K931340 Endoscopic Instruments 
Baxter Healthcare 
Corp. 
7/1/1993 GCS  
Various manually positioned, motor 
driven endoscopic instruments 
including grasp forceps, scissors, 
dissectors, and a needle holder 
K960400 
Diamond-Touch And Micro 
Diamond-Touch 
Instruments/Diamond-Line 
Instruments/Diamond-Port 
(Access Parts) 
Snowden-Pencer 3/12/1996 
FBM 
GCJ 
GEI 
Various endoscopic 
instruments for use in 
laparoscopic cardiac 
surgical procedures 
Manual endoscopic instruments, 
including an access port, 
endoscopes, needle holders, 
graspers and clamps, scissors, 
probes, knife blade handles, 
clippers, and other instruments 
K975001*** 
Intuitive Surgical 
Endoscopic Instrument 
Control System and Select 
Instruments 
Intuitive Surgical, 
Inc. 
N/A N/A  
Multiple manipulator arms (8 DOF 
each) with attached endoscope and 
endoscopic instruments controlled 
from a surgeon console to view and 
perform surgical procedures 
K930666 
Reusable Laparoscopic 
Instruments W/ 
Electrocautery 
Snowden-Pencer 5/19/1994 GEI  
Various laparoscopic instruments 
with reusable handles which 
incorporate wire electrodes to 
generate heat, which is used to 
burn away unwanted tissue and 
seal blood vessels during surgery 
K930667 
Reusable Laparoscopic 
Instruments 
Snowden-Pencer 5/16/1994 GCJ  
Various laparoscopic instruments 
with reusable handles which 
 
*Intended use information only available for devices with approval application summaries present in the public 
510(k) database 
 
** The name for this device referenced in the approval application summary is the Intuitive Surgical Endoscopic 
Instrument Control System 
 
*** This device is referenced in the approval summary for K990144 by K# and Device Name. However, the K# 
listed does not appear in the FDA database, and the name corresponds with K965001 
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The Da Vinci IS1200 trace includes devices from eight unique manufacturers, although 
Computer Motion later combined with Intuitive Surgical in 2003. Devices belong to eight unique 
device product code classifications. It is worth noting that in addition to the four K-Numbers 
marketed under the Da Vinci Model ISI 1000 (those in the first predicate generation), K-
Numbers K930666 and K930667 are both associated with the Snowden-Pencer Reusable 
Laparoscopic Instruments. This means that this trace contains only 9 unique devices which were 
manufactured and introduced to the market, compared to 14 difference devices when referenced 
from a regulatory perspective. Since the successful performance of each predicate device on the 
market is part of the body of evidence to support the safety claims of the new device, a smaller 
number of unique devices with market performance data effectively reduces the level of 
assurance of safety for the subject device, in this case the Da Vinci IS1200. 
 
To identify instances of predicate creep within the trace, I have compiled in Table 3 a list of the 
technological differences between each of the subject-predicate pairs present in this trace. The 
numbered predicate relationship corresponds to the numbers identified in grey in Figure 
 3. 
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Table 3: Differences in technological characteristics between the two devices in each predicate relationship 
(identified by number in Figure 3) within the Da Vinci IS1200 approval history 
Predicate 
Relationship 
Subject Device Predicate Device 
New Technological Characteristics 
in Subject Device 
1 
Da Vinci Surgical System, 
Model IS1200 
Monarch Laparoscopic 
Manipulator 
The IS1200 incorporates a 3D vision system 
and specialized endoscopic instruments 
designed to mimic the motion of a human wrist 
2 
Da Vinci Surgical System, 
Model IS1200 
Da Vinci Endoscopic Control 
System 
The IS1200 incorporates a 3D vision system 
and specialized endoscopic instruments 
designed to mimic the motion of a human wrist 
3 
Da Vinci Surgical System, 
Model IS1200 
Da Vinci Surgical System, Model 
ISI 1000 
The IS1200 includes updated software and a 
3rd manipulator arm 
4 
Da Vinci Surgical System, 
Model IS1200 
Intuitive Surgical Reposable 
Endoscopic Instruments and 
Accessories 
The Da Vinci includes a surgeon console, 3D 
vision system and manipulator arms for control 
and positioning of existing endoscopic 
instruments 
5 
Monarch Laparoscopic 
Manipulator 
AESOP (Automated Endoscopic 
System for Optimal Positioning 
The Monarch includes multiple teleoperated 
arms with increased range of motion, is 
controlled from a surgeon console, and is used 
to perform surgical procedures using 
endoscopic instruments in addition to 
positioning and stabilization of an endoscope 
6 
Monarch Laparoscopic 
Manipulator 
Endex Endoscopic Positioning 
System 
The Monarch includes multiple teleoperated 
arms with increased range of motion, is 
controlled from a surgeon console, and is used 
to perform surgical procedures using 
endoscopic instruments in addition to 
positioning and stabilization of an endoscope 
7 
Monarch Laparoscopic 
Manipulator 
Auto Suture(R) Endoscopic Fan 
Retractor 
Monarch incorporates articulated instrument 
control arms and multiple instruments operated 
from a console 
8 
Monarch Laparoscopic 
Manipulator 
Endoscopic Blunt Dissector 
Monarch incorporates articulated instrument 
control arms and multiple instruments operated 
from a console 
9 
Monarch Laparoscopic 
Manipulator 
Kittner Dissector 
Monarch incorporates articulated instrument 
control arms and multiple instruments operated 
from a console 
10 
Intuitive Surgical Reposable 
Endoscopic Instruments and 
Accessories 
Baxter Healthcare Endoscopic 
Instruments 
The Intuitive instruments have a unique control 
interface which enables use with the Intuitive 
Endoscopic Control System 
11 
Intuitive Surgical Reposable 
Endoscopic Instruments and 
Accessories 
Diamond-Touch And Micro 
Diamond-Touch 
Instruments/Diamond-Line 
Instruments/Diamond-Port 
(Access Parts) 
The Intuitive instruments have a unique control 
interface which enables use with the Intuitive 
Endoscopic Control System 
12 
Intuitive Surgical Reposable 
Endoscopic Instruments and 
Accessories 
Intuitive Surgical Endoscopic 
Instrument Control System and 
Select Instruments 
No technological changes identified between 
instruments 
13 
Diamond-Touch And Micro 
Diamond-Touch 
Instruments/Diamond-Line 
Instruments/Diamond-Port 
(Access Parts) 
Reusable Laparoscopic 
Instruments W/ Electrocautery 
No technological changes identified 
14 
Diamond-Touch And Micro 
Diamond-Touch 
Instruments/Diamond-Line 
Instruments/Diamond-Port 
(Access Parts) 
Reusable Laparoscopic 
Instruments 
No technological changes identified 
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An initial overview of the technological differences identified in Table 3 reveals that almost 
every device present in the trace demonstrated some level of technological creep. In some cases, 
technology creep was limited to the introduction of a new mechanical control interface or the 
addition of an extra arm, but in other cases the degree of technological difference is striking. This 
is most conspicuous in the comparison of the various endoscopic instruments to the Monarch 
Laparoscopic Controller, which incorporates telemanipulator arms and a surgeon console to 
move the instruments and perform procedures. However, the Monarch is a system which 
incorporates versions of these instruments, so it appears that they are serving as predicates only 
for the endoscopic end effectors and are not intended to provide any assurance of safety or 
efficacy for the system as a whole. However, the technological gap between the AESOP and 
ENDEX Systems and the Monarch is still quite large. The Monarch not only incorporates 
additional degrees of freedom into the manipulator arm, but it also consists of multiple arms, is 
controlled by a surgeon sitting at a separate viewing console, and is used to perform actual 
surgical procedures without the surgeon directly contacting the patient. This is a huge change in 
technology within a single predicate relationship.  
 
5.2 EXPANSION TO RELATED DEVICES 
 
Examination of the wide variety of technological characteristics present across a given predicate 
generation in the Da Vinci IS1200 trace led me to wonder how the technological characteristics 
of the Da Vinci compare to other devices in its own generation. Therefore, I decided to identify 
other devices which share a common predicate with the Da Vinci IS1200, in order to identify the 
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degree of difference between different devices within the same technological generation and 
theoretically also the same device family. The predicate which I chose to base my trace off of 
was the AESOP system, both because it is the oldest device within the IS1200 trace which is not 
a basic surgical instrument, and because it is the ultimate predicate which is most similar to the 
Da Vinci in terms of technological characteristics, complexity, and function. 
 
5.2.1 DEVICE IDENTIFICATION 
 
While tracing backwards through substantial equivalence relationships identifies predicates with 
different characteristics ultimately present in a subject device, tracing forward from a given 
predicate to subsequent subject devices should reveal a group of devices which share the 
common characteristics of the initial predicate. Based on the definition of substantial 
equivalence, these devices should share a common intended use and similar technological 
characteristics. However, this type of tracing is extremely difficult to do within FDA databases, 
as devices approved based on a specific device are not identified anywhere in that device’s 
approval information. Therefore, I used the brute-force search methodology to identify a total of 
seven additional devices predicated on AESOP, including a newer model of the AESOP system. 
The ancestry of each device was then traced to construct a tree connected to the Da Vinci trace as 
shown in Figure 4. Rather than identify generations based on predicate distance, the number of 
predicates between the two devices, for this tree generations were grouped based on the number 
of subject devices between the two devices, known as subject device distance. As a result, while 
previous trees were constructed to trace the approval history of a device backwards in time 
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through predicate generations, this tree was used to trace forwards in time and identify 
generations of subject devices approved based on the AESOP System. 
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 Figure 4: Ancestry tree illustrating devices predicated on the AESOP System. Arrows indicate a substantial 
equivalence relationship pointing from newer subject device to older predicate device, with “subject generation 
zero” including the oldest devices (far right). 
The trace above illustrates the substantial equivalence relationships between the devices 
predicated on the AESOP system. To identify any safety issues identified while on the market, 
each device was run through the FDA recall database. Of the eleven devices included in this 
trace, only the Da Vinci model IS1200 had any recalls associated with it. The IS1200 has 
undergone a total of 18 Class II recalls, recalls of moderate severity, ranging from user manual 
mistakes to incorrect component installation which may cause power loss. Table 4 (below) 
provides additional information about the devices in this trace, along with a brief technical 
description of each device. 
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Table 4: Summary of Devices in Expanded AESOP Trace  
510(k) 
Number 
Device 
Name 
Manufacturer 
Approval 
Date 
Product 
Code 
Device Description 
Generation 
(Subject) 
K931783 
AESOP 
Laparoscopic 
Positioning and 
Control System 
Computer Motion 11/22/93 GCJ 
An endoscopic telemanipulator consisting 
of a motorized arm with 6 degrees of 
freedom, controlled by a foot pedal to 
manipulate and stabilize an endoscope 
0 
K922626 
Endex 
Endoscopy 
Instrument 
Positioning 
System / Adept 
Instrument 
Positioning 
System 
Andronic Devices 10-19-92 GAD 
A jointed arm which can be manually 
positioned by a surgeon to position and 
stabilize an endoscope. A single motor-
driven linear joint (1 DOF) controlled by a 
foot pedal is used to move the endoscope 
into and out of the body. 
0 
K973249 EndoAssist 
Armstrong 
Healthcare 
Limited 
11/26/97 GCJ 
A freestanding arm mounted on an 
extended boom with 2 DOF. It is 
controlled by a head-tracking system 
which tracks the head motion of the 
surgeons and is engaged using a foot 
pedal. 
1 
K972699 AESOP 3000 Computer Motion 12/19/97 GCJ 
An endoscopic telemanipulator consisting 
of a motorized arm with 6 degrees of 
freedom, controlled by a foot pedal to 
manipulate and stabilize an endoscope 
1 
K050027 
Laparocision 
Scope Controller 
System 
GMP 1/25/05 GCJ N/A 1 
K965001 
Monarch 
Laparoscopic 
Manipulator 
INTUITIVE 
SURGICAL, INC. 
7/31/1997 GCJ 
Multiple manipulator arms (8 DOF each) 
with attached endoscope and endoscopic 
instruments controlled from a surgeon 
console to view and perform surgical 
procedures 
1 
K082233 ViKY EndoControl 12/18/08 GCJ 
An endoscope holder consisting of a 
jointed arm with three actuated degrees 
of freedom which can be attached directly 
to an operating table and a command 
from which the surgeon can control 
position using a footswitch or verbal 
commands 
1, 2 
K021036 
Da Vinci 
Surgical System, 
Model IS1200 
INTUITIVE 
SURGICAL, INC. 
6/26/2002 NAY 
Three manipulator arms (8 DOF each) 
with attached endoscope and endoscopic 
instruments, controlled by a surgeon from 
a console with a 3D vision system, used 
to perform laparoscopic surgical 
procedures 
2 
K023735 
LapMan 
Laparoscopic 
Manipulator 
Medsys 8/7/07 GCJ 
An actuation arm composed of two 
parallel kinematic joints and one linear 
joint to provide 3 DOF, located on a 
moveable cart and controlled with a 
wireless joystick for use in gynecological 
surgery. 
2 
K043284 EndoAssist 
Armstrong 
Healthcare 
Limited/Prosurgics 
2/25/05 GCJ 
A freestanding arm mounted on an 
extended boom with 2 DOF. It is 
controlled by a head-tracking system 
which tracks the head motion of the 
surgeons and is engaged using a foot 
pedal. 
2, 3 
K090340 Freehand Prosurgics 5/22/09 GCJ 
A portable arm mounted to the operating 
table with 3 DOF. It is controlled by a 
head-tracking system which tracks the 
head motion of the surgeons and is 
engaged using a foot pedal. 
2, 4 
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Including the Da Vinci IS1200, this ancestry tree contains a total of eleven devices spanning four 
equivalence generations (plus the originating generation). These devices are classified under 
three different product codes; 1 device under code NAY, 1 device under code GAD, and the 
remaining 9 under GCJ. The common use of product code GCJ implies that the technological 
characteristics of the majority of devices contained in the trace should be extremely similar.  The 
only devices not classified under product code GCJ, which refers to devices described as 
“endoscope and accessories” for laparoscopic and general surgery (FDA, 2018d), are the 
originating predicate devices and the Da Vinci itself.  
 
Except for the Da Vinci, all the devices within this trace share two originating predicates, the 
Endex Instrument Positioning System and the AESOP system. The Endex System is classified 
under code GAD, which refers to a retractor with a regulatory description of “manual surgical 
instrument for general use” (FDA, 2018d). Code NAY, under which the Da Vinci is classified, 
refers specifically to computer controlled surgical devices with the base function of “endoscope 
and accessories” (FDA, 2018c). Code GCJ has a more general device description than code 
NAY, similar to code GAD, although devices classified under this code share similar technical 
characteristics to devices in code NAY, such as the inclusion of a manipulator arm. However, the 
addition of “computer controlled” to the device description for code NAY implies that the level 
of technical complexity in the control system of Da Vinci may be higher than in other devices in 
this trace classified under code GCJ, despite sharing the same regulatory description of 
“endoscope and accessories”.  This correlation between changes in product code classifications 
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and technical complexity is supported by the comparison of actual device technical 
characteristics as described in Table 4. 
 
5.2.2 OBSERVATIONS 
 
Inspection of the predicate relationships within the AESOP subject device trace reveals an 
interesting pattern. Although there were six additional subject devices introduced in this tree, 
tracing the branch lines of the devices creates a web where the subject device equivalence refers 
to earlier existing predicates multiple times. This results in an equivalence tree with only two 
ultimate predicates, AESOP and the Andronic Endex Instrument Positioning System. Only the 
Da Vinci refers to a different set of ultimate predicate devices. Although this interrelatedness is 
not entirely unexpected, as there are a limited number of devices available to serve as predicates 
for any given device function, it does make the width and variety of the Da Vinci trace appear 
unusual. Considering the technological characteristics of the devices, one possible implication of 
the size of the Da Vinci trace, which is primarily caused by the presence of multiple predicated 
for each 510(k) application, is that Intuitive Surgical used multiple predicate devices to justify 
the relatively large differences in technological characteristics when compared directly to each 
individual predicate.  
  
Additionally, the appearance of one predicate device multiple times within the trace in different 
generations illustrates that the intermediary predicates serve as stepping stones, introducing 
slight changes in technological characteristics but ultimately referring back to a single set of 
ultimate predicates. This method introduces new technological characteristics incrementally into 
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the ultimate subject device, while keeping the majority of the dependence for evidentiary support 
of the safety of new characteristics on the ultimate predicate(s).  
 
5.3 EXPANSION TO DA VINCI SI 
 
Due to the age-based limitations of the 510(k) database, it proved to be impossible to expand the 
Da Vinci trace past three predicate generations using publicly available data. As a result, a lack 
of scientific evidence reduces the significance of observations made using the trace. However, 
one option to create a larger ancestral trace is to begin the trace using newer models of the Da 
Vinci. As new technological characteristics, and subsequently new predicate devices, were 
introduced into the Da Vinci S and Si models, the size of the traceable ancestry tree expanded. 
Patterns identified in this larger trace may be more indicative of the regulatory behavior on the 
part of both Intuitive Surgical and the FDA. 
 
5.3.1 PREDICATE ANCESTRY TRACE 
 
The predicate ancestry of the Da Vinci Si Model was traced using the same method described 
previously for the Da Vinci IS1200 predicate tree development. Unlike the previous trees, the 
number of devices and predicate relationships contained in this trace is too large to be easily 
illustrated with a traditional ancestry tree diagram, so an alternative diagram was constructed 
using network mapping techniques as shown in Figure 5.   
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Within this network mapping diagram each device is represented by a dot, with the dot size 
increasing based on the total number of substantial equivalence relationships that device is 
involved in. Substantial equivalence relationships (also known as predicate-subject device 
relationships) are represented by lines drawn between the two devices involved. Each dot is 
labeled with the K# of the device which it corresponds to. The trace begins with the main subject 
device (i.e. the Da Vinci) on the left side of the trace, and advances toward the left, with each 
line originating at a subject device and terminating at its respective predicate. Therefore, the 
oldest devices present in the trace are located on the right side, although vertical alignment does 
not correlate exactly to approval date, and the newest devices are to the left of the trace. 
 
Figure 5: Expanded Da Vinci Si predicate trace originating from the Da Vinci Si (far left) with each predicate 
device represented by a dot and identified by K# (see Appendix 2). Trace lines indicate substantial equivalent 
relationships with the arrowhead pointing towards the predicate device and relative dot size indicating the number 
of substantial equivalence relationships associated with each device. 
 
64 
 
The expanded equivalence tree, which uses the Da Vinci Si as the subject device, includes 2618 
device instances, with a total of 50 unique devices. The unique devices within this trace are 
classified under a total of 15 different product codes, with the majority of devices, including the 
various Da Vinci models, categorized under code NAY. Additional information about each 
device, including the manufacturer, approval date, and any recalls issued, can be found in 
Appendix 2.  
 
Recall data from the FDA database, which tracks recalls issued by the manufacturer either due to 
an error identified internally or in response to a series of incidents traced directly to a problem 
with the device, was used to identify devices in the Da Vinci ancestry with significant safety 
issues. The FDA classifies recalls based on the severity of potential impact to the patient. Class 
III recalls are minor and not likely to cause any adverse health effects. Class II recalls occur 
when exposure may cause temporary or reversable adverse health effects, or where there is a low 
probability of serious adverse effects. Class I is the most severe type of recall, in which there is a 
reasonable probability that exposure will result in serious adverse effects or death. While a 
couple of Class II or III recalls will likely have minimal effect on overall device safety, repeated 
Class II recalls or any Class I recall is directly indicative of potential device issues.  
 
Of the 50 devices included in the Da Vinci Si trace, 7 devices, all manufactured by Intuitive 
Surgical as part of a DaVinci system, had multiple recalls associated with the device. These 
recalls include 18 for the Da Vinci Model IS1200, 43 for the Da Vinci IS2000 (aka Da Vinci S), 
and 24 for the Da Vinci Si. All the recalls associated with these devices were Class II, which 
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means that although there was no immediate risk of patient death due to the issue, there was still 
significant risk of harm to the patient.  
 
 
Figure 6: Da Vinci Si Trace with devices which have undergone 3 or more recalls highlighted in red. 
 
When the devices with associated recalls are highlighted in the ancestry trace, it becomes clear 
that all of these devices are newer, complex devices which were approved relatively recently. 
Furthermore, despite the high numbers of recalls associated with early Da Vinci models, 
Intuitive continued to release subsequent Da Vinci models whose approval was directly reliant 
on the previous models. 
 
Looking at the overall spread of the ancestry trace, certain patterns within the predicate structure 
begin to emerge. The initial central portion of the trace includes a number of devices with many 
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overlapping substantial equivalence lines. These devices are mostly developed by Intuitive 
Surgical, with the majority of identified as either sub-components or iterations of the Da Vinci 
Surgical System. However, as the trace expands the inter-related predicates are replaced with 
five distinct groups of predicate devices with no overlap between substantial equivalence lines. 
Each group appears to contain devices with similar characteristics, where each of the five groups 
representing diverse technological characteristics which were later combined together to form 
the more complex Da Vinci system. 
 
Figure 7: Da Vinci Si trace with the five distinct predicate branches highlighted. 
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5.3.2 GROUPING VIA REGULATORY MECHANISMS 
  
Considering the size of this data set, attempting to identify the exact technological characteristics 
of each device contained within to try to identify specific examples of predicate creep would be 
extremely difficult and time consuming. However, categorizing the devices in the trace by 
product code can help identify patterns within the trace using more general device characteristics 
to identify trends over time. 
 
A list of the codes, the device identification key, and the regulatory description for each code is 
shown in the table below. The device identification key is a set of functions or characteristics 
which distinguish devices in that product classification, while the regulatory description is the 
primary function or intended use as identified by the FDA. 
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Table 5: Product Codes in Da Vinci Si Trace 
Code # Devices Device Identification Regulatory Description 
FBM 1 Cannula and Trocar, Suprapubic, Non-Disposable 
Suprapubic urological catheter and 
accessories 
NEY 3 System, Ablation, Microwave and Accessories 
Electrosurgical cutting and coagulation device 
and accessories 
NAY 17 System, Surgical, Computer Controlled Instrument Endoscope and accessories 
HET 1 Laparoscope, Gynecologic (And Accessories) Gynecologic laparoscope and accessories 
GEI 5 Electrosurgical, Cutting & Coagulation & Accessories 
Electrosurgical cutting and coagulation device 
and accessories 
LFL 4 Instrument, Ultrasonic Surgical N/A 
OCL 5 
Surgical Device, For Cutting, Coagulation, And/Or 
Ablation of Tissue, Including Cardiac Tissue 
Electrosurgical cutting and coagulation device 
and accessories 
GEH 6 Unit, Cryosurgical, Accessories Cryosurgical unit and accessories 
GCJ 6 Laparoscope, General & Plastic Surgery Endoscope and accessories 
GDY 1 Gauze/Sponge, Internal, X-Ray Detectable Nonabsorbable gauze for internal use 
FQO 1 Table, Operating-Room, Ac-Powered 
Operating tables and accessories and 
operating chairs and accessories 
GCS 1 Endoscope, Battery-Powered and Accessories Endoscope and accessories 
GAD 1 Retractor Manual surgical instrument for general use 
MAV 1 Syringe, Balloon Inflation Angiographic injector and syringe 
HQO 1 Unit, Cautery, Thermal, Ac-Powered Thermal cautery unit 
 
A breakdown of the devices present in the trace color-coded by product code is pictured in 
Figure 8 below. The most prevalent code is NAY for computer controlled surgical systems, as 
mentioned previously. The next two most prevalent codes are GEH for cryosurgical units and 
GCJ for general laparoscopic surgery. Color-coding devices by code highlights common device 
functions within the trace and allows for easy identification of technical characteristics as they 
evolve through predicate generations.  
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Figure 8: Da Vinci Si Trace with devices color-coded by product classification code (See Appendix 3 for full list of 
product code definitions). 
 
Looking at the tree breakdown by product code in Figure 8, we can see the progressive evolution 
of devices from more general laparoscopic surgical tools (to the right) to the more 
technologically complex computer-controlled system of the Da Vinci. The five distinct branches 
identified earlier emerging from the intertwined trace center are each dominated by one or two 
distinct product codes, while the devices within the central web belong almost exclusively to the 
same product classification as the Da Vinci. This implies that the technological characteristics 
the FDA uses to identify devices belonging to code NAY are a combination of the characteristics 
present in each distinct predicate group. This illustrates how larger “jumps” in technological 
complexity of devices new devices can occur through the 510(k) Process, by combining the 
characteristics of multiple well-understood devices into a new type of device. 
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Another perspective to examine the technological evolution within the ancestral trace is based on 
the regulatory description rather than the product code. While the product code considers both 
the intended use and specific characteristics of a device, the regulatory description is a broader, 
more general description based on the function of the device as defined by the FDA. For 
example, the specific device description for product code GCJ is “laparoscope, general and 
plastic surgery,” which specifies both a particular type of device and use, while the regulatory 
description “endoscope and accessories” specifies only a general classification of devices. 
Because of these broader descriptions, there is often overlap between the regulatory descriptions 
of different product codes. In this trace, devices from 15 product codes can be placed into 11 
groups based on regulatory descriptions, resulting in the formation of two larger groups which 
contain the majority of devices within the trace.  
 
The regulatory definition breakdown reveals that approximately half of the devices (24) within 
the trace are classified from a regulatory perspective as endoscope and accessories. A further 
~25% (13 total) are classified as electrosurgical cutting and coagulation devices, devices which 
use a high frequency electrical current to perform surgical operations. 6 of the devices are 
cryosurgical units, all classified under product code GEH, with the remaining devices 
representing a wide variety of functions and characteristics.  
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Figure 9: Da Vinci Si trace sorted by product classification code with the upper predicate branch highlighted for 
identification. 
 
Unlike a grouping by product code, which highlights the evolution of specific technical 
characteristics over time as new codes are introduced to the trace, viewing the trace based on the 
regulatory description highlights groups of predicates based on general device functions. For 
example, in the product code trace the upper branch is comprised of four distinct product codes. 
However, when color-coded by regulatory description it becomes apparent that the originating 
predicate (branch tips) are all cryosurgical units with accessories, which serve as predicates to 
the electrosurgical cutting and coagulation devices the make up the middle of the branch, which 
in turn serve as predicated for the computer controlled surgical devices present in the web center. 
While color-coding by the product code specifically identifies groups of devices which the FDA 
considers similar enough to be substantially equivalent, devices with the same intended use and 
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technological characteristics, color-coding by regulatory description makes it easier to trace the 
general progression of technology over time based on the general function of these devices.  
    
Figure 10: Direct comparison of devices in upper Da Vinci Si predicate branch (See Figure 9) color-coded by 
product code (left) and regulatory description (right). The new central group present in the regulatory description 
trace combines two product codes to create a more general device grouping. 
 
Figure 11 shows the devices in the entire DaVinci Si Trace color-coded by regulatory 
description. The teal nodes and lines represent devices approved as “endoscopic instruments and 
control systems” under code NAY. 
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Figure 11: Da Vinci Si Trace with devices color-coded by regulatory description.  
 
This style of coding based on regulatory description also draws attention to predicate devices 
with unusual functional characteristics that do not fit with the primary function of most devices 
within the trace. In some cases, this may be an indication of an unnecessary or ineffective 
predicate relationship, while in others it may be indicative of secondary device functions.  
 
For example, in this trace there is a device identified as a non-absorbable gauze/sponge for 
internal use. This device, the Medical Perspectives Kittner Dissector, is a sponge used during 
surgical procedures to prevent bleeding. It was identified as a predicate of the Monarch 
Laparoscopic Manipulator system, which included customized versions of many basic surgical 
instruments such as gauze. Although there is a purpose for including this device as a predicate 
for a custom surgical tool, this part of the system is secondary to the main function of the Da 
Vinci as a computer controlled surgical system.  
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In fact, sorting predicates by regulatory description appears to allow for easy identification of 
both primary and secondary device functions, based on the prevalence and location of a given 
function in the trace.  Primary device functions would be those identified directly by the 
regulatory description of the given device, while secondary functions would be functions present 
in predicate devices but absent in the regulatory description of the subject device. The more 
prevalent a function is in the predicate history, the more likely it is to be present in the subject 
device in at least a secondary capacity. Additionally, the significance of a particular secondary 
function to the overall function of the device appears to correspond to the number of predicates 
with that secondary function identified as a primary function. For example, the second most 
prevalent regulatory description in the Da Vinci trace is “electrosurgical cutting and coagulation 
device and accessories,” which corresponds to the function of an essential component of the Da 
Vinci system. Although this is no longer listed as a primary function for the Da Vinci, it is an 
important component of the system. 
 
However, this absorption of a primary predicate device function into a secondary system 
function draws attention to the increasing complexity of devices over time, where the Da Vinci 
represents a particularly large leap in complexity. While the five main predicate branch 
groupings each generally contain one or two primary device functions which evolve and become 
more complex over time, the Da Vinci suddenly combines all those functions together into a 
single device where none of the functions serve as the primary function. The listed primary 
function “endoscope and accessories,” is a very generalized term which only identifies the device 
as one used for internal imaging, even though it includes all the other secondary functions 
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derived from the predicate devices, and is in fact used to directly perform surgeries. This 
indicates that the regulatory description for product code NAY, and possibly other product codes 
classified under this regulatory description, is much too broad to characterize the actual function 
of the devices it describes. 
 
5.3.3 GENERAL TRACE OBSERVATIONS 
 
The overall dimensions of the expanded Da Vinci Si equivalence tree are somewhat unequal, 
with the longest branch-line (depth) among over 100 branches (width) encompassing only 8 
generations. The reason for these uneven dimensions appears to be due to the choice of 
participants in the regulatory process to include inter-related predicates in approval applications. 
That is to say, the application for the Da Vinci Si is predicated on both the Da Vinci S V1.1 and 
the Da Vinci S, even though the Da Vinci S V1.1 is itself predicated on the Da Vinci S. This 
essentially creates a duplicate set of predicates in the ancestral history. This practice of using 
inter-related predicates appears often in the predicate history of the Da Vinci, resulting in an 
extremely wide tree with an extremely high instance of duplication. This is why, although there 
are over 2500 instances of predicates referenced in the trace, less than 2% of those device 
instances are unique. Of those unique devices, just over half of them have identifiable predicate 
device relationships. The remaining 24 ultimate predicates represent devices for which no further 
equivalence information is available, terminating the branch-line trace.  
 
The intention of the current regulatory system is for all devices to be clearly traceable via 
substantial equivalence to a device legally marketed Pre-Amendment or post-amendment 
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through the PMA process. However, only one branch line was traced to an originating predicate 
classified as a Pre-Amendment device. Most ultimate predicates in the Da Vinci trace were 
approved via the 510(k) Process and therefore were declared equivalent to another previously 
cleared device, but the traceability of approval information for older devices is limited by the 
availability of data.  
5.4 TRACE COMPARISON 
 
Investigation into the approval history of the Da Vinci Surgical System revealed evidence of 
technological creep in predicate devices. However, the limited availability of data on older 
predicate devices makes it difficult to trace the origin of many significant technological 
characteristics present in the system, including the use of a computer-controlled manipulator 
arm. Expansion of the substantial equivalence tree to include subject devices in the same 
technological generation as the Da Vinci revealed that, although the devices did share similar 
technological characteristics, the functionality of the Da Vinci system was significantly more 
complex than other devices classified as endoscopic manipulators.  
 
In an effort to determine whether patterns identified in the Da Vinci trace were unique to this 
device or common across the approval process, I made the decision to expand my research to 
other Class II devices. To directly compare the new device traces to that of the Da Vinci, I 
selected devices which the FDA designates as “robotic surgical devices.” Although these 
technologies do not have the exact same intended use as the Da Vinci, they do possess 
technological characteristics which are extremely similar to the Da Vinci. This allowed for direct 
comparison of predicate device relationships and other trace patterns, which in turn allowed me 
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to make broader observations about how the FDA regulates complex surgical technologies 
through the 510(k) Process. 
 
The method used to identify robotic-based surgical systems with similar functions and levels of 
technological complexity as the Da Vinci, was a search of the 510(k) database using the 
keywords “robot” and “surgical system” in the device name category. The search was limited to 
the 510(k) database rather than the wider FDA database in order to identify systems approved 
through the 510(k) Process with a traceable predicate history. The term “robot” returned 62 
results, and the term “surgical system” returned 173 results. Each of these results was then 
reviewed in order to identify systems with similar technological characteristics to the Da Vinci. 
After eliminating devices which did not meet this criteria, and duplicates of devices with 
multiple models on the market, this method resulted in the identification of ten devices for 
investigation (See Table 6). 
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Table 6: Identified Robotic Surgical Devices 
510(k) Number Approval Date Manufacturer Device Name Product Code 
K171120 10/13/2017 TransEnterix, Inc. Senhance Surgical System NAY, GCJ 
K021152 09/24/2002 Computer Motion. Inc. ZEUS' MicroWrist Surgical System NAY 
K072629 8/6/2008 
Integrated Surgical 
Systems, Inc. 
DigiMatch ROBODOC® Surgical System OJP, HAW 
K143420 10/30/15 IMRIS Inc SYMBIS Surgical System HAW 
K101791 9/23/10 MedTech S.A. ROSA Surgical Device HAW 
K172796 01/18/2018 
Medrobotics 
Corporation 
Medrobotics Flex® Robotic System and 
Flex® Transabdominal Drive 
HET, GCJ 
K162330 5/4/17 
Medrobotics 
Corporation 
Flex Robotic System and Flex Colorectal 
Drive 
FDF 
K093425 02/24/2010 MAKO Surgical Corp 
(RIO) Robotic Arm Interactive 
Orthopedic System -THA 
OLO 
K003431 10/05/2001 Computer Motion. Inc. Zeus Robotic Surgical System GCJ 
K003661 10/05/2001 Computer Motion. Inc. Socrates Robotic Telemonitoring System NEQ 
 
Further investigation of these devices revealed some substantial equivalence relationships, where 
one device was predicated on another device identified for investigation, which resulted in the 
creation of four device groups which could each be used to construct a separate predicate tree. 
The Senhance Surgical System, ZEUS MicroWrist Surgical System, and DigiMatch ROBODOC 
were all predicated on an iteration of the Da Vinci System, and could be added to the existing Da 
Vinci Si trace. The SYMBIS Surgical System is predicated on the ROSA Surgical device, and 
the two Medrobotics systems are related to each other. The Zeus and Socrates systems had no 
available predicate information, so they were removed from consideration. Thus, I was able to 
identify a total of three additional systems to trace beginning from the SYMBIS Surgical System, 
MAKO RIO – THA Surgical System, and Medrobotics Flex Transabdominal System (Flex). The 
raw data and an overview of the findings from each trace can be found in Appendices 4, 5, and 6 
respectively. 
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Using the data contained in the four predicate traces described above, it is possible to make 
comparisons between the devices to evaluate the regulatory process. Table 7 contains a summary 
of the information derived from each trace.  
 
 
Table 7: Comparison of Robotic Surgical Device Traces 
 Predicates 
Identified 
Unique 
Devices 
Number of 
Companies 
Ultimate 
Predicates 
Earliest 
Approval 
Date 
Unique 
Codes 
Most 
Prevalent 
Code 
Unique 
Regulatory 
Descriptions 
Most Prevalent 
Regulatory 
Description 
Da Vinci Si 2618 50 18 24 Pre-1976 15 NAY 9 
Endoscope and 
accessories 
SYMBIS 43 26 13 10 6/2/1981 2 HAW 2 
Stereotaxic 
instrument 
RIO - THA 590 53 17 21 12/15/1986 7 HAW 6 
Stereotaxic 
instrument 
Flex 109 42 10 21 1/3/1985 23 GCJ, EOB 10 
Endoscope and 
accessories 
 
 
Comparison of the number of predicate relationships identified in each trace indicates that the Da 
Vinci Si trace is the largest by a significant margin. However, the number of unique devices 
present in each trace indicates that the Da Vinci trace is fact smaller than the RIO -THA trace. 
This discrepancy is due to redundancies in predicate identification, where Intuitive Surgical 
identified the same device as a predicate multiple times within the approval history. Although 
this redundancy is present to some extent within all of the traces, it is far more visible within the 
Da Vinci trace than any of the others. 
 
Comparison of the number of companies present within each trace reveals an interesting pattern 
in the methodology used by companies to select predicate devices. Each trace contains a number 
of companies that is at most half the number of unique devices within the trace. As a limited 
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number of medical device manufacturers exists, and most specialize in a specific type of medical 
device, it is not unexpected that a manufacturer might show up multiple times in a predicate 
trace. However, the number of recurrences of companies listed within these four traces indicates 
this pattern was created by choice rather than coincidence. For example, 38 of the 42 unique 
devices identified within the trace of the Flex System were developed by the Olympus 
Corporation. The common repetition of this pattern across multiple traces indicates that 
manufacturers may be preferentially selecting their own devices to serve as predicates, rather 
than other devices on the market.  
 
This theory is further supported by the lack of overlap between the traces constructed, all of 
which are classified as robotic surgical systems, and which share similar technological 
characteristics. In fact, the only overlap of predicates present in any combination of the four 
traces is a small group of 9 devices in the SYMBIS and RIO traces, all of which serve as ultimate 
predicates or originate ultimate predicate branches, and therefore lack significant connection to 
the core section of the trace. The lack of major overlap between the two traces, even though the 
shared dominant product code and regulatory description indicates that devices contained within 
the trace should be extremely similar, supports the idea that companies are preferentially 
choosing predicate devices with which they are familiar.  
 
The only device identified through this expanded investigation which overlaps more than two 
traces is the DigiMatch ROBODOC, which is predicated on three (K043153, K991081, and 
K052851) present in the Da Vinci Si, SYMBIS, and RIO - THA traces respectively. In fact, the 
ROBODOC is directly predicated on the Da Vinci Model ISI 1000 and the MAKO Voyager 
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Linux with Tactical Guidance System, both important predicates in their respective traces. The 
ROBODOC system uses diagnostic images to assist in planning and performance of total hip 
arthroplasty (THA) procedures under direct control of a surgeon, incorporating additional 
technological components from the Voyager Linux guidance system, and the Da Vinci System, 
which performs surgeries using a robotic arm guided by a surgeon. Although the ROBODOC 
does not serve as a predicate device itself, and therefore cannot be used to make any major 
observations about predicate creep past the technological components it shares with predicates, 
its existence as a device predicated directly on components of multiple major traces investigated 
within this thesis validates the selection of devices for predicate history comparison. 
 
A combined trace of all four RAS systems is shown in Figure 12 below to illustrate the 
relationships between the predicate ancestries. Unlike the diagrams for the individual traces, the 
combined trace originates from the newest devices located at the center of the trace, with older 
devices serving as ultimate predicates located at the outer edges of the combined trace. Each 
RAS System trace is color coded, with the overlap devices between the RIO and SYMBIS trace 
identified in yellow, and the DigiMatch ROBODOC identified in purple. 
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Figure 12: Combined predicate trace of the four robotic surgical systems analyzed, with the newest devices located 
closest to the center of the combined trace. The only overlap between the traces is highlighted in yellow between the 
RIO-THA and SYMBIS traces. 
 
 
Although the Da Vinci Si and Flex Transabdominal System share a common regulatory 
description, if you exclude the ROBODOC, there is no overlap at all between the traces. 
Considering the different intended use and overall technological characteristics of the two 
devices, the lack of overlap is understandable, especially since there is also little overlap between 
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the product codes present in the trace. However, the amount of variation in intended use and 
technological characteristics between devices and traces with a common regulatory description 
does indicate that definitions assigned using the current method may be too broad. In fact, these 
broad regulatory definitions may be contributing to increased levels of technology creep present 
within the 510(k) approval system by allowing approval of devices based on predicates with 
significant technological differences due to the broad terms used in approval applications. 
 
5.4.1  RECALLED PREDICATES 
 
In Section 5.3.1, the devices contained within the predicate ancestry of the Da Vinci Si were 
analyzed through the FDA’s Recall Database to identify potential safety flaws. The results 
included multiple Class II recalls for the Si and many of its immediate predicates, the majority of 
which were classified as robotic surgical devices. While a couple of Class II or III recalls will 
likely have minimal effect on overall device safety, repeated Class II recalls or any Class I recall 
is directly indicative of potential device issues. To determine whether this issue with repeated 
recalls was unique to the Da Vinci product line, or a more general issue with complex robotic 
devices, the devices contained within the SYMBIS, RIO-THA, and Flex Robotic System 
predicate traces were analyzed for comparison. Table 8 below summarizes each instance of 
repeated recalls identified within the traces, with a full overview of recall information included 
in Appendices 2, 4, 5, and 6. 
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Table 8: Summary of predicate devices with more than two registered recalls. Devices are sorted based on which 
device trace they belong to. 
Trace K Number Device Name Manufacturer Approval Date Recalls 
Da Vinci Si 
K081137 
Intuitive Surgical Da Vinci Si Surgical System: 
Model IS3000 
INTUITIVE SURGICAL, INC. 2/18/2009 24 – Class II 
K063220 Da Vinci S Surgical System-V1.1, Model IS2000 INTUITIVE SURGICAL, INC 12/1/2006 4 – Class II 
K050369 
Intuitive Surgical Da Vinci Surgical System, 
Model IS2000 
INTUITIVE SURGICAL, INC. 4/29/2005 43 – Class II 
K021036 
Intuitive Surgical Da Vinci Surgical System, 
Model IS1200 
INTUITIVE SURGICAL, INC. 6/26/2002 18 – Class II 
K012833 Intuitive Surgical Bipolar Forceps INTUITIVE SURGICAL, INC 11/16/2001 4 – Class II 
SYMBIS K101791 ROSA SURGICAL DEVICE MEDTECH SAS 9/23/2010 12 – Class II 
K092239 ROSA SURGICAL DEVICE, MODEL ROSA 1.1 MEDTECH S.A. 11/17/2009 9 – Class II 
K050438 STEALTHSTATION SYSTEM UPDATE 
MEDTRONIC SURGICAL 
NAVIGATION TECHNOLOGIES 
6/2/2005 11 – Class II 
RIO – THA 
K060336 
NAVITRACK SYSTEM-OS KNEE UNIVERSAL, 
MODEL PRO-05002 
ORTHOSOFT, INC. 4/28/2006 
2 – Class II 
1 – Class III 
K022365 STRYKER NAVIGATION SYSTEM - HIP MODULE STRYKER INSTRUMENTS 1/22/2003 10 – Class II 
K001284 
STEALTHSTATION SYSTEM GOLDENEYE MICRO-
MAGNETIC TRACKING SYSTEM 
MEDTRONIC SURGICAL 
NAVIGATION TECHNOLOGIES 
6/12/2000 
27 – Class II 
1 – Class III 
K993239 
STRYKER NAVIGATION SYSTEM - NEURO 
MODULE, MODEL 6000-XXX-XXX 
STRYKER CORP. 1/18/2000 
2 – Class I 
4 – Class II 
K990214 
FLUORONAV MODULE FOR THE 
STEALTHSTATION SYSTEM 
SURGICAL NAVIGATION 
TECHNOLOGIES, INC. 
4/22/1999 29 – Class II 
 
Examination of the devices with multiple recalls identified through this research revealed a few 
key findings. First, while the Flex system had no instances of repeated recalls within its predicate 
ancestry, both the SYMBIS and RIO-THA had multiple instances with comparable levels of 
severity to the recalls issues for Da Vinci Si predicates. This indicates that the level of 
complexity of robotic surgical technology may be partially responsible for the repeated recalls, 
rather than a specific flaw with the Da Vinci System. 
 
Second, two Class I recalls were issued for the Stryker Navigation System – Neuro Model, a 
device which serves as a predicate in the RIO – THA trace. These recalls were issued in 
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November of 2009, after the approval of multiple subsequent device generations, in response to a 
series of software problems which rendered the device unusable and unsafe. Although this is the 
only instance of a Class I recall, it does illustrate the potential for devices with serious safety 
flaws to be used as predicate devices, if those flaws are not discovered prior to approval of the 
subject device seeking approval.  
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6 DISCUSSION 
 
6.1 PREDICATE CREEP 
 
It is clear from the data gathered in this research that predicate creep, and technology creep in 
general, does indeed exist to some extent within the 510(k) Process. Due to the limited 
availability of detailed information on the technical characteristics and testing procedures of new 
devices presented in approval application summaries, it can be difficult to determine the amount 
of scientific evidence provided to mitigate predicate creep within a device’s approval history. 
However, even without knowledge of the evidence provided to support substantial equivalence 
claims, correlations can be about the impact of predicate creep on the 510(k) Process.  
 
The 510(k) Process uses a combination of predicate performance data and design validation 
testing data to determine if a device is both substantially equivalent to a predicate and safe to be 
placed on the market. However, unless the validation testing performed includes clinical trials, 
there is no way to ensure for certain that a device will perform as expected when it enters the 
market and is used on patients. Therefore, in the absence of clinical trials, the only data used to 
support device safety is the performance of predicate devices. As a result, if technology creep 
occurs between predicates, even if all the new aspects of a device are tested thoroughly in non-
clinical settings, there is no way to 100% guarantee that the new device will perform as 
anticipated. However, it is extremely difficult to mitigate this small scale form of predicate creep 
without the use of mandatory clinical trials, which would defeat the purpose of the 510(k) 
Process entirely. Instead, requirements for non-clinical testing are used to mitigate much of the 
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risk associated with small scale predicate creep, which in most cases works effectively. 
However, there are two scenarios in which non-clinical evidence may be insufficient to 
adequately mitigate the risks associated with small scale predicate creep.  
 
The first case is when the non-clinical evidence provided to support substantial equivalence 
claims is insufficient to ensure that new technological characteristics do not introduce new safety 
issues within a device design. Given the data available for analysis in this thesis, it was not 
possible to determine whether any instances of insufficient evidence were present within the Da 
Vinci or other device traces.   
 
The second scenario in which non-clinical evidence is insufficient to support device safety is if 
multiple generations of devices approved via substantial equivalence each possess a degree of 
technology creep. This is the theory of predicate creep discussed in previous literature, where 
technology creep causes subtle changes in device form and function to build up over time, until 
eventually a device is introduced to market which bears no resemblance to the original device. 
Although each individual device characteristic is supported by some form of non-clinical 
evidence, the only clinical evidence supporting the approval of newer devices is based on a 
device which they are essentially unrelated to. A simple example of this type of creep is 
illustrated using shapes in Figure 13 below, where each change present in a new iteration of the 
shape is relatively small and well supported logically.  
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Figure 13: An example of the impact of small scale predicate creep over multiple device generations, where a solid 
blue triangular shape is transformed step-by-step into a hollow green rectangle which bears no resemblance to the 
original shape. 
 
The final device (or shape in the example above) is essentially a totally different device than the 
original predicate upon which it is based. However, the original predicate is the only device that 
was actually tested pre-market for safety. This means that the cumulative effect of continuous 
technology creep over time is large scale predicate creep, where changes in device characteristics 
result in the creation of entirely new device types without any clinical evidence of safety and 
efficacy. Even if the effects of small scale predicate creep are mitigated by non-clinical testing, 
the effects magnified on a larger scale result in the development of entirely new device types 
without clinical evidence, essential circumventing the requirements of the PMA process over 
time.  
 
This research was able to detect the presence and analyze the effects of large scale predicate 
creep (referenced simply as predicate creep) for the data sets using three different methods of 
predicate analysis; technological characteristic comparison, regulatory structure comparison, and 
predicate relationship analysis. 
 
6.1.1 TECHNOLOGY CHARACTERISTICS 
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The first method used to identify technology creep is the traditional method of direct 
characteristic comparison described in the methods section. Comparison of the technical 
capabilities of devices in a substantial equivalence relationship highlights the exact device 
component which represents a new technological innovation, thus making it easy to identify 
instances of technology creep. The severity of technology creep varies based on the degree of 
change between the technological characteristics of the device, from minor changes of a single 
components to major changes in device function. 
 
An examination of the traces constructed in this research finds that, even without detailed 
technical descriptions, many instances of technology creep can be identified from the device 
descriptions provided in approval application summaries. For example, following one five 
generation branch line in the SYMBIS trace connects the SYMBIS system (K143420), which 
uses jointed mechanical arm guided from a surgeon console to position stereotactic instruments, 
to the Brown-Roberts-Wells Stereotaxic System (K811452), which uses a CT scanner and 
physical structure comprised of a series of rods and a curved metal frame to position stereotaxic 
instruments for neurosurgery (Apuzzo & Fredricks, 1988). Although both devices have the same 
core function, there are significant changes in the technological characteristics between the two 
devices. Even the device which the Brown-Roberts-Wells System serves as an immediate 
predicate for, the Neuromate Stereotactic System, incorporates significant new technological 
components, primarily the use of a jointed mechanical arm for positioning. Another major 
example of technology creep from the RIO-THA trace is the progression, within a single 
predicate generation, from a handheld flexible endoscope to a system incorporating a robotic arm 
for endoscope and tool positioning driven from a separate console as described in Appendix 5. 
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Other instances of technology creep include the progression from an intraoperative image 
guidance system with a handheld probe (K052213) to a guidance system with a robotic arm 
serving an “intelligent” tool holder to provide feedback (K072806) in the Mako RIO trace and 
the progression from individual manual surgical instruments to a robotic surgical system within 
the Da Vinci Si trace. In fact, even based on the limited information available through approval 
summaries, the majority of substantial equivalence relationships examined within this thesis 
appear to possess some degree of technology creep. Although it may be expected due to the 
nature of the regulatory process, these many examples confirm that technology creep is prevalent 
within the 510(k) Process.  
 
The traces within the research where it is easiest to directly identify technological characteristics 
are the initial Da Vinci Model IS1200 trace and the AESOP System trace, due to the relatively 
small trace size and availability of technical device descriptions. An example of short-term, high 
impact technology creep is the branch line between the AESOP and Da Vinci Systems, which 
moves from an assistive endoscope positioning system to a system performing robotic surgeries 
in only two generations. Starting from AESOP, the line passes to the Monarch (a sub-component 
of Da Vinci Model ISI 1000) which incorporates multiple manipulator arms, a console for 
controlling the arms, and primary functionality of the arm(s) from scope positioning to actual 
surgery, then directly to the Da Vinci IS1200 which incorporates a 3D vision system and 
specialized instruments. This significant amount of change within just three generations is 
somewhat startling, as it implies that the level of similarity required between technological 
characteristics for substantial equivalence is extremely low.  
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The high degree of technology creep within the Da Vinci trace becomes even more apparent 
when compared to other devices in the AESOP trace, which share the same predicate device. 
Although there is also predicate creep present within these branch lines, the degree of 
technological change is significantly less. For example, all of the devices in the same generation 
as the Da Vinci within this trace share the same basic function as the AESOP system, to position 
and hold an endoscope during surgery. The major technological innovations present in these 
devices are changes in the number of movable joints in the manipulator arm, and the arm control 
interface. Comparatively, the Da Vinci incorporates many additional core device functions, such 
as manipulation of surgical tools, cutting and electrocautery, as well as the inclusion of multiple 
new manipulator arms and a new control platform. While the other second generation devices 
within the Da Vinci trace are examples of low-impact technology creep, where the resulting 
predicate creep is small scale and unlikely to introduce major safety concerns, the high-impact 
technology creep present in the Da Vinci branch is an example of large scale predicate creep. 
Although the stated intended use of these devices is the same, the Da Vinci represents a sudden 
“leap” in technology by effectively introducing a new intended use in addition to the prior 
intended use of endoscope positioning.  
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6.1.2 MULTIPLE PREDICATES 
 
One of the major indicators of technology creep is the use of multiple predicates in an approval 
application. If a device is approved based on a single predicate, then technological changes 
between the two predicates are easily identifiable and can be directly addressed through non-
clinical testing. However, in an approval application with multiple predicate devices the 
characteristics of the subject device are typically a combination of characteristics from the 
predicate device. This new combination of technological characteristics, which have not 
previously been tested, make it more difficult to identify and test for potential device flaws, and 
subsequently increase the probability of device failure. This exact problem was responsible for 
the failure of the Dupuy ASR XL, which possessed a unique combination of material and 
geometry never before tested on patients (Ardaugh et al., 2013). Further, although these devices 
often represent significant leaps in technology, they are often approved without additional 
clinical testing, as was the case for the ASR XL. In these instances, non-clinical tests alone are 
insufficient to assure device safety and mitigate the effects of small scale predicate creep. 
 
Examining the predicate relationships of the Da Vinci Si and other systems, the use of multiple 
predicate devices in approval applications appears to have changed over time. Older devices 
approved prior to the early 1990’s, when predicates are traceable, typically use only one or two 
predicate devices. However, newer devices, especially those approved in the late 1990’s - early 
2000’s, often use three or more predicate devices. Although other factors may also contribute, it 
appears that this change is mostly due to the increasing pace of technological innovation within 
medical device fields. Devices which use more than two predicates typically appear to represent 
more significant innovations and changes in technological characteristics compared to devices 
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with fewer predicates. For example, in the Da Vinci Si trace 15 of the 20 devices (75%) 
associated directly with the Da Vinci System (i.e. the system and components) have three or 
more predicate, while only 5 of the remaining 29 predicates (17%) have three or more predicates. 
The exception to this rule is when companies use one approval application to approve a group of 
devices, for example a line of surgical instruments, rather than a single device. 
 
In addition to larger leaps in technical innovation, the use of multiple predicates as split 
predicates also contributes heavily to predicate creep. The FDA defines a split predicate as the 
use of one predicate device to validate equivalence of intended use, and different a predicate (or 
predicates) to support equivalence of technical characteristics (CDRH, 2010). Using this method, 
devices can be approved for new applications without ever undergoing testing to prove that the 
device is safe for that application. Further, if the device also combines characteristics of multiple 
technical predicates in addition to introducing a new intended use, it is nearly impossible to 
ensure that the new device is safe without clinical trials. Previously, companies validated the use 
of split predicates by claiming that the term “predicate” in the definition of substantial 
equivalence refers to the combination of all prior devices identified in an approval application, 
rather than each individual device. However, in the 2010 Working Group report and subsequent 
guidance documents issued by the CDRH, the term “predicate” in the definition of substantial 
equivalence is clearly interpreted to apply to a single device already on the market. Under this 
interpretation of the definition, the use of split predicates as defined by the FDA clearly violates 
the terms of substantial equivalence.  
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The FDA’s interpretation of the definition of substantial equivalence means that every single 
device identified as a predicate is subject to the entirety of the definition of substantial 
equivalence, and therefore MUST possess the same intended use as the subject device. However, 
there are many instances within the predicate histories investigated in this research where 
predicates are identified for the purpose of validating technical characteristics of the subject 
device without possessing the same intended use as the subject device. For example, the Intuitive 
Monarch Laparoscopic Manipulator/Endoscopic Control System shares the same intended use 
and many technological characteristics of the AESOP system, one of its immediate predicate 
devices. However, the Monarch also cites three different types of manual surgical tools as direct 
predicates, none of which share the same intended use of “control of instruments during surgical 
procedures.” By the FDA’s interpretation of substantial equivalence, these surgical tools do not 
qualify as valid predicate devices. But without the inclusion of these surgical tools, Intuitive 
would not have been able to validate the use of the Monarch System for any surgical tasks other 
than endoscope positioning, which was an essential step to the subsequent approval of the Da 
Vinci System. These “partial predicates”, which are used to validate technological characteristics 
of a device without possessing the same intended use, are often included on approval 
applications of “leap” devices, which contain major technological innovations in one or two 
predicate generations. 
 
In 2012, to mitigate some of the risk introduced by split predicates while still allowing for larger 
technological innovations like those present in the Da Vinci trace, the FDA created a new 
regulatory mechanism called Reference Devices. Unlike a predicate device, which is required to 
possess the same intended use as the subject device, a reference device can be used to validate 
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the safety of technological characteristics without possessing the same intended use as the new 
device. However, a reference device can only be used in addition to a valid predicate device and 
cannot on its own serve as sufficient validation for device approval. One example of a device 
approved using reference devices was found in the Medrobotics Flex Transabdominal System, 
described in Appendix 6. 
 
This new regulatory mechanism does address the issue of split predicates as they are defined by 
the FDA. However, instances of split predicates are extremely rare, to the point where no 
examples can be identified within any of the four traces constructed here. Instead within these 
traces there are many instances of partial predicates, which are often associated with the leap 
devices that contribute so heavily to technology and predicate creep. Rather than address 
potential safety issues with the approval of technology for untested use scenarios, the FDA has 
essentially given the green-light to continue using these partial predicates by giving them an 
official regulatory definition as Reference Devices. Although it is difficult to determine the 
potential impacts to the regulatory process of such a new mechanism, the effects of previous 
examples of partial predicates indicate that reference devices will be used to approve devices 
with significant new innovations for market without the use of clinical trials.  
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6.1.3 PRODUCT CODES AND REGULATORY DESCRIPTIONS 
 
Another interesting pattern is the evolution of product code classifications over time within the 
traces. The FDA designates product codes based on the intended use and technical characteristics 
of devices, combining those characteristics to identify a device type and basic regulatory 
description. If the FDA finds that a device does not fit into an existing product code, they will 
designate a new code, even if the device was approved via 510(k). As a result of technological 
creep and innovations over time, new product codes are often introduced into the device traces. 
For example, in the RIO trace the majority of the devices were classified under code HAW, 
while the originating predicates were classified under a variety of different product codes. 
Similarly, the devices in the Da Vinci Si trace were classified under a variety of product codes 
prior to the designation of code NAY, which subsequently included all of the newer devices in 
the trace. Looking at the characteristics of devices under the codes which existed in the trace 
prior to the introduction of the dominant code gives clues to the technological characteristics 
present in devices classified under the dominant code. Examining the differences between 
subject and predicate devices with different codes also gives insight into what level of 
technological change triggers the creation of a new product code.  
 
  
97 
 
6.2 OTHER ISSUES 
 
6.2.1 REDUNDANT PREDICATES 
 
As discussed within the Research Expansion section, there is a large discrepancy between the 
number of identified predicate relationships and the number of unique devices present within 
each trace. This is caused by redundant predicates, where a subject device references a predicate 
device multiple times within its ancestral trace. This creates multiple ties to a single predicate 
device, which rapidly expands the size of the ancestral equivalence tree. Figure 14 illustrates the 
three types of predicate redundancies identified within the ancestral traces, with redundant 
predicate relationships highlighted in red. 
 
  
Figure 14: Sample illustration of the different types of predicate redundancy in both compressed and expanded tree 
forms, with the redundant predicates highlighted in red. 
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On the left is a basic predicate trace with no redundancy, which consists of the subject device 
and 6 predicate devices with a total of 6 substantial equivalence claims, one per unique device. In 
the center an example of generational redundancy, where the subject device directly references a 
predicate which also appears as a predicate device for another device in the same generation. 
This creates a single redundancy, with Predicate C now appearing twice in the trace. The effect 
of redundancies is magnified by inter-generational redundancy, where a predicate device present 
in the trace references another predicate device within the trace. As seen in the example shown 
above, the redundant relationship causes the entire branch originated by Predicate B, circle in 
red, to become redundant, which results in a total of 9 equivalence claims for a trace consisting 
of only 6 devices. The effects of inter-generational redundancy cause entire branches to be 
duplicated, creating a stacking effect that turns the relatively straight expanded trace into a web-
like structure when condensed.  
 
There are two major issues with the use of redundant predicate devices in the approval process. 
First, although redundancy increases the number of appearances of a particular predicate device 
within a trace, this number does not necessarily correlate to the degree of equivalence between 
the predicate and subject device. This is because the 510(k) Process makes no differentiation 
between predicates used to introduce a single technological characteristic and predicates which 
are nearly identical to the subject device. For example, in an expanded version of the Da Vinci Si 
trace where all redundant predicate instances are visible, the Baxter Healthcare Endoscopic 
Instruments (K931340) appear 170 times, while the AESOP System (K931783) appears only 143 
times. Examining the actual technical characteristics of each device, it is apparent that the Baxter 
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Instruments are traditional handheld endoscopic surgical instruments used as predicates for the 
end effector instruments of the Da Vinci system, while the AESOP system serves as a predicate 
for many of the complex technological components of the Da Vinci System such as the 
manipulator arms and software control. Based on these technical descriptions, it is apparent that 
the AESOP system has a higher degree of technological similarity to the Da Vinci System, and is 
therefore more relevant for proving safety and efficacy from a regulatory standpoint. However, 
the number of appearances of each predicate device within the trace does not reflect the actual 
degree of technical similarity to the Da Vinci.  
 
Because the natural tendency of an observer is to assume that devices which are cited more often 
have a higher level of significance within the trace, this lack of discussion on degree of 
equivalence may result in an undue amount of importance being placed on redundant predicates. 
This is particularly problematic when predicates which appear more often within the trace have 
few technical characteristics in common with the subject device, as the level of evidence for 
safety assurance provided by these predicates is significantly less than that provided by other, 
more technologically similar devices. 
 
The second issue with redundant predicates is the use of repeated device citation to increase the 
number of devices on the market that a new device is being compared, and subsequently the 
amount of evidence supporting substantial equivalence claims, without increasing the size of the 
actual body of evidence present. For example, the Da Vinci Si trace has 2618 different instances 
of equivalence claims, where a device is cited as a predicate, but only 50 unique devices actually 
present within the trace due to the repeated use of inter-generational redundancy. This 
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redundancy is present when Intuitive cites both the previous model of the Da Vinci system and 
the devices which served as a predicate for that model. While such duplications may make sense 
at first glance, since a greater number of immediate predicates for a new device means more 
evidence to support its safety, these duplications are actually indicative of potential flaws within 
the previous Da Vinci model.  
 
Since direct predicate device(s) are supposed to provide evidence of safety and efficacy via 
performance on the market, the fact that Intuitive felt the need to cite the predicates of the 
previous Da Vinci model, in addition to the model itself, indicates that they believe there is 
insufficient evidence to support approval of the new model based on the previous model alone. 
While this belief may or may not be true, it highlights the potential issues with highly complex 
devices introduced to market via the 510(k) Process without a direct predicate device which 
shares the same technological characteristics. As a result of the lack of safety evidence provided 
by the initial version of such a device, companies like Intuitive are forced to redundantly cite the 
predicates of that device in addition to the device itself when filing for approval of subsequent 
device models. However, since regulators typically only look at the evidence provided by direct 
predicates, and the additional devices already served as predicates to the original model, this 
effectively disguises the fact that the only additional evidence provided to support approval of 
the new model is the performance of the old model. The initial model of the device therefore 
served as a “step” device to incrementally introduce new technological characteristics into the 
marketplace before more significant innovations could be introduced in the second model.  
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Although incremental development is a common and necessary component of technological 
innovation, the use of redundant predicates as a regulatory mechanism to get these innovations to 
market can go too far. If a device with innovative components can stand on its own as a predicate 
from a safety and efficacy perspective, or with minimal redundancy, then it is valid to use it for 
incremental innovation. However, when a company repeatedly cites the same predicate devices 
for each incremental innovation of a device, it indicates that either the company habitually cites 
prior predicates without purpose, or duplication of earlier predicates is required to prove the 
safety of each incremental innovation. Requirement of redundant predicates for device approval 
indicates that the amount of innovations present in the new device may be too significant for the 
510(k) Process to provide effective assurance of device safety. 
 
 
6.2.2 SELF-CITATION 
 
The trace maps constructed through this research illustrate the evolution process of technological 
characteristics in new medical devices over time. Comparison of four different robotic surgical 
device traces reveals an interesting pattern of independent branch line development. While logic 
would dictate that devices with similar technological characteristics should share common 
predicate devices, these traces reveal instead the development of parallel branch lines, where 
technological improvements in one line are made independently of other lines. 
  
Of the four independently traced lines, only the Mako RIO and SYMBIS systems have any 
overlap, and that overlap consists of 4 devices contained in a single branch. The only device 
identified which truly overlaps multiple traces is the DigiMatch ROBODOC, which is predicated 
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on the Da Vinci (K043153), a direct predicate of the Mako RIO called the Mako Voyager Linux 
(K052851), and the Frameless Nueromate (K991081) by Integrated Surgical Systems, which 
appears in the SYMBIS Trace. Other than these devices, all the devices identified in the approval 
traces were unique. However, comparison of the product codes and regulatory descriptions 
associated with the traces reveal that many of the predicate devices share similar characteristics. 
The methodology for the selection of predicate devices by applicants must therefore be 
influenced by factors other than the particular technological characteristic of the device. 
  
One of the most likely factors influencing the selection of predicates is based on the intellectual 
property and availability of technical information associated with device. When there are many 
similar devices available within the market to serve as predicates, a company will select a device 
which they believe they have best access to information about. Most often, this is a device 
previously released by the company or a subsidiary for which the company has full access to 
both the intellectual property and previous scientific evidence to support equivalence claims. 
This practice is evident within all four of the constructed traces, with each trace including a 
number of manufacturers less than half the number of unique devices. 
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Table 9: Trace Comparison 
  Unique Devices Number of Companies 
SYMBIS 26 13 
Da Vinci 50 18 
Flex 42 10 
RIO 48 15 
  
This practice of using familiar predicate devices is advantageous to companies, as it reduces the 
number of unknown variables present in the approval process. However, it has created a pattern 
in which multiple companies often independently develop new technological innovations rather 
than piggybacking on existing technologies. This may ultimately slow the overall progress of 
technological innovation. 
 
6.2.3 LACK OF INFORMATION ABOUT SOFTWARE CONTROLS 
 
One of the major components of the Da Vinci System and other similar robotic surgical devices 
is the software package developed to control the device. In fact, it can be argued that the 
software package for the Da Vinci system, capable of interpreting surgeon motions and directly 
controlling multiple manipulator arms while providing feedback in real time, was the major 
innovation of the device. However, the information available through the FDA databases and 
Intuitive Surgical’s website focuses almost exclusively on the physical infrastructure and 
capabilities of the device, rather than the software that runs it. In fact, the only information 
related to the Da Vinci software infrastructure in the available 510(k) approval summaries was a 
statement saying that its exists and has been updated for each new Da Vinci Model.  
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At the time of the approval of the original Da Vinci Model ISI 1000 in 2001, the information 
regarding device software included in a 510(k) submission was regulated by a guidance 
document issued by the FDA in 1998. This document describes how to classify a device based 
on the “Level of Concern,” or severity of potential failure implications, and then lays out 
requirements for software architecture design, traceability, and verification as well as 
international consensus standards which the software should meet (U.S. FDA, 1998). The 
document was subsequently updated in 2005 and again in 2016 to clarify when software changes 
necessitate resubmission of a 510(k) application.  
 
Creation of standards for validation and testing of software-based device components is 
particularly essential given the growing level of software complexity present in newer medical 
devices. For a more traditional hardware-based device potential failures of major components 
such as motors or switches can be easily predicted and tested using physical methods. However, 
the structure of software programs, with thousands of lines of code requiring extremely 
specialized knowledge to create and interpret, makes potential software failures much more 
difficult to identify or predict. This is especially true of small glitches or “bugs” within the 
program, which don’t affect the overall device functionality and appear only under a very 
specific set of conditions. Detection of these bugs requires a wide variety of rigorous testing 
procedures to ensure that nothing with the potential to harm patients slips through the cracks. 
However, although the FDA does require information about software testing to ensure device 
safety, specific requirements for testing procedures are covered only by general industry 
standards which may or may not be applicable to the medical device being tested. 
105 
 
 
Given the existing FDA regulations at the time, and the lack of major recalls or reports regarding 
problems with the Da Vinci software, it was presumably evaluated using various standards to 
ensure device safety. However, the lack of evidence surrounding this software testing and that of 
subsequent software iterations is somewhat concerning. Since the complexity of the Da Vinci 
software is relatively high compared to other devices on the market at the time of its approval, 
there is subsequently a higher likelihood of an existing flaw causing major safety issues. 
Although there have been no severe recalls on the Da Vinci system due to software malfunctions, 
another device in the predicate history of the RIO - THA, the Stryker Navigation System – 
Neuro Model, was the subject of two separate Class I Recalls in 2009 due to software flaws 
which had the potential to cause fatal injuries to patients. 
 
While the Stryker system illustrates the potential for severe risk posed by software-based 
medical devices, the structure of the Da Vinci system, where software directly controls the 
motion of the device performing surgery, magnifies the potential risk posed by software 
malfunctions. In most other surgical devices at the time of the Da Vinci’s approval, and even in 
many of the newer devices examined within this research, the surgeon is still in direct physical 
control of the motion of the tool manipulator. This means that, while a software flaw could 
potentially freeze the tool in place or provide inaccurate information, the surgeon is still 
ultimately in control of the tool motion. However, with the Da Vinci platform the software 
directly controls the tools performing surgery, which means a small software glitch could have 
catastrophic consequences. For example, if a small software bug causes the manipulator arm 
motor to reverse direction or move more than directed during surgery at the wrong time, it could 
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potentially sever a blood vessel and cause internal bleeding or worse before the surgeon has a 
change to notice or stop it. Although Intuitive has obviously performed software tests to prevent 
such occurrences from happening, the lack of information about the testing conducted makes it 
difficult to determine whether their success in prevention of such issues is due to intensive 
testing or luck.   
 
6.2.4 RECALLED PREDICATES 
 
One of the notable findings identified in the previously reviewed study conducted by Zuckerman 
et al. was the presence of devices which had undergone major recalls within the predicate history 
of newly approved medical devices (Zuckerman et al., 2014). Similar instances of devices 
continuing to serve as predicates after undergoing major recalls or even being removed from the 
market were also identified as one of the issues which led to the failure of the DuPuy ASR XL 
(Ardaugh et al., 2013). A predicate which has undergone major recalls can be indicative of 
inherent safety issues with the technological basis of subsequent devices if they share major 
technological characteristics with that predicate. Even if a predicate has not undergone any major 
recalls, patterns of multiple minor recalls for similar recurring issues may still be indicative of an 
issue with the device design. Alternatively, patterns of multiple minor recalls may indicate that 
the associated technology was insufficiently developed or rushed to market without a strong 
technical foundation to support the functions it provides. To determine whether there was any 
impact from recalled predicates on the devices studied in this thesis, each of the predicates 
identified within the four major traces were run through the FDA Recall Database. 
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Based on the results of the Recall Database analysis discussed in section 5.3.1 and 5.4.1, there is 
a definitive pattern of related device technologies present among the devices with multiple Class 
II recalls. All the devices with multiple recalls present in the Da Vinci trace were either iterations 
or components of the Da Vinci system itself. Although none of the recalls were due to 
catastrophic failures, the repeated pattern of recalls for different, moderately severe issues 
indicates that the technology entered the market before it was perfected. This is reinforced by the 
fact that issues continued to arise even with subsequent models of the device. Additionally, the 
variety of issues which triggered recalls, ranging from overheating batteries to user manual 
updates and incompliant factory testing, is likely indicative of the complexity of the system both 
as a device to operate and a device to manufacture. It is notable that all the recalls within the Da 
Vinci trace were issued for devices manufactured by Intuitive Surgical, which may also point 
towards a level of inexperience with this type of device manufacturing as a relatively new 
company (it was founded in 1995 and exclusively manufactures the Da Vinci and accessories) in 
addition to issues created by the technical complexity of the Da Vinci. Like the Da Vinci system, 
the three iterations of the Stealthstation system present across the RIO – THA and SYMBIS 
traces have a combined 68 recalls between them. Yet despite the high number of recalls, the 
device continues to serve as not only a predicate, but also an active component of the SYMBIS 
Surgical System.  
 
However, whether inexperience on the part of Intuitive Surgical contributes to the high number 
of recalls or not, the Da Vinci is not the only complex surgical system which experienced high 
rates of recalls. Both iterations of the ROSA surgical system, the direct predicate to the SYMBIS 
System, experienced a large number of Class II recalls within a relatively short period of time 
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during 2017. Similar to the Da Vinci, the reasons for these recalls varied, but the majority were 
directly associated with potentially faulty components used during the manufacturing process. 
This brings up one of the major issues with highly complex medical devices, which is that they 
often rely on third-party vendors for most of the component sourcing and manufacturing. As a 
result, even if the design is sound, the sheer number of components and manufacturers involved 
in the creation of such a device makes the probability of device failure significantly higher than 
less complex devices.  
 
Finally, although not necessarily as prevalent within these traces as in previous research, there 
have been significant recalls on devices which continue to serve as predicates for new products. 
For example, in the case of the Stryker Navigation – Neuro Model the RIO-Total Hip 
Arthroplasty (THA) was approved based on devices predicated on the Neuro Model after the 
recall was issued without additional investigation of the intermediary device safety. Nowhere in 
any of the documentation presented for approval requests was reference made to any existing 
product recalls, and no subsequent evidence to reinforce device safety despite recalls was 
provided. Additionally, there was no record anywhere within the publicly available data of the 
FDA returning to previously cleared devices to reevaluate safety in light of a new product recall 
on a predicate device. This leads to the conclusion that the FDA currently does not possess a 
mechanism for evaluating the potential impact of device recalls on devices cleared through the 
510(k) Process. 
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6.3 AVAILABILITY OF DATA 
 
In the 510(k) database, information required for determination of substantial equivalence, such as 
predicate devices, intended use, indications for use, and scientific evidence, is located within the 
application summary attached to the main device summary page. However, the level of 
information contained within these summaries varies widely, and in many cases these summaries 
do not exist at all, due to the gradual evolution of requirements for 510(k) application 
submissions. Although the 510(k) Process was officially implemented via the 1990 Safe Medical 
Devices Act, official guidelines for the contents of submissions, including the creation of 
summaries detailing equivalence claims, were not issued by the FDA until 1994. (Medical 
devices; Substantial equivalence, 1994) Further, use of the standardized “Indications for Use” 
form was not implemented until 1996, (CDRH, 2010) and specific guidelines for the formatting 
of traditional and abbreviated 510(k) applications were not issued until 2005. (CDRH, 2005) As 
a result, the level of information available in the 510(k) database varied widely based on the date 
of approval. Devices approved prior to 1992 typically only include the basic information 
available on the device-summary page, and in some cases are not present in the database at all. 
Data available for devices approved between 1992 and 2005 is inconsistent, with some results 
containing full PDF summaries of approval applications, including identification of predicate 
devices and intended use, and others containing only a statement certifying equivalence claims or 
no information at all. Consistent inclusion of application summaries in the database does not 
begin until applications filed around 2005-06. Even within applications which include 
summaries, the level of information varies as 510(k) application guidelines were modified 
multiple times, most notable in 2007 and 2012. 
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The lack of consistent data is one of the major challenges to research which seeks to understand 
the impacts of the evolution of the 510(k) Process. In cases without an application summary, 
such as the device summary shown on the left, it is impossible to identify the predicate device(s) 
based on the available public information. 
 
The difficulty of locating relevant data became evident almost immediately during this research 
process, as there is no information within wither the FDA database or Intuitive Surgical’s own 
website about the approval process utilized with the first model of the Da Vinci Surgical System, 
Model IS1000. The lack of publicly available information about the approval process for the 
IS1000 model is troubling, as it obscures both the regulatory and technical origins of the device 
function. While Intuitive Surgical’s website history section references several medical 
innovations created in the early 1990’s with similar technological functions as the Da Vinci, 
including the Laparoscopic Assistant Robotic System (LARS) and the Stanford Research 
Institute’s Telepresence Surgery System, there is no way to determine whether these devices 
served as predicates for the initial model of the Da Vinci. 
  
Theoretically, a map of all of the predicate relationships for every device approved via 510(k) 
should resemble a web, where different spurs originating pre-1976 initiate groups of device 
based on a primary function which then evolves over time. The density of devices contained 
within the map should increase somewhat exponentially reflecting the pace of technological 
innovation moving through time away from the web origin. However, if the contents of the entire 
510(k) database was mapped today, it would resemble a donut with a large hole in the center due 
to lack of information about older devices. 
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The impact of this lack of data varies depending on the intended use of the mapping structure. 
From a regulatory perspective, older devices are mostly obsolete, and have been replaced by 
newer devices. These new devices would still be visible grouped by device function, due to 
mutual originating Pre-Amendments devices, around the central ring. The impact of the lack of 
data about older devices is felt only when one attempts to trace technological characteristics to 
their origin device. While this type of trace is not performed often, it can be used to identify the 
level of scientific evidence supporting claims of device safety and efficacy, which can be useful 
when disasters occur. 
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7 CONCLUSIONS 
7.1 SUMMARY OF FINDINGS 
 
This thesis set out to explore the 510(k) Approval Process as it is applied to complex medical 
devices, with particular focus on robotic surgical systems such Intuitive Surgical’s Da Vinci 
System. The goal of this research was to develop a methodology to identify predicate 
relationships using publicly available data and to determine the validity of concerns expressed by 
previous researchers surrounding the potential impact of predicate creep and other issues with 
the existing approval process. In this section I will summarize my findings on the impact and 
policy implication of predicate creep and other issues within the 510(k) Process. 
7.1.1 TECHNOLOGY CREEP 
 
Given the purpose of the 510(k) Process, to bring new medical devices to market, it should be 
expected that there is a level of technology creep inherent in the process. If manufacturers are 
limited to only submitting identical devices for approval through the 510(k) Process, there can be 
no innovation. Even in new versions of existing devices submitted by the same manufacturer, 
such as the Da Vinci Models IS1000 and IS1200, there can be somewhat significant 
technological changes. Removing all technology creep from the process would only hinder 
progress within the medical devices industry.  
 
Inherent predicate creep in limited amounts, where the new device can be guaranteed safe based 
on available scientific evidence, appears to actually be beneficial to companies, patients, and 
regulators alike. However, there are instances, evidenced both within these traces and in other’s 
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research, where technology creep goes too far. Devices are approved via 510(k) which bear little 
resemblance to predicates or possess a unique combination of predicate technological 
characteristics never before tested on a patient, making it impossible to assure the safety of the 
new device through predicate evidence alone.  
 
In the case of devices which bear little resemblance to predicates, it appears from this data that 
approval through the 510(k) Process is accomplished by manipulating vague regulatory 
definitions using broad device descriptions and general intentions for use to make a device 
appear more closely related to a predicate than it actually is. This is especially evident in the case 
of the Da Vinci system. 
 
The regulatory description of the Da Vinci as an endoscope, an instrument that is introduced into 
the body to view its internal parts, and accessories rather than as a device which directly 
performs surgeries offers an important clue into the inner workings of the regulatory process. A 
device which is performs a surgical procedure without direct physical control by a surgeon has 
significantly more inherent risk than a simple viewing device, and might therefore fall under 
Class III regulatory guidelines. Additionally, while endoscopes and accessories are considered to 
be well understood devices with clear predicates and a defined intended use, no device has ever 
been approved as a “robotic surgical system”. Therefore, any device seeking approval under this 
classification would be considered a new device and automatically placed into Class III. By 
identifying the Da Vinci as an endoscope with accessories, although the endoscope isn’t the only 
major function of the device, it allows the manufacturer and regulators to circumvent the more 
stringent and lengthy Class III regulatory requirements. 
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Whether devices approved through this method do in fact pose a safety hazard to the public is a 
question which cannot be answered without further study. However, it is apparent that the broad 
interpretation of regulatory descriptions combined with the discretionary manner in which 
special controls to mitigate safety issues are applied, leaves room for unsafe devices to 
potentially slip through the cracks and into the market.  
 
7.1.2 MEASURING PREDICATE CREEP 
 
The major contribution of this research to the discussion surrounding the 510(k) Approval 
Process for medical devices is the development of two novel methods for identifying predicate 
creep: through the use of product classification codes and by identifying instances of multiple 
predicates. While many scholars have identified predicate creep as a potential problem within the 
510(k) Approval Process, existing literature on the topic is primarily limited to theoretical 
discussion. In the few instances where attempts were made to prove the existence of predicate 
creep, the methodology used was limited to identification of technological characteristics and 
scientific evidence present in each individual predicate within the approval history (Ardaugh et 
al., 2013; Zuckerman et al., 2014).  
 
While identifying specific technological characteristics is an effective method for identifying 
instances of technology creep, especially for characterizing the nature and extent of the creep to 
determine potential impacts, it has many limitations including time, access to data, and 
knowledge to interpret data into meaningful results. In particular, this method requires not only 
identification of predicates, itself a time consuming process often limited by data availability, but 
also identification and understanding of specific technical properties for each predicate. The 
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amount of technical data available in FDA databases is extremely limited and often purposefully 
vague, most likely to protect proprietary rights, which means that technical details must be 
gleaned from other sources such as patent applications or manufacturer publications. However 
these publications are not always readily available for devices, such as in the case of the Da 
Vinci Model IS1000, and when they are available specialized technical knowledge is often 
required to interpret the information provided. As a result, although this method is effective for 
identifying predicate creep in specific instances where a particular technical characteristic is 
under investigation, it is unnecessarily complicated for identifying general instances of predicate 
creep. 
 
Using information readily available in FDA databases, this research developed two methods to 
identify instances of predicate creep without requiring additional device information. Like the 
method described above, each new method begins by tracing the predicate history of the subject 
device. The first method then looks at the developed ancestry tree and identifies instances where 
a device has multiple predicates, particularly 3 or more, as predicate creep. This is because to be 
substantially equivalent, the subject device must share the same intended use and, most likely, 
some technological characteristics as each predicate device. In most of these cases, the subject 
device takes specific characteristics from each predicate device and combines them together into 
a unique device. This means that the device is not identical to any of the predicate devices, which 
is predicate creep. The only way predicate creep would not occur in this instance is if all of the 
predicates are essentially identical to each other, which is highly improbable due to intellectual 
property laws, especially in the case of more than two devices. Therefore, there must be some 
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degree of technological difference between and the subject device and at least one of its 
predicates, which is predicate creep.  
 
The second method looks at product classification codes, a regulatory mechanism developed by 
the FDA to classify medical devices based on device characteristics. Specifically, a product code 
is supposed to identify a group of devices with the same intended use and similar technological 
characteristics that can serve as predicates for other similar devices. Since possessing the same 
intended use is a requirement for a substantial equivalence finding, it can be assumed that all 
devices within the predicate history of a given subject device have essentially the same intended 
use. Therefore, any time a device with a different product code than the subject is identified as a 
predicate, it must indicate the introduction of new technological characteristics in the subject 
which necessitated the new product code, and therefore indicates predicate creep. Although 
instances of predicates with different intended uses were identified within this research, which is 
a violation of the principle of substantial equivalence, even these instances can be considered a 
form of predicate creep, as a new use for a device was introduced without additional evidence to 
support safety or efficacy of that use. 
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7.2 LIMITATIONS 
 
The depth of this study and significance of conclusions are limited by several factors. First, the 
investigations performed in this study were based solely on data available publicly through FDA 
databases. Predicate devices are identified within the database only when application summaries 
are provided, which was not required for inclusion until the mid 2000’s. This significantly limits 
the number of devices with traceable predicate histories, and thus the scope of this investigation. 
Additionally, the information available through these databases is from general device 
summaries which are written to protect intellectual property rights, including minimal details 
about the specific technological characteristics of each device and the evidence provided to 
support equivalence claims. Since this information is essential to identifying the level of 
technology creep present using traditional comparison techniques, this thesis attempted to 
develop alternative methods to identify predicate creep. However, without the information to 
correlate findings to actual technological characteristics and the evidence used to support their 
existence, it is difficult to evaluate the significance of findings. Further, the lack of insider 
information regarding decision making of FDA officials during the review process creates a 
knowledge gap, where a given equivalence determination may appear strange on paper, but 
regulators may have had good reasons for making that determination. 
  
Another limiting factor for this study was time, as the process for identifying predicate devices is 
rather arduous due to the current structure of the database. Application summaries, including 
information such as identification of predicates and intended device use upon which substantial 
equivalence determinations are based, are attached to device summary page in PDF documents. 
This information is not identified anywhere else within the searchable text of the database, and 
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these documents lack a standard format and may be typed, scanned, or hand written. This lack of 
standardized formatting makes a computer-automated search of summary information nearly 
impossible. As a result, tracing the predicate history of each device required manual construction 
of a database before any analysis could be performed. This is time consuming and significantly 
more prone to human error, requiring additional effort and making the overall process extremely 
time consuming. 
  
Another limiting factor which may impact the significance of conclusions is the choice to limit 
the scope of this research to robotic surgical devices. Conclusions drawn from this research 
about patterns present in the larger regulatory picture may be biased by practices specific to the 
regulation of robotic surgical devices. In particular, the technical complexity of robotic surgical 
devices may lead to a higher number of predicate devices than would be present in less-complex 
devices. The high number of predicates per generation in this investigation was determined to be 
partially responsible for the high rate of predicate creep, so other types of devices may not have 
such significant predicate creep.  
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7.3 IMPLICATIONS OF FINDINGS 
 
7.3.1 IMPLICATIONS FOR FUTURE RESEARCH 
 
7.3.1.1 Non-public Data 
 
Since the information available in the database is incomplete, particularly with respect to devices 
approved prior to 1994, I was unable to trace many of the predicate origins to the originating pre-
amendment or Class III device. Further information about substantial equivalence applications of 
earlier devices could be obtained with the use of Freedom of Information Act (FOIA) requests. 
  
Another limitation related to the availability of data is the lack of inside information about the 
process of substantial equivalence determinations. While the general process is outlined by 
regulatory guidelines, many of the decisions used to implement these regulations are made at the 
discretion of regulators. Conducting interviews with regulatory officials would provide 
additional perspectives not available through examination of predicate data, and may provide 
explanations for some of the common regulatory patterns identified by this investigation. 
 
7.3.1.2 Expansion to Other Device Types 
 
The choice to limit this investigation to robotic surgical devices allowed for an in-depth 
exploration of the predicate history and technological development of a particular device type. 
This investigation proved the presence of technological creep in predicate histories and made 
observations about common regulatory patterns and practices, which were then generalized to 
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the overall regulatory process. However, the choice to focus this investigation on robotic surgical 
systems, a device type known for its technical complexity, may have biased the resulting 
conclusions drawn. Exploring the predicate history of additional device types with primary 
functions unrelated to the devices observed for this investigation would allow for comparison of 
regulatory patterns across device types and validate the conclusions of this investigation. 
  
Long-term, the creation of a map of the full 510(k) database could provide useful information to 
regulators and applicants about devices eligible to serve as predicates. A complete map would 
reveal common patterns in predicate relationships which could be used as a basis for identifying 
viable predicates for new technologies. For example, the Da Vinci trace revealed a strong 
equivalence connection between endoscope controllers and robotic surgical systems. The map 
might also be used for market research by companies, to identify areas of the medical device 
market which are developing or have space for development, or areas which are oversaturated. 
  
Another potential use of this map would include the identification of devices predicated on 
recalled devices or devices with known regulatory problems, such as those identified by 
Zuckerman et al. (2014). The FDA currently does not have a mechanism for identifying these 
devices, which results in the devices remaining on the market and continuing to serve as 
predicates for future devices without additional scrutiny to determine whether safety concerns 
exist. 
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7.3.1.3 Balancing FDA Approval with Patent Requirements 
 
While the 510(k) Process purports to identify predicate devices based on substantial equivalence 
in both functionality and technology, the patent process in the US requires proof that an idea is 
new and novel to secure a patent. For medical devices, the requirements of substantial 
equivalence and novelty appear to be in direct conflict. If a device is substantially equivalent, 
how can it then be novel enough to be granted a patent? 
  
In the US, the most comprehensive database to track and identify new technologies is part of the 
patent system, which provides legal protection of innovative technologies in return for public 
disclosure. In the medical community it is common practice to apply for patent rights and FDA 
approval concurrently to ensure a first-to-market advantage. Examination of the patent literature 
for devices which appear in the ancestral equivalence tree constructed from the regulatory 
history might allow for identification of new technological characteristics introduced in each 
device.  Theoretically, larger technological “leaps” present in substantial equivalence trees 
should correspond to a stronger patent presence for a given device. 
  
For substantial equivalence, applicants are required to provide evidence that the technological 
characteristics of the device are similar to existing devices. Conversely, when applying for a 
patent companies are required to prove that new technological characteristics do not correspond 
to an existing device by referencing all existing devices upon which particular characteristics are 
based and defining how the new device is different. Considering the apparent conflict between 
the requirements of substantial equivalence and patent rights, it is also likely that some 
correlation exists between device relations in the patent and 510(k) databases. 
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7.3.2 IMPLICATIONS FOR POLICY 
 
Looking at the regulatory process from an outside perspective, it is clear that predicate creep 
exists inherent within the substantial equivalence process. When this technology creep occurs on 
a small scale, introducing a new technology feature or application which slightly alters the form 
or function of the device while preserving the overall function and technological characteristics 
of the predicate, there is little potential impact to the safety of the public. In fact, purposeful 
inclusion of small amounts of technology creep is necessary to allow for innovation and 
improvement in medical device design. However, the effects of predicate creep over time have 
allowed for the development and approval of entirely new devices without undergoing the 
stricter PMA approval process. Because this snowballing effect is directly dependent on small-
scale predicate creep, it is difficult to address the problem without negatively impacting the 
ability of manufacturers to bring innovative devices to market. Therefore, rather than trying to 
prevent the snowballing effect in its entirety, my recommendation is for the FDA to develop a 
comprehensive, easily accessible database of predicate relationships which can be used to 
identify break points, where a new device is significantly different from the closest predicate 
with scientific evidence of safety. At these break points the FDA can then require additional 
scientific evidence of the overall device function, such as a small clinical trial, to ensure that no 
safety flaws have been introduced in the device due to predicate creep. This would allow for the 
continued use of small-scale predicate creep for technical innovation, while mitigating the 
introduction of untested technical characteristics and potential safety flaws over time.  
 
However, the largest problem identified through this research is not the presence of predicate 
creep over time, but rather the sudden introduction of devices with high levels of technical 
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complexity into the market through the 510(k) Process. While a combination of various flawed 
elements within the approval process make this possible, it appears based on the evidence 
presented here that one way companies take advantage of the substantial equivalence process is 
by creating “step” devices, which are approved for the specific purpose of serving as a predicate 
for technical characteristics, rather than as a marketable medical device. These “step” devices 
serve as intermediate predicates to allow more innovative devices with larger technological 
“leaps” into the market. Although devices with larger technological leaps are not necessarily 
unsafe or ineffective, for example the Da Vinci has remained on the market for over 15 years 
without a major recall, they do inherently possess more potential risk due to the fast-paced 
introduction of less-understood technologies into the marketplace. 
  
Although the FDA makes efforts to mitigate this risk through existing regulatory mechanisms, 
the lack of clearly defined substantial equivalence requirements makes it difficult to determine 
whether measures taken for a particular device are sufficient. For example, in their analysis 
Ardaugh et. al (2013) found that insufficient measures were taken during the approval process 
for the DuPuy ASR XL, which ultimately resulted in approval of a device with serious safety 
concerns without any significant new scientific or clinical evidence provided to support safety 
claims. The FDA possesses tools to mitigate this risk, including the ability to require clinical 
trials or additional scientific evidence for approval, but there are no clear guidelines to determine 
when this extra evidence might be required. Like the substantial equivalence determinations 
themselves, requirements for evidence are currently left to the discretion of FDA officials. This 
results in inconsistent regulatory requirements and creating cracks in the regulatory process 
through which potentially unsafe devices, such as the ASR XL, might slip. 
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In the future, the FDA should make efforts to identify the “leap” devices and create a more 
targeted approval process that addresses new questions raised by these technologies, perhaps 
through a hybridized version of the 510(k) and PMA processes that allows for substantial 
equivalence evidence while still requiring a level of clinical assurance. Defining clear guidelines 
for the amount scientific evidence required based on the significance of new technological 
characteristics for device approval would help reduce this inherent systematic risk. 
 
Through the data and subsequent findings gathered in this research, I have identified three 
categories of medical devices within Class II based on the technological characteristics and 
intended application of the device which can be used to develop guidelines for evidentiary 
requirements to support substantial equivalence claims as follows: 
 
1. If the new device is identical to an existing device but being used for a new application, 
or introduces a minor technological change, such as replacing one type of motor with 
another or using a new material, bench testing adhering to existing standards is sufficient 
for defining substantial equivalence.  
2. If a device introduces a new technological component which does not exist in a 
previously approved device, such as a new software system, or utilizes a novel 
combination of technological characteristics from multiple previously approved devices, 
additional testing to verify the safety of the novel technological characteristics should be 
required.  
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3. If a device introduces multiple new technological components at once or possesses a 
novel use scenario, such as the Da Vinci System allowing a surgeon to remotely perform 
surgical procedures rather than requiring the surgeon to make contact with the patient, 
clinical trials should be required to ensure patient safety and identify possible failure 
modes within the design.  
 
These guidelines are not intended to create any additional burden for regulators or 
manufacturers, and the testing requirements identified are all currently utilized at the discretion 
of the CDRH. Rather these guidelines are intended to standardize testing requirements across 
510(k) approval applications and close some of the gaps which have allowed the approval of 
“leap” devices. 
 
The FDA has recently begun taking steps to address the presence of extreme technology creep, 
so-called “leap” devices, in the regulatory process by creating more stringent guidelines for 
identification of predicate devices. These new guidelines reject the use of split predicates, where 
a device identifies one predicate for intended use and a separate predicate for technological 
characteristics. Although rarely utilized, this form of predicate identification is especially 
dangerous, as without additional scientific evidence it provides no assurance that a technology is 
safe for a particular use scenario. However, most “leap” devices identified in this research were 
not approved using split predicates, but rather multiple predicates comprised of “step” devices 
specifically designed to advance the desired use case for a particular technology. Although the 
FDA discourages the use of multiple predicates when possible, it is still considered a viable 
approval mechanism IF the intended use of the predicates and subject device are the same. Based 
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on the high number of multiple predicate relationships identified in the approval history of the 
Intuitive Da Vinci and other devices analyzed in this research, I would recommend that the FDA 
take steps to create specific guidelines limiting the number of predicates which can be identified 
in a single predicate generation. 
 
7.4 CONCLUDING THOUGHTS 
 
Given the number of new medical devices entering the market each year, and the increasing 
technical complexity of those devices, it is unsurprising that new regulatory challenges have also 
emerged. However, many scholars and experts agree that the regulatory challenges which have 
emerged from major device failures in recent years are not due solely to the introduction of new 
technologies, but rather are symptomatic of inherent flaws in the foundation of the regulatory 
process. In particular, researchers point to the use of substantial equivalence for determining 
device safety and efficacy in the 510(k) Approval Process as a mechanism by which many flaws, 
such as predicate creep and lack of scientific evidence, are introduced into the regulatory 
process. 
 
This research focused specifically on examining the 510(k) Approval Process as it was applied to 
various Robotic Assisted Surgical systems, an emerging technology with a high degree of 
technical complexity, with specific focus on the Intuitive Da Vinci Surgical System. The 
objective of this research was to examine the predicate history of these devices in order to 
explore the level of information publicly available about the approval process, assess whether 
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significant predicate creep or other issues occurred within the regulatory process, and identify 
resulting implications for policy. 
 
The primary method used to address these objectives was the development of multiple predicate 
ancestry trees using information available through FDA databases. Although the amount of 
available data is significantly limited due to database restrictions, particularly the lack of 
approval summaries for older devices, the predicate traces developed contained enough 
information to draw conclusions about the approval process. Through analysis of these traces, 
including the use of additional regulatory information such as product classification codes, I was 
able to conclude that there is indeed predicate creep present within the 510(k) Approval Process. 
In fact, upon examination of the relationship between the 510(k) Process and technological 
innovation in medical devices, I found that small amounts of technology creep must exist in 
predicate relationships for new medical devices to possess any level of innovation or value to the 
market. This small-scale predicate creep between one device and the next has minimal impact on 
the safety of new medical devices, if the guidelines laid out in the approval process are followed 
and adequate precautions are taken to ensure that new device characteristics are safe. 
This research has found, however, that although small-scale predicate creep has a place in the 
approval process, inadequate measures have been taken to address the impact of large-scale 
predicate creep and other regulatory issues, such as multiple predicates, which have allowed for 
approval of entirely new devices via the 510(k) Process. Large-scale predicate creep occurs over 
time, as repeated small-scale innovations slowly change a device until it no longer resembles the 
original predicate. Although this process technically violates the intention of the 510(k) Process 
by ultimately approving new devices with minimal scientific evidence, there is some assurance 
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of device safety provided by the market success of existing predicates. If all the preceding 
predicate devices are safe, and precautions are taken to mitigate small-scale predicate creep, in 
many cases devices exhibiting large-scale predicate creep may still be safe. The potential 
problems with large scale predicate-creep arise when the lack of scientific evidence is combined 
with unsafe predicates or other regulatory issues.  
 
Although predicate creep was identified by other researchers as one of the primary concerns with 
the regulatory process, this research found that the most pressing concern with the 510(k) 
Process is the presence of “leap” devices. While large-scale predicate creep occurs through a 
series of steps over a long period of time, allowing for some risk mitigation at each step, a “leap” 
device is one in which there is a sudden increase or change in the technological complexity and 
characteristics of a device. Combinations of vague regulatory definitions, broad device 
descriptions, and use of multiple predicates under the current regulatory process have allowed 
the approval of these “leap” devices, which display high levels of technology creep in a short 
period of time. The regulatory process as it currently exists is unable to consistently ensure the 
safety of such devices, as the powers to require additional evidentiary support are applied at the 
discretion of FDA officials, and few guidelines exist for when they should be applied. Therefore, 
my recommendation is to implement a modified version of the 510(k) Process, which provides 
definitive guidelines for the level of scientific evidence required to support safety and effectivity 
claims based on the degree of new technological characteristics or functions in a device.  
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APPENDIX 1: PRODUCT CODE NAY DATABASE 
 
K Number Decision Date Device Name Company Application Type Determination 
K965001 7/31/97 
Intuitive Surgical Monarch Laparoscopic 
Manipulator Intuitive Surgical Traditional SE 
K990144 1/15/99 Endoscopic Instrument and Accessories Intuitive Surgical Traditional SE 
K002489 3/2/01 DaVinci Endoscopic Control System Intuitive Surgical Traditional SE 
K011002 5/30/01 DaVinci Surgical System Model ISI 1000 Intuitive Surgical Traditional SE 
K011281 7/24/01 Intuitive Surgical Ultrasonic Shears Intuitive Surgical Traditional SE 
K012833 11/16/01 Intuitive Surgical Bipolar Forceps Intuitive Surgical Traditional SE 
K021036 6/26/02 
Intuitive DaVinci Surgical System Model 
IS1200 Intuitive Surgical Traditional SE 
K021152 09/24/02 
ZEUS Microwrist Surgical System and 
Accessories Computer Motion Traditional SE 
K022574 11/12/02 
Intuitive Surgical da Vinci Endoscopic 
Instrument Control System and Endoscopic 
Instruments or da Vinci Surgical System Intuitive Surgical Traditional SE 
K030578 6/24/03 
Bipolar Grasper and Bipolar Scissors for 
the ZUES Microwrist Surgical System Computer Motion Traditional SE 
K040948 5/5/04  Intuitive Surgical Special SE 
K040237 7/7/04  Intuitive Surgical Traditional SE 
K042855 11/12/04  Intuitive Surgical Special SE 
K043153 12/15/04  Intuitive Surgical Special SE 
K050005 1/25/05  Intuitive Surgical Special SE 
K043288 3/3/05  Intuitive Surgical Traditional SE 
K050369 4/29/05  Intuitive Surgical Traditional SE 
K050802 6/29/05  Intuitive Surgical Traditional SE 
K060391 4/10/06  Intuitive Surgical Special SE 
K061260 5/18/06  Intuitive Surgical Special SE 
K063220 12/1/06  Intuitive Surgical Traditional SE 
K072627 2/7/08  Intuitive Surgical Traditional SE 
K070947 2/14/08  Intuitive Surgical Traditional SE 
K080291 3/19/08  Intuitive Surgical Traditional SE 
K081207 12/19/08  Intuitive Surgical Traditional SE 
K081137 2/18/09  Intuitive Surgical Traditional SE 
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K Number Decision Date Device Name Company Application Type Determination 
K082497 5/7/09  Intuitive Surgical Traditional SE 
K090993 12/16/09  Intuitive Surgical Traditional SE 
K093217 1/21/10  Intuitive Surgical Traditional SE 
K101743 2/4/11  Intuitive Surgical Traditional SE 
K101581 4/8/11  Intuitive Surgical Traditional SE 
K110451 8/26/11  Intuitive Surgical Traditional SE 
K112584 9/29/11  Intuitive Surgical Special SE 
K112263 10/7/11  Intuitive Surgical Special SE 
K112208 12/8/11 
Intuitive Surgical DaVinci Single-site 
Instruments and Accessories Intuitive Surgical Traditional SE w/ limits 
K110639 12/28/11  Intuitive Surgical Traditional SE 
K120215 4/30/12 
Intuitive Surgical da Vinci Single-Site 
Instruments and Accessories Intuitive Surgical Special SE w/ limits 
K113706 10/17/12  Intuitive Surgical Traditional SE 
K121921 10/25/12  Intuitive Surgical Traditional SE 
K123463 12/3/12  Intuitive Surgical Special SE 
K123840 2/14/13  Intuitive Surgical Special SE 
K122532 2/21/13 
Intuitive Surgical da Vinci Single-Site 
Instruments and Accessories Intuitive Surgical Traditional SE w/ limits 
K130726 6/7/13 
Da Vinci Single-Site Permanent Cautery 
Hook Intuitive Surgical Special SE w/ limits 
K130266 8/29/13  Intuitive Surgical Traditional SE 
K131861 3/28/14  Intuitive Surgical Traditional SE 
K131861 3/28/14  Intuitive Surgical Traditional SE 
      
K131962 4/17/14 
Da Vinci Sp Surgical System, Model 5P999, 
Endo Wrist Sp Instruments, and 
Accessories Intuitive Surgical Traditional SE w/ limits 
K140189 6/5/14  Intuitive Surgical Traditional SE 
K140553 7/25/14  Intuitive Surgical Traditional SE 
K141077 8/12/14  Intuitive Surgical Traditional SE 
K123329 9/17/14 
Intuitive Surgical da Vinci, da Vinci S and 
da Vinci Si Surgical Systems and EndoWrist 
Instruments and Accessories Intuitive Surgical Traditional SE w/ limits 
K141075 9/26/14 Single-Site Wristed Needle Driver Intuitive Surgical Traditional SE w/ limits 
K143217 12/3/14  Intuitive Surgical Special SE 
K142683 12/10/14  Intuitive Surgical Traditional SE 
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K Number Decision Date Device Name Company Application Type Determination 
K150837 3/30/15  Intuitive Surgical Special SE 
K143132 4/2/15  Intuitive Surgical Traditional SE 
K150284 5/15/15  Intuitive Surgical Special SE 
K151794 1/15/16  Intuitive Surgical Traditional SE 
K152421 3/4/16  Intuitive Surgical Traditional SE 
K152448 3/9/16  Intuitive Surgical Traditional SE 
K152578 3/30/16  Intuitive Surgical Traditional SE 
K152892 4/29/16  Intuitive Surgical Traditional SE 
K161271 7/11/16  Intuitive Surgical Special SE 
K153276 8/7/16  Intuitive Surgical Traditional SE 
K162411 9/21/16  Intuitive Surgical Special SE 
K161178 1/19/17  Intuitive Surgical Traditional SE 
K162973 2/6/17  Intuitive Surgical Traditional SE 
K170508 3/10/17  Intuitive Surgical Traditional SE 
K170865 4/21/17  Intuitive Surgical Traditional SE 
K171294 5/26/17  Intuitive Surgical Special SE 
K171388 5/31/17  Intuitive Surgical Special SE 
K170713 6/13/17  Intuitive Surgical Traditional SE 
K171426 6/13/17  Intuitive Surgical Special SE 
K171699 7/28/17  Intuitive Surgical Traditional SE 
K170644 9/11/17  Intuitive Surgical Traditional SE 
K170645 9/11/17  Intuitive Surgical Traditional SE 
K170875 9/12/17  Intuitive Surgical Traditional SE 
K171632 9/19/17  Intuitive Surgical Traditional SE 
K170641 9/21/17  Intuitive Surgical Traditional SE 
K170879 9/21/17  Intuitive Surgical Traditional SE 
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APPENDIX 2: DA VINCI SI PREDICATES 
 
K Number Device Name Manufacturer Approval Date Product Code Recalls 
K081137 Intuitive Surgical Da Vinci Si Surgical System: Model Is3000 INTUITIVE SURGICAL, INC. 2/18/2009 NAY 24 – Class II 
K063220 Da Vinci S Surgical System-V1.1, Model Is2000 INTUITIVE SURGICAL, INC 12/1/2006 NAY 4 – Class II 
K050802 
Modification To Intuitive Surgical Da Vinci Surgical System 
And Endoscopic Instruments 
INTUITIVE SURGICAL, INC. 6/29/2005 NAY 0 
K050369 Intuitive Surgical Da Vinci Surgical System, Model Is2000 INTUITIVE SURGICAL, INC. 4/29/2005 NAY 43 – Class II 
K050404 
Intuitive Surgical Da Vinci Surgical System And Endoscopic 
Instruments 
INTUITIVE SURGICAL, INC. 4/21/2005 HET 0 
K043288 
Modification To Intuitive Surgical Da Vinci Surgical System 
And Endoscopic Instruments 
INTUITIVE SURGICAL, INC 3/3/2005 NAY 0 
K050005 
Intuitive Surgical Monopolar Curved Scissors, Model 
400179; Tip Cover Accessory, Model 400180 
INTUITIVE SURGICAL, INC. 1/25/2005 NAY 2 – Class II 
K043153 
Intuitive Surgical Da Vinci Surgical System And Endoscopic 
Instruments, Models Is1200 & Is1000 
INTUITIVE SURGICAL, INC. 12/15/2004 NAY 0 
K042855 Intuitive Surgical Harmonic Curved Shears Instrument INTUITIVE SURGICAL, INC. 11/12/2004 NAY 0 
K041340 Guidant Microwave Ablation System 
GUIDANT CORPORATION, 
CARDIAC SURGERY 
7/28/2004 
NEY 
OCL 
0 
K040237 
Intuitive Surgical Da Vinci Endoscopic Instrument Control 
System And Endoscopic Instruments 
INTUITIVE SURGICAL, INC. 7/7/2004 NAY 0 
K040948 
Intuitive Surgical Endopass Endoscopic Delivery 
Instrument, Model P/N 400170 
INTUITIVE SURGICAL, INC. 5/5/2004 NAY 0 
K022574 
Intuitive Surgical Endoscopic Instrument Control System & 
Endoscopic Instruments, Model Da Vinci ISI 1000/1200 
INTUITIVE SURGICAL, INC. 11/12/2002 NAY 0 
K021036 Intuitive Surgical Da Vinci Surgical System, Model IS1200 INTUITIVE SURGICAL, INC. 6/26/2002 NAY 18 – Class II 
K013946 Flex 10 Accessory For The Afx Microwave Ablation System AFX, INC. 2/27/2002 
NEY 
OCL 
0 
K013416 Intuitive Surgical Endowrist Endoscopic Instrument Family INTUITIVE SURGICAL, INC. 1/10/2002 GEI 0 
K012833 Intuitive Surgical Bipolar Forceps INTUITIVE SURGICAL, INC 11/16/2001 NAY 4 – Class II 
K011281 Intuitive Surgical Ultrasonic Shears INTUITIVE SURGICAL, INC. 7/24/2001 
NAY 
LFL 
0 
K011002 Intuitive Surgical Da Vinci Surgical System, Model Isi 1000 INTUITIVE SURGICAL, INC. 5/30/2001 NAY 0 
K003978 
Afx Microwave Generator, Flex Ablation Wand, Lynx 
Ablation Wand, Model Series 1000, P/N 102006, P/N 
102007 
AFX, INC. 5/22/2001 
NEY 
OCL 
0 
K002489 Intuitive Surgical Da Vinci Endoscopic Control System INTUITIVE SURGICAL, INC. 3/2/2001 NAY 0 
K990144 
Intuitive Surgical Endoscopic Instruments, Intuitive Surgical 
Endoscopic Instrument Control System 
INTUITIVE SURGICAL, INC. 7/11/2000 NAY 3 – Class II 
K993054 
Ultracision Harmonic Scalpel Coagulating Shears, Models 
Lcs-C5, Lcs-C1, Cs-23c, Cs-231, Cs-14c, Cs-141 
ETHICON ENDO-SURGERY, 
INC. 
12/9/1999 LFL 0 
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K Number Device Name Manufacturer Approval Date Product Code Recalls 
K991859 Dexide Bipolar Forceps Ii ** Device 
UNITED STATES SURGICAL, A 
DIVISION OF TYCO HEALTHC 
6/23/1999 GEI 0 
K980099 
Ultracision Laparosonic Coagulating Shears (Lcs-5(Lcsk5 
And Lcsb5)) 
ETHICON ENDO-SURGERY, 
INC. 
4/9/1998 LFL 0 
K974320 Cryogen Cardiac Cryosurgical System CRYOGEN, INC. 2/3/1998 OCL 0 
K972662 Cryogen Cryosurgical System CRYOGEN, INC. 10/1/1997 GEH 0 
K972415 Minisite*Bipolar Forceps** Device 
UNITED STATES SURGICAL, A 
DIVISION OF TYCO HEALTHC 
9/19/1997 GEI 0 
K965001 Intuitive Surgical Monarch Laparoscopic Manipulator INTUITIVE SURGICAL, INC. 7/31/1997 GCJ 0 
K971861 Ultrasonic Hand Instruments 
UNITED STATES SURGICAL, A 
DIVISION OF TYCO HEALTHC 
7/1/1997 LFL 0 
K970496 Heartport Maze System: Cryoprobe Set HEARTPORT, INC. 5/9/1997 OCL 0 
K964971 Cryogen Cryosurgical System CRYOGEN, INC. 3/28/1997 GEH 0 
K960400 
Diamond-Touch And Micro Diamond-Touch 
Instruments/Diamond-Line Instruments/Diamond-Port 
(Access Parts) 
SNOWDEN-PENCER 3/12/1996 
FBM 
GCJ 
GEI 
0 
K953637 CMS Accuprobe 550/530 CRYOMEDICAL SCIENCES, INC. 12/4/1995 GEH 0 
K953059 Kittner Dissector 
MEDICAL PERSPECTIVES 
CORP. 
9/14/1995 GDY  0 
K930666 Reusable Laparoscopic Instruments W/ Electrocautery SNOWDEN-PENCER 5/19/1994 GEI 0 
K930667 Reusable Laparoscopic Instruments SNOWDEN-PENCER 5/16/1994 GCJ 0 
K933169 Inman Endoscopic Blunt Dissector INMAN MEDICAL CORP. 4/19/1994 GCJ 0 
K936308 Endex Endoscopic Positioning System ANDRONIC DEVICES, LTD. 3/31/1994 FQO 0 
K931783 
AESOP (Automated Endoscopic System For Optimal 
Positioning) 
COMPUTER MOTION, INC 11/22/1993 GCJ 0 
K931340 Grasp Forceps/Scissors/Needle Holder/Dissector BAXTER HEALTHCARE CORP. 7/1/1993 GCS 0 
K925699 Harmonic Scalpel Laparosonic Clamp Coagulator Acc. ULTRACISION, INC. 5/17/1993 GCJ 0 
K914190 Auto Suture(R) Endoscopic Fan Retractor 
UNITED STATES SURGICAL, A 
DIVISION OF TYCO HEALTHC 
5/6/1992 GAD 0 
K912544 Bipolar Forceps EVEREST MEDICAL CORP. 6/24/1991 MAV 0 
K904421 CMS Oncoprobe CRYOMEDICAL SCIENCES, INC. 4/8/1991 GEH 0 
K882568 130 Cryo Unit & Assoc. Cryoprobes & Spray SPEMBLY MEDICAL LTD. 9/27/1988 GEH 0 
K874367 Various Cardiac Cryoprobes Having Dia. & Cos. Diff SPEMBLY MEDICAL LTD. 1/4/1988 HQO 0 
K811390 Ccs100 Cryosurgical System 
FRIGITRONICS OF 
CONNECTICUT, INC. 
6/16/1981 GEH 0 
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APPENDIX 3: PRODUCT CODE DEFINITIONS 
 
Product 
Code Device Regulation Description 
FBM Cannula And Trocar, Suprapubic, Non-Disposable Suprapubic urological catheter and accessories 
NEY System, Ablation, Microwave And Accessories 
Electrosurgical cutting and coagulation device and 
accessories 
NAY System, Surgical, Computer Controlled Instrument Endoscope and accessories 
HET Laparoscope, Gynecologic (And Accessories) Gynecologic laparoscope and accessories 
GEI Electrosurgical, Cutting & Coagulation & Accessories 
Electrosurgical cutting and coagulation device and 
accessories 
LFL Instrument, Ultrasonic Surgical  
OCL 
Surgical Device, For Cutting, Coagulation, And/Or Ablation Of Tissue, 
Including Cardiac Tissue 
Electrosurgical cutting and coagulation device and 
accessories 
GEH Unit, Cryosurgical, Accessories Cryosurgical unit and accessories 
GCJ Laparoscope, General & Plastic Surgery Endoscope and accessories 
GDY Gauze/Sponge, Internal, X-Ray Detectable Nonabsorbable gauze for internal use 
GCS Endoscope, Battery-Powered And Accessories Endoscope and accessories 
MAV Syringe, Balloon Inflation Angiographic injector and syringe 
HQO Unit, Cautery, Thermal, Ac-Powered Thermal cautery unit 
FAJ Cystoscope And Accessories, Flexible/Rigid Endoscope and accessories 
OWB Interventional Fluoroscopic X-Ray System Image-intensified fluoroscopic x-ray system 
EOQ Bronchoscope (Flexible Or Rigid) Bronchoscope (flexible or rigid) and accessories 
DRF Catheter, Electrode Recording, Or Probe, Electrode Recording 
Electrode recording catheter or electrode recording 
probe 
EOB Nasopharyngoscope (Flexible Or Rigid) 
Nasopharyngoscope (flexible or rigid) and 
accessories 
NWB Endoscope, Accessories, Narrow Band Spectrum Endoscope and accessories 
FAM Sigmoidoscope And Accessories, Flexible/Rigid Endoscope and accessories 
FDF Colonoscope And Accessories, Flexible/Rigid Endoscope and accessories 
HRX Arthroscope Arthroscope 
FET Endoscopic Video Imaging System/Component, Gastroenterology-Urology Endoscope and accessories 
FER Anoscope And Accessories Endoscope and accessories 
FED Endoscopic Access Overtube, Gastroenterology-Urology Endoscope and accessories 
GCF Proctoscope Endoscope and accessories 
FCG Biopsy Needle Gastroenterology-urology biopsy instrument 
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Product 
Code Device Regulation Description 
DXX System, Catheter Control, Steerable Steerable catheter control system 
DYB Introducer, Catheter Catheter introducer 
LZA Polymer Patient Examination Glove Non-powdered patient examination glove 
FDS Gastroscope And Accessories, Flexible/Rigid Endoscope and accessories 
GWG Endoscope, Neurological Neurological endoscope 
ERL Drill, Surgical, Ent (Electric Or Pneumatic) Including Handpiece 
Ear, nose, and throat electric or pneumatic surgical 
drill 
OXO Image-Intensified Fluoroscopic X-Ray System, Mobile Image-intensified fluoroscopic x-ray system 
FDT Duodenoscope And Accessories, Flexible/Rigid Endoscope and accessories 
MDA Elastomer, Silicone, For Scar Management Silicone sheeting 
DZP Instrument, Diamond, Dental Dental diamond instrument 
FJL Resectoscope Endoscope and accessories 
FBN Choledochoscope And Accessories, Flexible/Rigid Endoscope and accessories 
HTZ Instrument, Cutting, Orthopedic Manual surgical instrument for general use 
CAL Laryngoscope, Non-Rigid Flexible laryngoscope 
FBO Cystourethroscope Endoscope and accessories 
HSZ 
Instrument, Surgical, Orthopedic, Pneumatic Powered & 
Accessory/Attachment 
Surgical instrument motors and 
accessories/attachments 
KIJ 
Instrument, Surgical, Orthopedic, Dc-Powered Motor And 
Accessory/Attachment 
Surgical instrument motors and 
accessories/attachments 
ODB Endoscopic Contamination Prevention Sheath Endoscope and accessories 
JAB System, X-Ray, Fluoroscopic, Non-Image-Intensified Non-image-intensified fluoroscopic x-ray system 
JAA System, X-Ray, Fluoroscopic, Image-Intensified Image-intensified fluoroscopic x-ray system 
HWE 
Instrument, Surgical, Orthopedic, Ac-Powered Motor And 
Accessory/Attachment 
Surgical instrument motors and 
accessories/attachments 
GCT Light Source, Endoscope, Xenon Arc Endoscope and accessories 
FGA Kit, Nephroscope Endoscope and accessories 
FAL Panendoscope (Urethroscope) Endoscope and accessories 
EOX Esophagoscope (Flexible Or Rigid) Esophagoscope (flexible or rigid) and accessories 
DRA Catheter, Steerable Steerable catheter 
MQB Solid State X-Ray Imager (Flat Panel/Digital Imager) Stationary x-ray system 
KGE Forceps, Biopsy, Electric Endoscopic electrosurgical unit and accessories 
GCI Laryngoscope, Endoscope Endoscope and accessories 
FGB Ureteroscope And Accessories, Flexible/Rigid Endoscope and accessories 
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Product 
Code Device Regulation Description 
KNS Unit, Electrosurgical, Endoscopic (With Or Without Accessories) Endoscopic electrosurgical unit and accessories 
HAW Neurological Stereotaxic Instrument Stereotaxic instrument. 
LLZ System, Image Processing, Radiological Picture archiving and communications system 
OLO Orthopedic Stereotaxic Instrument Stereotaxic instrument. 
GAW Suture, Nonabsorbable, Synthetic, Polypropylene Nonabsorbable polypropylene surgical suture 
EPT Microscope, Surgical Surgical microscope and accessories 
LNH System, Nuclear Magnetic Resonance Imaging Magnetic resonance diagnostic device 
IZH System, X-Ray, Mammographic Mammographic x-ray system 
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APPENDIX 4: ANALYSIS OF SYMBIS SURGICAL 
SYSTEM PREDICATES 
 
 
Figure 15: SYMBIS Surgical System (T., 2015) 
 
The IMRIS (now Deerfield Imaging) SYMBIS Surgical System was designed as a spatial 
positioning and orientation guide for instruments in needle based brain biopsies. The system is 
comprised of three components, a manipulator arm located on a mobile base, a surgeon 
workstation, and a robotic control rack containing electronic equipment. The trajectory of a 
stereotactic instrument is guided by the surgeon from the workstation, which includes haptic 
feedback and 3D imaging for position control, using a manipulator arm with six degrees of 
freedom. The positioning mechanism of the device uses a robotic manipulator controlled from a 
separate surgeon control station similar to the method used in the Da Vinci Surgical system. 
However in the SYMBIS System the surgeon is required to manually perform portions of the 
surgery, including final deployment of the biopsy needle (Pena, 2015). The design of the 
SYMBIS Surgical System relies heavily on the incorporation of previously approved third-party 
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technologies into the design for key functions, including specifying use of the Medtronic 
StealthStation (K133444) for navigation and the Medtronic Biopsy Needle Kit (K971247) for 
instrumentation (Pena, 2015). 
 
The traceable predicate history of the SYMBIS Surgical System is comprised of 43 identified 
predicate relationships which includes 26 unique devices that can be traced to 10 ultimate 
predicate devices. The immediate predicate of the SYMBIS System is the ROSA Surgical 
Device (see Table 6), a computer-controlled electromechanical arm intended to aid in the spatial 
positioning and orientation of stereotaxic instruments (Eydelman, 2009). The intended use and 
technological characteristics of the ROSA System are very similar to those described for the 
SYMBIS System, with technological differences primarily associated with the incorporation of 
third-party positioning systems in the SYMBIS System (Pena, 2015 ). An overview of the 
predicate history for the SYMBIS Surgical System is shown in Figure 16 below. 
 
 
 
 
Figure 16: SYMBIS Surgical System predicate trace (see section A4.1 for additional device information). 
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Detailed approval information about the devices which appear in this predicate tree can be found 
in the SYMBIS Trace database in Section A4.1.  
 
Additional information about the devices included in the predicate ancestry, particularly 
regarding predicate creep, can be gleaned from comparison of the product codes and regulatory 
descriptions associated with each device. The product code is an identifier designated by the 
FDA to group devices with the same intended use and similar technological characteristics. Each 
product code is assigned a regulatory description which describes the function and intended use 
based on the device type. The regulatory description is more general than the device description, 
which means that two product codes with slightly different device descriptions may possess the 
same regulatory description. For example, the SYMBIS was assigned product code HAW, which 
describes a neurological stereotaxic instrument with the regulatory description of stereotaxic 
instrument. The product code OLO describes orthopedic stereotaxic instruments, however it has 
the same regulatory description as code HAW, stereotaxic instrument. A percentage breakdown 
of the product codes and regulatory descriptions for the unique devices present in the SYMBIS 
trace is shown in Figure 17 below. 
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Figure 17: Breakdown of SYMBIS predicate devices by product code and regulatory description. Due to the nature 
of the devices in this trace, the two breakdowns are identical. 
 
Unlike the devices in the Da Vinci trace, and the other robotic surgical system traces described 
below, the devices in the SYMBIS trace fall under only two product codes, HAW and LLZ. 
Code HAW, as described previously, pertains to neurological stereotaxic instruments, while code 
LLZ pertains to radiological imaging processing systems under the regulatory description 
“picture archiving and communications system”. Because the two codes possess different 
regulatory description, the product code and regulatory description breakdowns for the SYMBIS 
System are identical. All but two devices contained in the trace fall under code HAW, making it 
the dominant device type in this trace. The two devices classified under code LLZ both serve as 
ultimate predicates along the branch originating from the Zimmer Knee Ortho Guidance 
Instruments (K033011), which incorporates CT scan modeling for surgical instrument guidance. 
Thus, these devices appear to be included in the trace to serve as predicates for the introduction 
of technological characteristics related to the imaging incorporated in later guidance systems. 
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A4.1     ADDITIONAL SYMBIS SYSTEM PREDICATE INFORMATION 
 
K Number Device Name Manufacturer Approval Date Product Code Recalls 
K143420 SYMBIS Surgical System IMRIS, Inc. 10/30/2015 HAW 0 
K101791 ROSA SURGICAL DEVICE MEDTECH SAS 9/23/2010 HAW 12 – Class II 
K092239 ROSA SURGICAL DEVICE, MODEL ROSA 1.1 MEDTECH S.A. 11/17/2009 HAW 9 – Class II 
K060556 BRIGIT SURGICAL DEVICE ZIMMER INC 7/31/2006 HAW 0 
K052425 
ZIMMER COMPUTER ASSISTED SOLUTIONS-
ELECTROMAGNETIC AND IMAGELESS KNEE 
INSTRUMENTATION 
ZIMMER, INC. 12/28/2005 HAW 0 
K050438 STEALTHSTATION SYSTEM UPDATE 
MEDTRONIC SURGICAL NAVIGATION 
TECHNOLOGIES 
6/2/2005 HAW 11 – Class II 
K043536 
NAVITRACK SYSTEM - S&N IMAGE FREE 
KNEE 
ORTHOSOFT, INC. 1/14/2005 HAW 0 
K033223 
ZIMMER ORTHO GUIDANCE SYSTEMS- HIP 
INSTRUMENTS 
ZIMMER, INC. 2/18/2004 HAW 0 
K023651 VECTORVISION CRANIAL/ENT BRAINLAB AG 2/17/2004 HAW 1 – Class II 
K033011 
ZIMMER ORTHO GUIDANCE SYSTEMS- KNEE 
INSTRUMENTS 
ZIMMER, INC. 2/12/2004 HAW 0 
K022126 
CATHETER INTRODUCER FOR THE 
STEALTHSTATION SYSTEM 
MEDTRONIC SURGICAL NAVIGATION 
TECHNOLOGIES 
1/3/2003 HAW 0 
K021760 
NAVITRACK SYSTEM-OPTICAL TKR CT-LESS, 
MODEL 900.120 
ORTHOSOFT, INC 8/27/2002 HAW 0 
K003589 
VECTORVISION CRANIAL, VECTORVISION 
SPINAL, VECTORVISION ENT 
BRAINLAB AG 5/21/2001 HAW 0 
K003347 ORTHOPILOT KINAMED, INC 2/23/2001 HAW 0 
K002053 
NAVITRAK SYSTEM-OPTICAL OPTION, 
MODEL 900.004 
ORTHOSOFT, INC. 8/3/2000 HAW 0 
K001801 
STEATHSTATION TREATMENT GUIDANCE 
PLATFORM 
MEDTRONIC SURGICAL NAVIGATION 6/30/2000 HAW 0 
K991081 FRAMELESS NEUROMATE INTEGRATED SURGICAL SYSTEMS, INC. 6/25/1999 HAW 0 
K983831 VECTORVISION2 BRAINLAB, AG 5/19/1999 HAW 0 
K964801 OPTICAL TRACKING SYSTEM (OTS) 
RADIONICS SOFTWARE APPLICATIONS, 
INC. 
6/2/1997 HAW 0 
K963256 NEUROMATE STEREOTACTIC SYSTEM INTEGRATED SURGICAL SYSTEMS, S. A 5/9/1997 HAW 0 
K961844 
OPERATING ARM SYSTEM (OAS) [WITH CT 
AND MR IMAGES] 
RADIONICS SOFTWARE APPLICATIONS, 
INC. 
10/23/1996 HAW 0 
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K Number Device Name Manufacturer Approval Date Product Code Recalls 
K954276 STEALTHSTATION 
SURGICAL NAVIGATION 
TECHNOLOGIES, INC. 
1/24/1996 HAW 1 – Class II 
K951262 OPERATING ARM SYSTEM (OAS) 
RADIONICS SOFTWARE APPLICATIONS, 
INC. 
11/13/1995 LLZ 0 
K911783 ALLEGRO VIEWING WAND I.S.G. TECHNOLOGIES, INC. 4/7/1994 LLZ 0 
K871046 
COMPASS STEREOTACTIC POSITIONING 
SYSTEM 
STEREOTACTIC MEDICAL SYSTEMS, INC 5/8/1987 HAW 0 
K811452 
BROWN-ROBERTS-WELLS STEREOTAXIC 
SYTEM 
TRENT WELLS, INC. 6/2/1981 HAW 0 
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APPENDIX 5: ANALYSIS OF MAKO RIO-THA 
SYSTEM PREDICATES 
 
 
Figure 18: MAKO RIO-THA System 
 
The MAKO (now Stryker Medical) Robotic Arm Interactive Surgical Operating System (RIO) is 
designed to provide stereotactic guidance during minimally invasive knee (K081867) and hip 
(K093425) procedures using patient CT scan data to assist a surgeon in pre-operative planning 
and intraoperative navigation. The system consists of three components, a computer station for 
inputting CT scan data and identifying markers, a viewing station, and the main RIO platform 
mounted on a moveable cart (Stryker, 2018 ). The main platform consists of a multi-jointed arm 
which uses sensors to provide real time visual, tactile, and auditory feedback as it is positioned 
manually by the surgeon during a procedure (Adventist Health Sonora, n.d.). The RIO arm aids 
in positioning and stabilization of tools to identify optimal locations for implant placement 
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during procedures to improve results and reduce complications. While the primary purpose of the 
Da Vinci system is to serve as a replacement for the surgeon’s hands to increase surgeon 
dexterity and reduce error in traditional MIS procedures, the primary purpose of the RIO system 
is to assist in optimal positioning of implants for a manually performed surgery. 
 
The traceable predicate history of the MAKO RIO-THA includes 590 predicate relationships 
between 53 unique devices, which can be traced to 21 ultimate predicate devices. The RIO 
system identified as the subject device for this trace is the RIO-THA, used in total hip 
arthroplasty procedures. Another version of the RIO System, used for applications in knee 
surgery serves, as a predicate device for the RIO-THA. An overview of the RIO System trace 
can be seen in Figure 19, with additional information about each device shown in the trace 
located in Section A5.1. 
 
 
 
Figure 19: MAKO RIO – THA predicate tree (see section A5.1 for additional device information). 
 
Examination of the RIO trace reveals patterns in the approval application process, including 
duplication of predicate devices between generations and within branches. This is evidenced by 
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the fact that there are only 53 unique devices identified among 590 substantial equivalence 
claims.  
 
The 48 devices present in the RIO trace are grouped into 7 different product codes, with 42 of 
the devices under code HAW for stereotaxic instruments. Of the remaining devices, 3 are under 
code OLO, also for stereotaxic instruments, 4 are classified under code LLZ for radiological 
image processing, and the remaining 4 devices each have a unique product code. Examination of 
this breakdown, as seen in Figure 20, reveals that the RIO trace is dominated by stereotaxic 
instruments, primarily designated for neurological applications. It is only the two versions of the 
MAKO RIO and another associated product in the first predicate generation (closest to RIO) 
which are designated for orthopedic use under Code OLO. 
 
 
Figure 20: Breakdown of RIO-THA predicates by product code and regulatory description, The overall structures of 
the breakdowns are similar, with a single classification (HAW and Stereotaxic Instrument) containing most 
predicates. However, the largest regulatory description contains devices under product codes HAW and OLO, 
making the resulting group slightly larger. 
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A5.1     ADDITIONAL RIO-THA PREDICATE INFORMATION 
 
K Number Device Name Manufacturer Approval Date Product Code Recalls 
K093425 
MAKO SURGICAL CORP ROBOTIC ARM INTERACTIVE 
ORTHOPEDIC SYSTEM-THA 
MAKO SURGICAL CORP. 2/24/2010 OLO 1 – Class II 
K091998 
ROBOTIC ARM INTERACTIVE ORTHOPEDIC SYSTEM-
HIP 
MAKO SURGICAL CORP. 9/28/2009 OLO 0 
K083644 MAKO SURGICAL TACTILE GUIDANCE SYSTEM-HIP MAKO SURGICAL CORP. 6/19/2009 OLO 0 
K081867 
MAKO SURGICAL TACTILE GUIDANCE SYSTEM 
VERSION 2.0 
MAKO SURGICAL CORP. 11/25/2008 HAW 2 – Class II 
K072806 MAKO SURGICAL TACTILE GUIDANCE SYSTEM (TGS) MAKO SURGICAL CORP. 1/24/2008 HAW 1 – Class II 
K072716 VECTOR VISION HIP BRAINLAB AG 10/12/2007 HAW 0 
K071714 
NAVITRACK SYSTEM - OS UNICONDYLAR KNEE 
UNIVERSAL, MODEL# PRO-06003 
ORTHOSOFT, INC. 7/20/2007 HAW 2 – Class II 
K062146 UNI KNEE SURGETICS NAVIGATION SYSTEM PRAXIM S. A 8/21/2006 HAW 0 
K060336 
NAVITRACK SYSTEM-OS KNEE UNIVERSAL, MODEL 
PRO-05002 
ORTHOSOFT, INC. 4/28/2006 HAW 
2 – Class II 
1 – Class III 
K060282 TOTAL KNEE SURGETICS NAVIGATION SYSTEM PRAXIM SA 4/10/2006 HAW 0 
K052851 
VOYAGER LINUX WITH TACTILE GUIDANCE SYSTEM 
(TGS) 
MAKO SURGICAL CORP. 11/18/2005 HAW 0 
K052213 NAVIGATION SW HIP 3.1 ON CI BRAINLAB AG 11/2/2005 HAW 0 
K031196 
SURGETICS ORTHO KNEELOGICS NAVIGATION 
SYSTEM 
PRAXIM 6/7/2005 HAW 0 
K050973 MODIFICATION TO: VOYAGER LINUX MAKO SURGICAL CORP. 5/17/2005 HAW 0 
K050615 
STRYKER NAVIGATION SYSTEM - CT-BASED HIP 
MODULE, MODEL 6007-621-000 
STRYKER INSTRUMENTS 4/21/2005 HAW 0 
K043536 NAVITRACK SYSTEM - S&N IMAGE FREE KNEE ORTHOSOFT, INC. 1/14/2005 HAW 0 
K040368 VECTORVISION HIP 3.0 BRAINLAB AG 8/23/2004 HAW 0 
K031454 ACUMEN SURGICAL NAVIGATION SYSTEM BIOMET, INC. 7/8/2004 HAW 0 
K031337 ACUMEN SURGICAL NAVIGATION SYSTEM BIOMET, INC. 9/15/2003 HAW 0 
K022364 
NAVITRACK SYSTEM TOTAL HIP REPLACEMENT, 
MODEL 900.200 
ORTHOSOFT, INC. 2/4/2003 HAW 0 
K022365 STRYKER NAVIGATION SYSTEM - HIP MODULE STRYKER INSTRUMENTS 1/22/2003 HAW 10 – Class II 
K023975 VOYAGER LINUX Z-KAT, INC. 12/20/2002 HAW 0 
K021306 VECTORVISION CT-FREE KNEE BRAINLAB AG 10/25/2002 HAW 0 
K021760 
NAVITRACK SYSTEM-OPTICAL TKR CT-LESS, MODEL 
900.120 
ORTHOSOFT, INC. 8/27/2002 HAW 0 
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K014256 KOLIBRI IGS SYSTEMS BRAINLAB AG 7/19/2002 HAW 0 
K013025 MODIFICATION TO FLOUROLAB PLUS Z-KAT, INC. 10/3/2001 HAW 0 
K Number Device Name Manufacturer Approval Date Product Code Recalls 
K010602 VECTORVISION HIP BRAINLAB, AG 9/12/2001 HAW 0 
K010612 VECTORVISION KNEE BRAINLAB, AG 9/6/2001 HAW 0 
K003589 
VECTORVISION CRANIAL, VECTORVISION SPINAL, 
VECTORVISION ENT 
BRAINLAB AG 5/21/2001 HAW 0 
K003347 ORTHOPILOT KINAMED, INC. 2/23/2001 HAW 0 
K002053 
NAVITRAK SYSTEM-OPTICAL OPTION, MODEL 
900.004 
ORTHOSOFT, INC. 8/3/2000 HAW 0 
K001284 
STEALTHSTATION SYSTEM GOLDENEYE MICRO-
MAGNETIC TRACKING SYSTEM 
MEDTRONIC SURGICAL 
NAVIGATION 
TECHNOLOGIES 
6/12/2000 HAW 
27 – Class II 
1 – Class III 
K000310 VOYAGER 6.0 SOFTWARE OPTION 
PHILIPS MEDICAL 
SYSTEMS(CLEVELAND), INC. 
2/15/2000 HAW 0 
K993239 
STRYKER NAVIGATION SYSTEM - NEURO MODULE, 
MODEL 6000-XXX-XXX 
STRYKER CORP. 1/18/2000 HAW 
2 – Class I 
4 – Class II 
K984298 Z KAT FLUROTACTIC GUIDANCE SYSTEM MKI Z-KAT, INC. 6/23/1999 HAW 0 
K983831 VECTORVISION2 BRAINLAB, AG 5/19/1999 HAW 0 
K990214 
FLUORONAV MODULE FOR THE STEALTHSTATION 
SYSTEM 
SURGICAL NAVIGATION 
TECHNOLOGIES, INC. 
4/22/1999 HAW 29 – Class II 
K964229 REGULUS NAVIGATOR COMPASS INTL., INC 8/19/1997 HAW 0 
K962939 VECTORVISION BRAINLAB, INC. 5/22/1997 HAW 0 
K970604 VIEWPOINT - 3.0 SOFTWARE 
PHILIPS MEDICAL 
SYSTEMS(CLEVELAND), INC. 
5/19/1997 HAW 0 
K963221 OPTICAL DIGITIZER OPTION FOR VIEW POINT 
PHILIPS MEDICAL 
SYSTEMS(CLEVELAND), INC. 
1/10/1997 HAW 0 
K961844 
OPERATING ARM SYSTEM (OAS) [WITH CT AND MR 
IMAGES] 
RADIONICS SOFTWARE 
APPLICATIONS, INC 
10/23/1996 HAW 0 
K960714 ISG VIEWING WAND I.S.G. TECHNOLOGIES, INC 5/29/1996 HAW 0 
K961168 VIEWPOINT 
PHILIPS MEDICAL 
SYSTEMS(CLEVELAND), INC. 
5/16/1996 GAW 0 
K954276 STEALTHSTATION 
SURGICAL NAVIGATION 
TECHNOLOGIES, INC. 
1/24/1996 HAW 1 – Class II 
K944612 
ACUSTAR I ADVANCED SURGICAL NAVIGATION 
SYSTEM 
Codman & Shurtleff, Inc. 12/11/1995 LLZ 0 
K951262 OPERATING ARM SYSTEM (OAS) 
RADIONICS SOFTWARE 
APPLICATIONS, INC. 
11/13/1995 LLZ 0 
K935456 REGULUS MEASUREMENT UNIT COMPASS INTL., INC. 10/13/1995 HAW 0 
K942233 
MKM (MULTIPLE COORDINATE MANIPULATOR) 
SYSTEM 
CARL ZEISS, INC. 7/1/1994 EPT 0 
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K Number Device Name Manufacturer Approval Date Product Code Recalls 
K911783 ALLEGRO VIEWING WAND I.S.G. TECHNOLOGIES, INC. 4/7/1994 LLZ 0 
K905070 VISTAR 
PHILIPS MEDICAL 
SYSTEMS(CLEVELAND), INC. 
1/2/1991 LNH  0 
K901679 RESUBMITTED ISG 3DMV WORKSTATION I.S.G. TECHNOLOGIES, INC. 5/29/1990 LLZ 0 
K861692 
FISCHER PPS/MAMMOTEST MAMMOGRAPHY 
SYSTEM 
FISCHER IMAGING CORP. 12/15/1986 IZH  1 – Class II 
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APPENDIX 6: ANALYSIS OF MEDROBOTICS FLEX 
ROBOTIC SYSTEM PREDICATES 
 
Figure 21: Medrobotics Flex System 
 
The primary function of the Medrobotics Flex Transabdominal Robotic System, as seen in 
Figure 21, is to serve as an assistive laparoscopic device for minimally invasive surgical (MIS) 
procedures in areas of the body which may be difficult to reach with traditional rigid scopes. The 
system is comprised of two main components, a moveable cart containing the jointed robotic arm 
and attached scope, and a surgical control station with an HD imaging display and a joystick for 
motion control. The primary innovation in the Flex System is the flexible, multi-jointed 
positioning mechanism within the scope and accompanying instruments that allow access to 
areas of the body that would traditionally be unreachable with MIS. This mechanism is 
structured similarly to a snake, with an external cable steered structure allowing for motion and 
an internal skeleton (see Figure 22), which allows the scope to be reliably placed in a stable 
position, and then used as a guide for positioning of the handheld Medrobotics Flex Instruments, 
which are used to perform the actual surgical procedure (Medrobotics, 2018). Unlike the Da 
Vinci System, where the system is controlled remotely to perform surgical procedures, the Flex 
System serves solely as an assistive device. Additionally, use of the Flex system is currently 
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limited to surgical procedures which can be performed via natural bodily orifices, specifically the 
mouth or anus, while the Da Vinci can be used to perform surgery via incisions. 
 
 
Figure 22: Medrobotics Flex System jointed scope structure (Medrobotics, 2018) 
 
The traceable predicate history of the Medrobotics Flex Transabdominal System includes 109 
substantial equivalence relationships between 42 unique devices, which can be traced to 21 
ultimate predicates. An overview of the Flex System trace can be seen in Figure 23, with 
additional information about each device shown in the trace located in Section A6.1. 
 
  
 
Figure 23: Medrobotics Flex System predicate trace (see section A6.2 for additional predicate information). 
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The 42 unique devices in the direct predicate trace for the Flex Transabdominal System are 
classified into 23 different product codes, with GCJ and EOB the most prevalent. Unlike the 
other three traces, which each possessed a clearly dominant product code, the Flex System has 5 
codes each containing 7 or 8 predicate devices. However, although the devices described in these 
codes possess slightly different intended use cases, the majority share a common regulatory 
description as an endoscope with accessories. As a result, there are significant difference 
between the structure of the product code breakdown and regulatory description breakdown (see 
Figure 24).  
 
 
Figure 24: Breakdown of Flex System predicates grouped by product code and regulatory description. The product 
code classification breakdown shows a large number of product codes with no dominant code(s). However, many of 
these product codes share a common regulatory description as evidenced by the appearance of a dominant 
regulatory description in that breakdown. 
A6.1     REFERENCE DEVICES IN THE TRACE 
 
Unlike the subject devices analyzed in the other three traces, the sole direct predicate of the 
Medrobotics Flex Transabdominal System is not identified as a robotic surgical system. Instead 
this device, the Olympus EndoEye Flex 3D Deflectable Videoscope and associated system, is a 
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flexible video endoscope used for three-dimensional viewing of endoscopic instruments during 
surgery within the thoracic and abdominal cavities (Lerner, 2013). This device, shown in Figure 
25, utilizes a similar cable-steered mechanism to make the scope flexible, however it does not 
include a powered arm for positioning and is controlled manually by the surgeon (Viviano, 
2018).  
 
 
Figure 25: Olympus EndoEye Flex 3D Deflectable Videoscope (Olympus Corp., 2018 ) 
 
To mitigate some of the risk introduced with the inclusion of new technological characteristics, 
including the robotic arm and software driven positioning system, the 510(k) application for the 
Flex System includes two 510(k) applications associated with the Medrobotics Flex Colorectal 
System as reference devices. This system is classified under product code FDF as a colonoscopy 
and accessories with the regulatory description of endoscope and accessories. Although the 
Colorectal System is nearly identical to the Transabdominal System (Viviano, 2018), it was 
approved specifically as a device for colorectal surgery and is therefore ineligible to serve as a 
predicate for the Flex Transabdominal, which is indicated for a different intended use. 
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Inclusion of the reference devices and their subsequent predicates in the substantial equivalence 
tree significantly increases the size of the trace. With the reference devices included, there are 
147 unique devices present in the trace classified under 48 different product codes (See 
Appendix 2). This trace expansion includes devices with a significantly wider array of 
technological characteristics, including the introduction of the robotic manipulator technology 
which is present in the subject device but missing in all the directly identified predicate devices. 
As reference devices are a relatively new regulatory mechanism, there is limited data available 
from this research to indicate whether reference devices could potentially impact the regulatory 
process. Since these devices are ineligible to serve as predicate devices, and therefore cannot 
directly contribute to predicate creep, analysis of the expanded trace was limited to the 
identification of reference devices and observation of introduced technological characteristics. 
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A6.2     ADDITIONAL FLEX SYSTEM PREDICATE INFORMATION 
 
Note that this table includes devices classified as reference devices and subsequent reference predicates, identified 
with red text, in addition to direct predicate devices. 
K Number Device Name Manufacturer Approval Date Product Code Recalls 
K011782 Rectosight SIGHTLINE TECHNOLOGIES LTD. 
N/A (no record 
in database) 
 0 
K172796 
Flex Robotic System And Flex Transabdominal 
Drive 
MEDROBOTICS CORPORATION 1/18/2018 
HET 
GCJ 
0 
K172036 Medrobotics Flex Robotic System Medrobotics Corporation 8/3/2017 FDF 0 
K162330 Flex Robotic System And Flex Colorectal Drive Medrobotics Corporation 5/4/2017 FDF 0 
K150776 Medrobotics Flex System MEDROBOTICS CORPORATION 7/17/2015 
EOB 
EOX 
GCI 
0 
K123365 
OLYMPUS LTF-190-10-3D, MAJ-Y0154, OLYMPUS 
CV-190 
OLYMPUS MEDICAL SYSTEMS CORP. 3/1/2013 
HET 
GCJ 
FGB 
NWB 
0 
K111004 
HANSEN MEDICAL VASCULAR CATHETER 
CONTROL SYSTEM AND CATHETER 
HANSEN MEDICAL, INC. 5/29/2012 
DXX 
DRA 
2 – Class II 
K111425 
OLYMPUS LTF-S190-10, OLUMPUS OTV-S190, 
OLYMPUS CLV-S190 
OLYMPUS MEDICAL SYSTEMS CORP. 4/20/2012 
HET 
EOB 
FGB 
GCJ 
NWB 
EOQ 
 
K112680 EVIS EXERA III VIDEO SYSTEM 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
2/16/2012 FDF 0 
K102733 
VISION-SCIENCES ENT-5000 VIDEO ENT SCOPE 
WITH ENDOSHEATH TECHNOLOGY, VISION-
SCIENCES DPU-5000/DPU-5050 VIDEO 
PROCESSOR 
VISION-SCIENCES, INC. 5/18/2011 
EOB 
GCJ 
HRX 
0 
K102379 LTF-Y0009; MAJ-YOO41; XOEV-3D1 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
1/5/2011 GCJ 0 
K102168 SENSEI X ROBOTIC CATHETER SYSTEM HANSEN MEDICAL, INC. 10/22/2010 DXX 1 – Class II 
K100584 EVIS EXERAII 180 SYSTEM 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
7/2/2010 
NWB 
FDF 
FDS 
0 
K093717 C-MOR VISUALIZATION DEVICE AXIS SURGICAL TECHNOLOGIES, INC 3/2/2010 HRX 0 
K091808 
SENSEI ROBOTIC CATHETER SYSTEM, MODEL 
02057 
HANSEN MEDICAL, INC. 9/10/2009 DXX 1 – Class II 
K090365 
HANSEN MEDICAL ARTISAN S CONTROL 
CATHETER 
HANSEN MEDICAL, INC. 5/7/2009 
DXX 
DRA 
1 – Class II 
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K Number Device Name Manufacturer Approval Date Product Code Recalls 
K080948 
HD ENDOEYE LAPARO-THORACO VIDEOSCOPE 
OLYMPUS LTF TYPE VH 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
9/26/2008 
HET 
GCJ 
NWB 
0 
K082293 SURGVIEW INTEGRATED VISUALIZATION SYSTEM BIOVISION TECHNOLOGIES, LLC 9/9/2008 
HRX 
GCJ 
0 
K081051 
SPINEVU ENDOSCOPIC SPINE SYSTEM (SESS), 
SPINEVU MINISCOPE 
SPINE VIEW, INC. 8/7/2008 
HRX 
GEI 
0 
K073225 SENSEI CATHETER CONTROL SYSTEM HANSEN MEDICAL, INC. 6/30/2008 
DXX 
DRA 
1 – Class II 
K080415 
DEVICE MODIFICATION TO PINNACLE 
DESTINATION PERIPHERAL GUIDING SHEATH 
TERUMO MEDICAL CORP. 3/7/2008 DYB 0 
K072879 INNERVUE DIAGNOSTIC SCOPE SYSTEM BIOMET ORTHOPEDICS, INC. 1/14/2008 HRX 2 – Class II 
K072073 
VISION-SCIENCES ENT-5000 AND ENT-5100 
VIDEO ENT SCOPE WITH ENDOSHEATH SYSTEM, 
DPU-5000/DPU-5050 VIDEO PROCESSOR 
VISION-SCIENCES, INC. 8/29/2007 EOB 0 
K070622 NEOGUIDE ENDOSCOPY SYSTEM NEOGUIDE SYSTEMS, INC. 8/14/2007 FDF 0 
K052480 
HANSEN MEDICAL CATHETER CONTROL SYSTEM 
(CCS) AND ACCESSORIES, HANSEN MEDICAL 
STEERABLE GUIDE CATHETER (SGC) AND SHEATH 
HANSEN MEDICAL, INC. 5/2/2007 
DXX 
DRA 
2 – Class II 
K062049 EVIS EXERA II 180 SYSTEM 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
9/22/2006 NWB 0 
K061313 EVIS EXERA 180 SYSTEM 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
8/31/2006 
EOQ 
EOB 
NWB 
0 
K061246 ENDOSCOPIC SPINE SYSTEM ARTHRO KINETICS INC. 8/23/2006 HRX 0 
K061345 MODIFICATION TO ENDIUS ATAVI SYSTEM ENDIUS, INC. 6/6/2006 HRX 1 – Class II 
K052241 DISC-FX SYSTEM ELLMAN INTERNATIONAL, INC. 2/24/2006 
HRX 
GEI 
0 
K052930 NAVIGATOR ENDOSCOPY SYSTEM NEOGUIDE SYSTEMS, INC. 1/31/2006 FDF 0 
K053267 ENDIUS ATAVI SYSTEM ENDIUS, INC. 1/13/2006 HRX 1 – Class II 
K051645 EVIS EXERA 160A SYSTEM 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
10/13/2005 
NWB 
FDF 
FDS 
0 
K052452 
VISERA RHINO-LARYNGOVIDEOSCOPE OLYMPUS 
ENF TYPE VT 
OLYMPUS MEDICAL SYSTEMS 
CORPORATION 
9/21/2005 EOB 0 
K051827 
JOIMAX ENDOSCOPE/MULTISCOPE, THESSYS 
FORAMINOSCOPE/MULTISCOPE, THESSYS 
LAMINOSCOPE/MULTISCOPE 
JOIMAX GMBH 8/12/2005 HRX 0 
K051601 
PINNACLE DESTINATION PERIPHERAL GUIDING 
SHEATH 
TERUMO MEDICAL CORP. 8/4/2005 DYB 0 
K050972 VISION-SCIENCES ENT-3000 SCOPE VISION-SCIENCES, INC. 4/29/2005 EOB 2 – Class II 
K043395 SMITH & NEPHEW VIDEOARTHROSCOPE SMITH & NEPHEW, INC. 1/12/2005 
HRX 
EOB 
0 
K040604 INNERVUE DIAGNOSTIC SCOPE SYSTEM ARTHROTEK, INC. 6/4/2004 GCJ 0 
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K Number Device Name Manufacturer Approval Date Product Code Recalls 
K040984 
VISION SCIENCES MODEL ENT-2000V FLEXIBLE 
NASOPHARYNGO-LARYNGOSCOPE 
VISION-SCIENCES, INC 4/27/2004 EOB 0 
K033954 SHAPE LOCKING ENDOSCOPIC OVERTUBE USGI MEDICAL, INC. 3/19/2004 
FED 
FDF 
0 
K032688 COLONOSIGHT MODEL 510B SIGHTLINE TECHNOLOGIES LTD. 3/5/2004 FDF 0 
K023902 SHAPE-LOCKABLE ENDOSCOPIC OVERTUBE USGI MEDICAL, INC. 8/20/2003 
FED 
FDF 
0 
K031648 
VISERA RHINO-LARYNGOVIDEOSCOPE OLYMPUS 
ENF TYPE V 
OLYMPUS OPTICAL CO., LTD. 7/24/2003 EOB 0 
K031591 
POWDER-FREE NITRILE PATIENT EXAMINATION 
GLOVE, WHITE (NON-COLORED), BLUE AND 
GREEN COLORED 
PERUSAHAAN GETAH ASAS SDN BHD 6/26/2003 LZA 0 
K030096 
VIDEO ARTHROSCOPE, MODELS AR-3050-30, AR-
3050T-30, AR-3050-70, AR-3051-30, AR-3052-30, 
AR3030AN, AR-3030AS, AR3030AW 
ARTHREX, INC. 3/18/2003 HRX 0 
K023984 
MODIFICATION TO OLYMPUS BRONCHOSCOPES 
BF-40 SERIES, BF-240 SERIES, AND BF-160 SERIES 
THE OLYMPUS OPTICAL CO. 1/31/2003 EOQ 0 
K021555 
STEREOTAXIS NIOBE MAGNETIC NAVIGATION 
SYSTEM 
STEREOTAXIS, INC. 1/15/2003 DXX 0 
K024095 
MODIFICATION TO VISION SCIENCES 
ENDOSHEATH SYSTEM 
VISION-SCIENCES, INC 1/9/2003 EOB 0 
K022199 ENDIUS ATAVI SYSTEM ENDIUS, INC. 10/2/2002 HRX 0 
K012543 VISION SCIENCES ENDOSHEATH SYSTEM VISION-SCIENCES, INC. 7/15/2002 EOB 0 
K021748 ENDIUS ATAVI SYSTEM ENDIUS, INC. 6/26/2002 HRX 0 
K021344 
B-F200 BRONCHOSCOPE WITH BSS-F21 
ENDOSHEATH SYSTEM 
VISION-SCIENCES, INC. 5/24/2002 EOQ 0 
K021074 
VISERA CYSTOVIDEOSCOPE OLYMPUS CYF TYPE 
V/VA 
OLYMPUS AMERICA, INC. 5/2/2002 FAJ 0 
K013484 
TELSTAR MAGNETIC NAVIGATION SYSTEMS 
[MNS}, TELSTAR BI-PLANE DIGITAL IMAGING 
SYSTEM, NIOBE ELECTROPHYSIOLOGY MAPPING 
CATH 
STEREOTAXIS, INC. 5/2/2002 
DRF 
DXX 
MQB 
0 
K021073 
VISERA RHINLARYNGOVIDEOSCOPE OLYMPUS 
ENF TYPE V 
OLYMPUS AMERICA, INC. 5/1/2002 EOB 0 
K020310 DAVLITE MICROENDOSCOPE & ACCESSORIES DAVLITE TECHNOLOGIES 3/20/2002 GCJ 0 
K013591 
XENF-TP RHINO-LARYNGOFIBERSCOPE, ITS 
ACESSORIES AND ANCILLARY EQUIPMENT 
OLYMPUS OPTICAL CO., LTD. 12/26/2001 EOB 0 
K012812 CAROTID GUIDING SHEATH TERUMO MEDICAL CORP. 11/14/2001 DYB 1 – Class II 
K011189 VIADUCT MICROENDOSCOPE AND ACCESSORIES ACUEITY, INC. 7/16/2001 GCJ 0 
K010811 PERC-D SPINEWAND ARTHROCARE CORP. 5/30/2001 HRX 0 
K011151 
EVIS EXERA GASTROINTESTINAL VIDEOSCOPE 
GIF-Q160Z 
THE OLYMPUS OPTICAL CO. 5/15/2001 FDS 0 
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K002749 
ENDOSCOPE CONTOUR DETECTION DEVICE, 
MODEL 3DX45 AND COLONOSCOPE, MODEL XCF-
Q140L/13D 
THE OLYMPUS OPTICAL CO. 12/4/2000 
FDF 
JAB 
0 
K002931 METRX SYSTEM MEDTRONIC SOFAMOR DANEK, INC. 11/24/2000 HRX 0 
K002437 ENDIUS ENDOSCOPIC ACCESS SYSTEM ENDIUS, INC. 10/2/2000 HRX 0 
K001766 
OLYMPUS XGIF-N200H GASTROINTESTINAL 
VIDEOSCOPE 
OLYMPUS OPTICAL CO., LTD. 9/8/2000 FDS 0 
K002018 NDO SURGICAL SURGICAL OVERTUBE SURGICAL, INC. 8/17/2000 FED 0 
K994130 RECTOSIGHT RS 300-04 SIGHTLINE TECHNOLOGIES LTD. 6/30/2000 
FER 
GCF 
0 
K001241 
EVIS EXERA COLONOVIDEOSCOPE CF-Q160 AL/I 
AND PCF-160 AL/I 
THE OLYMPUS OPTICAL CO. 5/9/2000 FDF 0 
K993041 
OLYMPUS XCYF-1T3 OES 
CYSTOFIBERSCOPE/NEPHROFIBERSCOPE 
ACCESSORIES AND ANCILLARY EQUIPMENT 
THE OLYMPUS OPTICAL CO. 3/30/2000 
FAJ 
FGA 
KGE 
KNS 
0 
K000046 KNIGHT ENDOSCOPIC SPINE SYSTEM (KESS) 
RICHARD WOLF MEDICAL 
INSTRUMENTS CORP 
3/30/2000 HRX 0 
K994425 
MODIFICATION TO ENDOSCOPIC SPINAL ACCESS 
SYSTEM 
ENDIUS, INC. 2/16/2000 HRX 0 
K991794 ENDOSCOPIC SPINAL ACCESS SYSTEM ENDIUS, INC. 8/13/1999 HRX 0 
K990354 ENDOSHEATH VISION-SCIENCES, INC. 3/31/1999 EOB 0 
K982819 ENDIUS SPINE ENDOSCOPE ENDIUS, INC. 1/27/1999 GWG 0 
K981543 
OLYMPUS LF-TP AND LF-DP TRACHEAL 
INTUBATION FIBERSCOPES, ACCESSORIES AND 
ANCILLARY EQUIPMENT 
THE OLYMPUS OPTICAL CO. 6/8/1998 EOQ 0 
K973405 YEUNG ENDOSCOPIC SPINE SYSTEM 
RICHARD WOLF MEDICAL 
INSTRUMENTS CORP. 
3/13/1998 HRX 0 
K974355 
INTERVENTIONAL MOBILE DIGITAL IMAGING 
SYSTEM (HEREIN CALLED IMDIS) 
GE DEC MEDICAL SYSTEMS 2/17/1998 
OWB 
JAA 
OXO 
1 – Class II 
K973500 BARD ENDOSCOPIC OVERTUBE (#000307) C.R. BARD, INC. 10/16/1997 FED 0 
K971253 
VARIOUS ARTHROSCOPES, ENDOSCOPIC BLADES, 
MANUAL INSTRUMENTS 
SMITH & NEPHEW, INC. 6/13/1997 HRX 0 
K963795 
VISION-SCIENCES MODEL B-F100 
BRONCHOSCOPE WITH MODEL BS-F21 
DISPOSABLE ENDOSHEATH 
VISION-SCIENCES, INC. 12/23/1996 EOQ 0 
K961228 KARL STORZ MAGNIFYING ARTHROSOCPES 
KARL STORZ ENDOSCOPY-AMERICA, 
INC 
10/10/1996 HRX 0 
K963033 
BF 240/P240/IT240 BRONCHOVIDEOSCOPE & 
ACCESSORIES 
OLYMPUS AMERICA, INC. 9/9/1996 EOQ 0 
K950809 
VISION-SCIENCES DISPOSABLE ENDOSHEATH FOR 
FLEXIBLE NASOPHARYNGO-LARYNGOSCOPES 
VISION-SCIENCES, INC. 8/5/1996 EOB 0 
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K961591 
DISPOSABLE ENDOSHEATH FOR E-F100 FLEXIBLE 
NASOPHARYNGOSCOPE 
VISION-SCIENCES, INC 7/2/1996 EOB 0 
K961570 
KEC-3840L/F, VIDEO COLONOSCOPE (*L OR F IN 
MODEL NUMBER DENOTES LENGTH) 
PENTAX PRECISION INSTRUMENT 
CORP. 
6/24/1996 FDF 1 – Class II 
K961563 EC-384OTL, VIDEO COLONSCOPE 
PENTAX PRECISION INSTRUMENT 
CORP. 
6/19/1996 FDF 0 
K954451 EVIS 140 SYSTEM OLYMPUS AMERICA, INC. 3/29/1996 FET 0 
K951579 EC-3800TL, VIDEO COLONOSCOPE 
PENTAX PRECISION INSTRUMENT 
CORP. 
3/21/1996 FDF 1 – Class II 
K951574 EC-3800L, VIDEO COLONOSCOPE 
PENTAX PRECISION INSTRUMENT 
CORP. 
3/21/1996 FDF 3 – Class II 
K955403 OES LAPARO-THORACO VIDEOSCOPE TYPE V OLYMPUS AMERICA, INC. 3/11/1996 
HET 
GCJ 
0 
K942265 
FLEXIBLE NASOPHARYNGO-LARYNGOSCOPE AND 
ENDOSHEATH 
VISION-SCIENCES, INC. 12/22/1995 EOB 0 
K943307 
3D SURGICAL ENDOSCOPY SYSTEM FOR GENERAL 
SURGERY 
OLYMPUS AMERICA, INC. 12/20/1995 GCJ 0 
K943304 
3D SURGICAL ENDOSCOPY SYSTEM FOR 
UROLOGY 
OLYMPUS AMERICA, INC. 12/20/1995 
FCG 
FAL 
0 
K954989 
DYONICS DISPOSABLE ENDOSCOPIC SURGERY 
BLADES 
SMITH & NEPHEW DYONICS, INC. 11/27/1995 ERL 0 
K943305 OLYMPUS 3D SURGICAL ENDOSCOPY SYSTEM OLYMPUS AMERICA, INC. 11/17/1995 HET 0 
K953910 PHILIPS BV 300 SERIES 
PHILIPS MEDICAL SYSTEMS NORTH 
AMERICA, INC. 
10/18/1995 OXO 1 – Class II 
K930191 DANEK(TM) SPINAL EPIDURAL ENDOSCOPIC SY SOFAMOR DANEK MFG., INC. 9/26/1995 HRX 0 
K953695 DYONICS DISPOSABLE ARTHROSCOPIC BLADES SMITH & NEPHEW DYONICS, INC 9/15/1995 HRX 0 
K953484 POLLUX OA/POLLUX 30A/POLLUX 70A POLLUX ENDOSCOPY, INC. 9/1/1995 HRX 0 
K945209 
PROCTOSCOPEA & ACCESSORIES, 
SIGMOIDOSCOPES & ACCESSORIES, 
PROCTOLOGY INSTRUMENTS 
KARL STORZ ENDOSCOPY-AMERICA, 
INC. 
3/6/1995 
GCF 
FAM 
0 
K950103 LAPAROSCOPE, HAND INSTRUMENTS OLYMPUS AMERICA, INC. 3/6/1995 GCJ 0 
K943895 VISION SYSTEM COLONSCOPE VISION-SCIENCES, INC. 2/3/1995 FDF 0 
K944072 OLYMPUS NASAL AND SINUS ENDOSCOPES OLYMPUS AMERICA, INC. 1/11/1995 EOB 0 
K942338 
OLYMPUS PF-8P OES PANCREATO FIBERSCOPE 
AND ACCESSORIES 
OLYMPUS CORP. 11/30/1994 FDT 0 
K942339 SKIN NEUVEAU SCAR TREATMENT PURITAS HEALTH CARE, INC. 11/28/1994 MDA  0 
K941036 
CURVED ROTATABLE DISPOSABLE 
ARTHROSCOPIC SURGERY BLADES 
SMITH & NEPHEW, INC 9/28/1994 HRX 0 
K941919 OKTAS ENDOSCOPY VIDEO CAMERA SYSTEM OKTAS 6/17/1994 FET 0 
K942044 BARD ENDOSCOPIC OVERTUBE C.R. BARD, INC. 6/10/1994 FED 0 
K941967 HSW LAPAROSCOPE AND ACCESSORIES HENKE-SASS WOLF, GMBH. 5/16/1994 GCJ 0 
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K932987 BIRTCHER LAPAROSCOPE AND ACCESSORIES BIRTCHER MEDICAL SYSTEMS, INC 4/25/1994 GCJ 0 
K922519 
MOD. PERCUTANEOUS ARTHROSCOPIC MICRO 
DISCECTOMY 
SMITH & NEPHEW, INC. 3/29/1994 HRX 0 
K932843 
FLEXIBLE VIDEO SIGMOIDOSCOPE SYSTEM 
W/DISP. SHEATH 
VISION-SCIENCES, INC. 2/14/1994 
FAM 
FET 
0 
K934299 
DYONICS DISPOSABLE ARTHROSCOPIC SURGERY 
BLADES MODIFICATION 
SMITH & NEPHEW DYONICS, INC 2/14/1994 
HRX 
HWE 
0 
K934918 EPM-3300 VIDEO PROCESSOR 
PENTAX PRECISION INSTRUMENT 
CORP. 
2/7/1994 
FET 
GCT 
0 
K934981 DENTAL DRILL EARE CONSULTING SERVICE 2/3/1994 DZP  0 
K934920 VB-1830/VB-1530, VIDEO BRONCHOSCOPE 
PENTAX PRECISION INSTRUMENT 
CORP. 
1/26/1994 EOQ 0 
K933247 
PROTECTIVE SHEATH FOR FLEXIBLE 
NASOPHARY/LARYGNOS 
VISION-SCIENCES, INC. 11/22/1993 EOB 0 
K931154 EVIS 200 SYSTEM OLYMPUS CORP. 10/7/1993 EOQ 0 
K924125 CRI ELECTRONIC CONTROL SYSTEM 
CATHETER RESEARCH C/O BURDITT, 
BOWLES & RADZIUS 
5/26/1993 DXX 0 
K924607 
ARROW FISCHELL KINK RESIST PERCUT SHEATH 
INTRO SET 
ARROW INTL., INC. 4/22/1993 DYB 
2 – Class II 
1 – Class III 
K923982 OLYMPUS OES LAPAROSCOPY SYSTEM OLYMPUS CORP. 3/15/1993 GCJ 1 – Class II 
K926056 9600 FLUOROSCOPIC IMAGING SYSTEM OEC-DIASONICS, INC. 1/21/1993 OXO 0 
K925421 ENDOSHEATH VISION-SCIENCES, INC. 1/15/1993 EOB 0 
K921690 FLEXIBLE FIBEROPTIC SIGMOIDOSCOPE SYSTEM VISION-SCIENCES, INC. 10/28/1992 
FAM 
ODB 
0 
K921244 DISPOSABLE PROTECTIVE SHEATH VISION-SCIENCES, INC. 10/6/1992 EOB 0 
K921707 
PENTAX NASO-PHARYNGO-LARYNGOSCOPE FNL-
15P2/15RP2 
PENTAX PRECISION INSTRUMENT 
CORP. 
7/1/1992 EOB 1 – Class II 
K920800 INTEGRATED ENDOSCOPY SYSTEM 1000 BIOMET, INC. 6/30/1992 HRX 1 – Class II 
K914559 SMALL JOINT SYSTEM SMITH & NEPHEW DYONICS, INC. 2/18/1992 HRX 0 
K904940 
OLYMPUS INFANT RESECTOSCOPE AND 
ACCESSORIES 
OLYMPUS CORP. 1/13/1992 FJL 0 
K912453 INTELIJET TM FLUID MANAGEMENT SYSTEM SMITH & NEPHEW DYONICS, INC. 8/26/1991 HRX 0 
K912120 
URF-P2 
URETERORENOFIBERSCOPE/CHOLEDOCHOFIBERS
COPE 
OLYMPUS CORP. 8/7/1991 FBN 1 – Class II 
K910423 BRONCHOSCOPE BF-N20 OLYMPUS CORP. 4/29/1991 EOQ 0 
K903842 ST-E1 OVERTUBE OLYMPUS CORP. 1/23/1991 FED 0 
K904284 ARTHROSCOPIC SURGICAL BLADE SMITH & NEPHEW DYONICS, INC. 12/5/1990 HRX 0 
K900765 STEEROCATH(TM) EP TECHNOLOGIES, INC. 5/7/1990 DRF 0 
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K900070 
MODIFIED USES OF THE ARTHROSCOPIC 
SURGICAL SYSTEM 
DYONICS, INC. 2/16/1990 HRX 0 
K880518 MOBILE C-ARM OMNI 325 FISCHER IMAGING CORP. 3/9/1988 OXO 0 
K853585 
OLYMPUS EVS-ENDOSCOPIC VIDEO IMAGE & 
DATA SYS 
OLYMPUS CORP. 1/21/1986 FET 0 
K853678 KAMBIN SPINAL INSTRUMENT SET PILLING CO. 9/24/1985 HTZ 0 
K850978 OLYMPUS LF-1 INTUBATION SCOPE OLYMPUS CORP. 5/23/1985 CAL 0 
K843084 OLYMPUS CHP-P10 NEPHROSCOPE/CYSTOSCOPE OLYMPUS CORP. 1/3/1985 FBO 0 
K844131 NUCLEOTOME 
MEDICAL INSTRUMENT 
DEVELOPMENT LABORATORIES, INC. 
11/29/1984 HSZ 0 
K833587 DISPOSABLE ARTHROSCOPY BLADE DYONICS, INC. 11/14/1983 HRX 0 
K822846 PENTAX FC-38LA & FC-38SA COLONOFIBER 
PENTAX PRECISION INSTRUMENT 
CORP. 
10/22/1982 FDF 0 
K820367 INTRA-ARTICULAR SURGICAL SYSTEM DYONICS, INC. 5/7/1982 KIJ 0 
K771218 INTRA-ARTICULAR SHAVER DYONICS, INC 2/1/1978 KIJ 0 
 
 
